doc_id,sentence,biomarker,drug,prediction
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",USA3,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",PR,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",PR,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",BMC,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",China4,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",Cancer1471,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",USA2,Silver,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",China5,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3101972887710.1186/1471-2407-9-310Research ArticleBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma Takikita Mikiko 1takikitm@mail.nih.govHu Nan 2nhu@mail.nih.govShou Jian-zhong 3shoujianzhong@hotmail.comWang Quan-Hong 4zhongmeiketi@yahoo.com.cnGiffen Carol 5GiffenC@imsweb.comTaylor Philip R 2ptaylor@mail.nih.govHewitt Stephen M 1genejock@helix.nih.gov1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health,  Bethesda, MD, USA2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China5 Information Management Services, Inc, Silver Spring, MD, USA2009 3 9 2009 9 310 310 22 4 2009 3 9 2009 Copyright (c)2009 Takikita et al; licensee BioMed Central Ltd.2009Takikita et al; licensee BioMed Central Ltd.",USA2009,Silver,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CMF,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CMF,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CMF,Adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CMF,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CMF,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CMF,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CAF,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CAF,epirubicin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CAF,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CAF,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CAF,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CAF,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",DFS,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",DFS,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",DFS,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",DFS,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",DFS,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",DFS,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CI,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CI,epirubicin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CI,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CI,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CI,Cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CI,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",EORTC,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",EORTC,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",EORTC,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",EORTC,Cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",EORTC,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",EORTC,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ELISA,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ELISA,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ELISA,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ELISA,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ELISA,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ELISA,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ER,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ER,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ER,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ER,Cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ER,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",ER,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CEF,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CEF,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CEF,Adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CEF,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CEF,Cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Abbreviations
A: Adriamycin; CEF/CAF: Cyclophosphamide and 5-fluorouracil with epirubicin/adriamycin; CI: Confidence interval; CMF: Cyclophosphamide-methotrexate-5-fluorouracil; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor;",CEF,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",JAF,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",TIMP-1,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",HR,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",AS,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",NB,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",MEMG,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",OS,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","HR: Hazard ratio; MMP: Matrix metalloproteinase; OS: Overall survival; PgR: Progesterone receptor; RT: Radiotherapy; TIMP-1: Tissue inhibitor of metalloproteinases-1

Competing interests
AS, MEMG, JAF and NB are co-applicants on the patent application ""Cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors"".

",MMP,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",PBS,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",PBS,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",DAKO,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",DAKO,biotin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",HRP,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",HRP,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",ABTS,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Bound Mabs were detected either by incubation with 100 ml HRP-conjugated polyclonal anti-mouse IgG diluted 1:1,000 in PBS/Tween (non-biotin-labelled Mabs) or by incubation with 100 ml StrepABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) with biotin-labelled Mabs for 1 h at 37degC and developed with ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulfonic acid)/H2O2.",ABTS,biotin,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Multivariate Cox models were also fitted, including patient's age, sex (female/male), stage (Dukes' B/C), differentiation grade (well or moderately differentiated/poorly differentiated or undifferentiated), Irinotecan containing adjuvant chemotherapy (No/Yes), Topo I expression (negative/positive), and TS expression (negative/positive).",Yes,Irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Multivariate Cox models were also fitted, including patient's age, sex (female/male), stage (Dukes' B/C), differentiation grade (well or moderately differentiated/poorly differentiated or undifferentiated), Irinotecan containing adjuvant chemotherapy (No/Yes), Topo I expression (negative/positive), and TS expression (negative/positive).",TS,Irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",The standard chemotherapy for pancreatic NET has been a combination of adriamycin and streptozotocin and to a lesser extent a combination of 5-fluorouracil (5-FU) and streptozotocin [3].,NET,adriamycin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",The standard chemotherapy for pancreatic NET has been a combination of adriamycin and streptozotocin and to a lesser extent a combination of 5-fluorouracil (5-FU) and streptozotocin [3].,NET,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",The standard chemotherapy for pancreatic NET has been a combination of adriamycin and streptozotocin and to a lesser extent a combination of 5-fluorouracil (5-FU) and streptozotocin [3].,FU,adriamycin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",The standard chemotherapy for pancreatic NET has been a combination of adriamycin and streptozotocin and to a lesser extent a combination of 5-fluorouracil (5-FU) and streptozotocin [3].,FU,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Statistics
All analyses were performed using Microsoft Excel 2002 SP3 (Microsoft Corporation) and Minitab Release 14.13 (Minitab Inc.).",SP3,Excel,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Nevertheless, in the absence of irinotecan treatment, positive TS expression tends to have a negative effect on survival (HR = 1.50, 95% CI 0.98-2.30, wald p = 0.068).",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Nevertheless, in the absence of irinotecan treatment, positive TS expression tends to have a negative effect on survival (HR = 1.50, 95% CI 0.98-2.30, wald p = 0.068).",HR,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Nevertheless, in the absence of irinotecan treatment, positive TS expression tends to have a negative effect on survival (HR = 1.50, 95% CI 0.98-2.30, wald p = 0.068).",TS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Relation between TS and Topo I status and benefit from adjuvant irinotecan containing chemotherapy
In total, 190 patients were treated with irinotecan and 5-FU/LV chemotherapy.",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Relation between TS and Topo I status and benefit from adjuvant irinotecan containing chemotherapy
In total, 190 patients were treated with irinotecan and 5-FU/LV chemotherapy.",TS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Relation between TS and Topo I status and benefit from adjuvant irinotecan containing chemotherapy
In total, 190 patients were treated with irinotecan and 5-FU/LV chemotherapy.",FU,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Relation between TS and Topo I status and benefit from adjuvant irinotecan containing chemotherapy
In total, 190 patients were treated with irinotecan and 5-FU/LV chemotherapy.",FU,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","After concentration measured by the BCA method, equal amounts of protein were electrophoresed on 12% SDS/polyacrylamide gels and subsequently transferred to a polyvinylidene difluoride membranes (PVDF) (Millipore, Billerica, MA) by electroblotting.",BCA,polyacrylamide,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","After concentration measured by the BCA method, equal amounts of protein were electrophoresed on 12% SDS/polyacrylamide gels and subsequently transferred to a polyvinylidene difluoride membranes (PVDF) (Millipore, Billerica, MA) by electroblotting.",PVDF,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","After concentration measured by the BCA method, equal amounts of protein were electrophoresed on 12% SDS/polyacrylamide gels and subsequently transferred to a polyvinylidene difluoride membranes (PVDF) (Millipore, Billerica, MA) by electroblotting.",SDS,polyacrylamide,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Later on, however, the increase was inhibited remarkably when AMD 3100 (1 mg/ml, Sigma), a CXCR4 antagonist, or infliximab, was added (P &#60; 0.01, respectively, Figure 6A).

",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Later on, however, the increase was inhibited remarkably when AMD 3100 (1 mg/ml, Sigma), a CXCR4 antagonist, or infliximab, was added (P &#60; 0.01, respectively, Figure 6A).

",AMD,infliximab,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",HR,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among patients treated with anthracycline-containing chemotherapy a trend towards a better outcome in TIMP-1 low patients compared with untreated patients was observed although neither TIMP-1 low nor TIMP-1 high patients had a significantly better DFS than untreated patients (TIMP-1 low patients: HR 0.71, 95% CI 0.42-1.19, P = 0.19; TIMP-1 high patients: HR 0.97, 95% CI 0.60-1.57, P = 0.90).",HR,anthracycline,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","*	P+	MST (95% CI, month)	P++	
Age			0.456		0.468	
 <= 60 years	55 (44.4)	39 (70.9)		21.0 (13.0-32.0)		
 &#62; 60 years	69 (56.6)	53 (76.8)		18.0 (13.0-26.0)		
Gender			0.175		0.046	
 ",CI,MST,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002	
		
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02	
	
Age	41-55 years vs. <= 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14	
					
	Stage 3 (&#62;5 cm or chest wall/skin involvement) vs. stage 1 (<= 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)		
	
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06	
					
	",CI,anthracycline,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Some reports have suggested a higher chemosensitivity of undifferentiated or poorly differentiated NET with etoposide-cisplatin combination [2,26].

",NET,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Some reports have suggested a higher chemosensitivity of undifferentiated or poorly differentiated NET with etoposide-cisplatin combination [2,26].

",NET,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Comparison with patients who did not receive adjuvant chemotherapy
First, we compared DFS of patients treated with adjuvant anthracycline-containing chemotherapy or adjuvant CMF with DFS of untreated patients.",DFS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Comparison with patients who did not receive adjuvant chemotherapy
First, we compared DFS of patients treated with adjuvant anthracycline-containing chemotherapy or adjuvant CMF with DFS of untreated patients.",CMF,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Comparison with patients who did not receive adjuvant chemotherapy
First, we compared DFS of patients treated with adjuvant anthracycline-containing chemotherapy or adjuvant CMF with DFS of untreated patients.",DFS,anthracycline,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",MCP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",COX-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",TIMP-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",TSP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",NOS-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Results
The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p &#60; 0.05), but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT.",MMP-9,endostatin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,glutamine,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,penicillin,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,Streptomycin,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,Penicillin,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,streptomycin,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,glutamine,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,glutamine,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,penicillin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,Streptomycin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,Penicillin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,streptomycin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","To minimize possible RNA degradation, organs resected in the operating room were immediately submerged in ice-cold saline solution.",RNA,saline solution,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","Despite improvements in surgical techniques and the advent of more targeted therapeutics such as bevacizumab, survival of patients with EOC stands at 45% at five years [1].",EOC,bevacizumab,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Unknown	131 (25)	85 (26)	17 (17)	29 (28)		
	
Primary treatment						
Lumpectomy	212 (40)	169 (52)	4 (4)	39 (38)	&#60;0.0012	
Mastectomy	313 (60)	155 (48)	95 (96)	63 (62)		
	
Events3						
Recurrences (disease failure)	268	140	58	70		
Deaths	149	75	32	42		
	
TIMP-1 (median, range)	12.5 (0- 113)	12.0 (0- 106)	13.5 (0-51.2)	13.8 (0- 113)	0.204	
All patients, N = 525; CMF-treated patients, N = 324; anthracycline-treated, N = 99; untreated patients, N = 102.

1Testing",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Unknown	131 (25)	85 (26)	17 (17)	29 (28)		
	
Primary treatment						
Lumpectomy	212 (40)	169 (52)	4 (4)	39 (38)	&#60;0.0012	
Mastectomy	313 (60)	155 (48)	95 (96)	63 (62)		
	
Events3						
Recurrences (disease failure)	268	140	58	70		
Deaths	149	75	32	42		
	
TIMP-1 (median, range)	12.5 (0- 113)	12.0 (0- 106)	13.5 (0-51.2)	13.8 (0- 113)	0.204	
All patients, N = 525; CMF-treated patients, N = 324; anthracycline-treated, N = 99; untreated patients, N = 102.

1Testing",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Unknown	131 (25)	85 (26)	17 (17)	29 (28)		
	
Primary treatment						
Lumpectomy	212 (40)	169 (52)	4 (4)	39 (38)	&#60;0.0012	
Mastectomy	313 (60)	155 (48)	95 (96)	63 (62)		
	
Events3						
Recurrences (disease failure)	268	140	58	70		
Deaths	149	75	32	42		
	
TIMP-1 (median, range)	12.5 (0- 113)	12.0 (0- 106)	13.5 (0-51.2)	13.8 (0- 113)	0.204	
All patients, N = 525; CMF-treated patients, N = 324; anthracycline-treated, N = 99; untreated patients, N = 102.

1Testing",Events3,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The median survival time of patients alive was 99 (range, 9-255) months (CMF-treated patients, 103 (range, 12-248) months; anthracycline-treated patients, 90 (range, 9-213) months; untreated patients, 93 (range, 15-255) months).

",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
",VO2peak in NSCLC patients is likely principally governed by poor cardiovascular O2 delivery and oxidative capacity as well as unfavorable fiber type distribution and muscle atrophy/weakness similar to the limitations to exercise described in patients with chronic obstructive pulmonary disease (COPD).,O2,COPD,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
",VO2peak in NSCLC patients is likely principally governed by poor cardiovascular O2 delivery and oxidative capacity as well as unfavorable fiber type distribution and muscle atrophy/weakness similar to the limitations to exercise described in patients with chronic obstructive pulmonary disease (COPD).,NSCLC,COPD,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","A total of 423 patients received adjuvant chemotherapy; 324 had CMF, 99 had an anthracycline-containing regimen, and 102 patients had no adjuvant systemic therapy.",CMF,anthracycline,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","GR plasmid (pSVLGR) is a gift from Keith Yamamoto (Univ. of Cal., SF).",GR,SF,-1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","GR plasmid (pSVLGR) is a gift from Keith Yamamoto (Univ. of Cal., SF).",pSVLGR,SF,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",We recently extended the in vitro studies to a human breast carcinoma cell line and showed that cells expressing high levels of TIMP-1 protein were significantly less sensitive to treatment with etoposide and epirubicin than cells expressing low levels of TIMP-1 [27].,TIMP-1,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",We recently extended the in vitro studies to a human breast carcinoma cell line and showed that cells expressing high levels of TIMP-1 protein were significantly less sensitive to treatment with etoposide and epirubicin than cells expressing low levels of TIMP-1 [27].,TIMP-1,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",We recently extended the in vitro studies to a human breast carcinoma cell line and showed that cells expressing high levels of TIMP-1 protein were significantly less sensitive to treatment with etoposide and epirubicin than cells expressing low levels of TIMP-1 [27].,TIMP-1,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",We recently extended the in vitro studies to a human breast carcinoma cell line and showed that cells expressing high levels of TIMP-1 protein were significantly less sensitive to treatment with etoposide and epirubicin than cells expressing low levels of TIMP-1 [27].,TIMP-1,etoposide,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients should be tested for truncated Her2, as trastuzumab cannot bind to Her2-molecules lacking the extracellular domain [7].",Her2,trastuzumab,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","==== Body
Background
Therapy with anthracycline and cytarabine results in modulation of a wide range of proteins including massive p53 protein activation followed by cell cycle arrest and apoptosis [1-3].",p53,anthracycline,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","==== Body
Background
Therapy with anthracycline and cytarabine results in modulation of a wide range of proteins including massive p53 protein activation followed by cell cycle arrest and apoptosis [1-3].",p53,cytarabine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",MMP-9,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",MCP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",TIMP-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",TSP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",HCC,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","In this study, the expression of angiogenic factors such as VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in AT was significantly higher than that in normal liver and HCC tissues.",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Furthermore, two recently presented studies suggested that tumours with PTEN-loss and activated PI3-Kinase pathways may be less responsive to trastuzumab [21,22].

",PTEN,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
",Trastuzumab (rhMab4D5) is a recombinant monoclonal humanized antibody targeting the extracellular domain of Her2.,Her2,Trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the meantime, a randomized phase III study reported results, suggesting that trastuzumab in combination with capecitabine is more active than chemotherapy alone upon progression on trastuzumab-based first-line treatment in terms of response rate and progression-free survival [17].",III,capecitabine,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the meantime, a randomized phase III study reported results, suggesting that trastuzumab in combination with capecitabine is more active than chemotherapy alone upon progression on trastuzumab-based first-line treatment in terms of response rate and progression-free survival [17].",III,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the meantime, a randomized phase III study reported results, suggesting that trastuzumab in combination with capecitabine is more active than chemotherapy alone upon progression on trastuzumab-based first-line treatment in terms of response rate and progression-free survival [17].",III,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients may be switched to lapatinib, a tyrosine-kinase inhibitor of EGFR and Her2, alternatively they may continue on trastuzumab in combination with capecitabine.",EGFR,lapatinib,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients may be switched to lapatinib, a tyrosine-kinase inhibitor of EGFR and Her2, alternatively they may continue on trastuzumab in combination with capecitabine.",EGFR,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients may be switched to lapatinib, a tyrosine-kinase inhibitor of EGFR and Her2, alternatively they may continue on trastuzumab in combination with capecitabine.",EGFR,capecitabine,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients may be switched to lapatinib, a tyrosine-kinase inhibitor of EGFR and Her2, alternatively they may continue on trastuzumab in combination with capecitabine.",Her2,lapatinib,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients may be switched to lapatinib, a tyrosine-kinase inhibitor of EGFR and Her2, alternatively they may continue on trastuzumab in combination with capecitabine.",Her2,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Patients may be switched to lapatinib, a tyrosine-kinase inhibitor of EGFR and Her2, alternatively they may continue on trastuzumab in combination with capecitabine.",Her2,capecitabine,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In contrast, in a large randomized phase III study, lapatinib plus capecitabine was active upon trastuzumab failure, and patients on lapatinib had a significantly lower incidence of brain metastases [18].

",III,lapatinib,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In contrast, in a large randomized phase III study, lapatinib plus capecitabine was active upon trastuzumab failure, and patients on lapatinib had a significantly lower incidence of brain metastases [18].

",III,lapatinib,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In contrast, in a large randomized phase III study, lapatinib plus capecitabine was active upon trastuzumab failure, and patients on lapatinib had a significantly lower incidence of brain metastases [18].

",III,capecitabine,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In contrast, in a large randomized phase III study, lapatinib plus capecitabine was active upon trastuzumab failure, and patients on lapatinib had a significantly lower incidence of brain metastases [18].

",III,trastuzumab,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","However, gender seemed to be a confounding factor of OS (MST: 17 months of male vs. 26 months of female, P = 0.046) (Figure 1A), whereas age, smoking status, pack-year, histology, application of chemotherapy, and radiation dose did not.",OS,MST,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_420.txt
","All three variants, codon 48G &#62; C (rs10012), codon 119G &#62; T (rs1056827) and 432 G &#62; C (rs1056836) have been shown to result in an increased metabolism of 16a-OH-estradiol [5].",T,estradiol,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",FIGO,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",FIGO,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",FIGO,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",FIGO,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",FIGO,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",FIGO,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,paclitaxel,1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,carboplatin,1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","Table 1 Summary of clinicopathologic characteristics of the patients

	Tumours
(from survivors/deceased patients)	
Total Tumours	98 (48/50)	
	
Tumours used in QPCR analysis	30 (15/15)	
	
Mean age (years)	60 (57/62) (range 28-81)	
	
FIGO Staging		
IIIa	10 (7/3)	
IIIb	14 (7/7)	
IIIc	73 (33/40)	
IV	1 (1/0)	
	
Surgery		
Radically operated	20 (13/7)	
Residual tumour	75 (34/41)	
Not available	3 (1/2)	
	
Differentiation		
Well	15 (10/5)	
Moderate	22 (10/12)	
Poor	59 (26/33)	
Not available	2 (2/0)	
	
Treatment		
farmorubicine, carboplatin and cyclophosphamide	31 (16/15)	
paclitaxel and carboplatin	67 (32/35)	
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and carboplatin were analysed with QPCR, performed as described by Partheen et al. [7].",QPCR,paclitaxel,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","The data presented here, the first immunohistochemical evidence of AMPK dysfunction in primary breast cancer supports further laboratory and clinical research targeting AMPK by metformin or its analogues in breast cancer.

",AMPK,metformin,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","The data presented here, the first immunohistochemical evidence of AMPK dysfunction in primary breast cancer supports further laboratory and clinical research targeting AMPK by metformin or its analogues in breast cancer.

",AMPK,metformin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",DME,glutamine,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",DME,streptomycin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",DME,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",T,glutamine,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",T,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",T,penicillin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",HEK293,glutamine,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",HEK293,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",HEK293,penicillin,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Effect of Topo I expression on DFS was not shown to be statistically significant in either irinotecan treated or non-treated patients (HR = 0.76, 95% CI 0.43-1.34, wald p = 0.338 and",CI,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Effect of Topo I expression on DFS was not shown to be statistically significant in either irinotecan treated or non-treated patients (HR = 0.76, 95% CI 0.43-1.34, wald p = 0.338 and",HR,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Effect of Topo I expression on DFS was not shown to be statistically significant in either irinotecan treated or non-treated patients (HR = 0.76, 95% CI 0.43-1.34, wald p = 0.338 and",DFS,irinotecan,1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
",The latter category included NSAID preparations other than aspirin and ibuprofen.,NSAID,aspirin,1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
",The latter category included NSAID preparations other than aspirin and ibuprofen.,NSAID,ibuprofen,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After three washing steps in TTBS, blots were incubated with biotin-labeled YB-1 Mab F-D2G5 diluted 1:2,000 and StreptABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) was added.",DAKO,biotin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After three washing steps in TTBS, blots were incubated with biotin-labeled YB-1 Mab F-D2G5 diluted 1:2,000 and StreptABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) was added.",D2G5,biotin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After three washing steps in TTBS, blots were incubated with biotin-labeled YB-1 Mab F-D2G5 diluted 1:2,000 and StreptABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) was added.",YB-1,biotin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After three washing steps in TTBS, blots were incubated with biotin-labeled YB-1 Mab F-D2G5 diluted 1:2,000 and StreptABComplex diluted 1:50 (DAKO Cytomation, Glostrup, Denmark) was added.",TTBS,biotin,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Endogenous binding sites were blocked using an avidin/biotin blocking kit (Vector laboratories Inc., California, USA, catalogue number SP-2001) according to the manufacturer's protocol.",USA,biotin,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Endogenous binding sites were blocked using an avidin/biotin blocking kit (Vector laboratories Inc., California, USA, catalogue number SP-2001) according to the manufacturer's protocol.",SP-2001,biotin,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","DDCt is calculated as difference in DCt-value between the sample and the reference sample)

Western Blot analysis
For western blotting snap frozen tumour tissue was lysed in 62.5 Tris-HCl, 2% SDS, 1.5% b-mercaptoethanol, 9% glycerol, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 0.00125% bromophenol blue, cooked 10 min, with intermitting stirring, and cooled on ice.

",SDS,aprotinin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Background
This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy (NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at identification of predictive markers for the long-term outcome in noninflammatory locally advanced breast cancer (NLABC).

",NLABC,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Background
This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy (NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at identification of predictive markers for the long-term outcome in noninflammatory locally advanced breast cancer (NLABC).

",NLABC,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, among patients treated with adjuvant anthracycline-based therapy we found a highly significant association with OS both when included as a continuous (HR 4.19, 95% CI 1.67-10.51, P = 0.002) and as a dichotomized variable (HR 2.59, 95% CI 1.14-5.88, P = 0.02).",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, among patients treated with adjuvant anthracycline-based therapy we found a highly significant association with OS both when included as a continuous (HR 4.19, 95% CI 1.67-10.51, P = 0.002) and as a dichotomized variable (HR 2.59, 95% CI 1.14-5.88, P = 0.02).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, among patients treated with adjuvant anthracycline-based therapy we found a highly significant association with OS both when included as a continuous (HR 4.19, 95% CI 1.67-10.51, P = 0.002) and as a dichotomized variable (HR 2.59, 95% CI 1.14-5.88, P = 0.02).",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, among patients treated with adjuvant anthracycline-based therapy we found a highly significant association with OS both when included as a continuous (HR 4.19, 95% CI 1.67-10.51, P = 0.002) and as a dichotomized variable (HR 2.59, 95% CI 1.14-5.88, P = 0.02).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, among patients treated with adjuvant anthracycline-based therapy we found a highly significant association with OS both when included as a continuous (HR 4.19, 95% CI 1.67-10.51, P = 0.002) and as a dichotomized variable (HR 2.59, 95% CI 1.14-5.88, P = 0.02).",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In our stratified univariate analysis the prognostic value of nuclear YB-1 expression became even more pronounced in the clinically important subgroup of stage pT1/T2 tumors and breast tumors with negative progesterone receptor status, respectively.",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In our stratified univariate analysis the prognostic value of nuclear YB-1 expression became even more pronounced in the clinically important subgroup of stage pT1/T2 tumors and breast tumors with negative progesterone receptor status, respectively.",T2,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Greece2009,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Greece5,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Greece6,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Greece3,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",BMC,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Greece2,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Cancer1471,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3391977548010.1186/1471-2407-9-339Research ArticleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy Kostopoulos Ioannis 1kostop@med.auth.grKaravasilis Vasilios 2karavasv@auth.grKarina Maria 2Maria.Karina@christie.nhs.ukBobos Mattheos 1mbobos@auth.grXiros Nikolaos 3nxiros@otenet.grPentheroudakis George 4gpenther@cc.uoi.grKafiri Georgia 5th_spinari@hecog.ondsl.grPapakostas Pavlos 6oncologydepart@hippocratio.grVrettou Eleni 1evrettou@med.auth.grFountzilas George 2fountzil@auth.gr1 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece2 Department of Medical Oncology ""Papageorgiou"" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece3 Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital ""Attikon"", Athens, Greece4 Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece5 Department of Pathology, ""Ippokration"" Hospital, Athens, Greece6 Oncology Department, ""Ippokration"" Hospital, Athens, Greece2009 24 9 2009 9 339 339 20 5 2009 24 9 2009 Copyright (c)2009 Kostopoulos et al; licensee BioMed Central Ltd.2009Kostopoulos et al; licensee BioMed Central Ltd.",Greece4,irinotecan,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Tandem MS data analysis
Data dependent MS analysis was performed by acquiring one MS scan (5 microscans averaged) followed by one zoom scan (5 microscans averaged) and one MS2 on the top 5 most intense peaks.",MS2,Tandem,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 1 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH &#62; 13.,DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 1 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH &#62; 13.,PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The Mann-Whitney U test was used to determine DNA damage statistical differences between control cells and those treated with etoposide.,DNA,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",USA3,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",BMC,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",PR,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",Cancer1471,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",USA4,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",USA2010,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4182069899410.1186/1471-2407-10-418Research ArticleSurvivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition Liu Xichun 12xcliu@tulane.eduGao Ruijuan 13rgao@tulane.eduDong Yan 34ydong@tulane.eduGao Lifang 1gaolifang1357@yahoo.com.cnZhao Yanying 1yanying0609@163.comZhao Lijuan 1titan2003@sina.comZhao Xuejian 1zhaoxuejian2007@yahoo.com.cnZhang Haitao 124hzhang@tulane.edu1 Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, Norman Bethune College of Medicine, Jilin University, Xinmin Street, Changchun, 130021, PR China2 Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA3 Department of Structural and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA4 Molecular Signaling Program, Louisiana Cancer Research Consortium, 1615 Poydras Street, Suite 1000, New Orleans, LA 70112, USA2010 10 8 2010 10 418 418 7 7 2009 10 8 2010 Copyright (c)2010 Liu et al; licensee BioMed Central Ltd.2010Liu et al; licensee BioMed Central Ltd.",China2,selenium,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Single cell gel electrophoresis
SCGE at pH &#62;13, which reveals SSBs, DRSs and ALSs, revealed a dose-dependent effect of etoposide treatment (2.07, 20.7 and 207 mM) on cells treated for 2 h and 24 h (Figure 1A, B respectively).",SCGE,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","These results demonstrate oxidative DNA damage generated by etoposide in non-stimulated blood cells, among others sources of ALS generation [35].

",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","These results demonstrate oxidative DNA damage generated by etoposide in non-stimulated blood cells, among others sources of ALS generation [35].

",ALS,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",We observed an increase in DNA-damage in all etoposide treatments showing the highest effect at 207 mM with respect to the control.,DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,streptomycin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,streptomycin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,streptomycin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,penicillin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,streptomycin,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Viability
Our observations of the cells following the dual cell-stain method for PHA-stimulated and non-stimulated whole blood cells revealed that cell viability was high after etoposide treatment for 2 h and 24 h. As shown in table 1, we observed cell viability rates that exceeded 70%.

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","We performed a one way ANOVA test in order to detect if there was an effect of the etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of akali-labile sites (ALS) in stimulated and non-stimulated cells at 2 h and 24 h.

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","We performed a one way ANOVA test in order to detect if there was an effect of the etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of akali-labile sites (ALS) in stimulated and non-stimulated cells at 2 h and 24 h.

",ANOVA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Student's t test was used to compare cell viability, and Exo III recognition sites between control and etoposide-treated cells.",III,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The NPC trial showed that the protective effect of selenium was limited to patients with baseline serum selenium in the lower 2 tertiles [25].,NPC,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The NPC trial showed that the protective effect of selenium was limited to patients with baseline serum selenium in the lower 2 tertiles [25].,NPC,selenium,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 1 Patient and tumor characteristics and comparisons of patient groups

Characteristic	All patients
N (%)	CMF-treated patients
N (%)	Anthracycline-treated patients
N (%)	Untreated patients
N (%)	P1	
Age						
<= 40 years	164 (31)	110 (34)	28 (28)	26 (25)	0.212	
41-55 years	361 (69)	214 (66)	71 (72)	76 (75)		
	
Involved lymph nodes						
1-3	292 (56)	217 (67)	47 (47)	28 (27)	&#60;0.0012	
&#62;3	233 (44)	107 (33)	52 (53)	74 (73)		
	
Steroid hormone rec. status						
Positive	432 (82)	269 (83)	76 (77)	87 (85)	0.242	
",CMF,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 1 Patient and tumor characteristics and comparisons of patient groups

Characteristic	All patients
N (%)	CMF-treated patients
N (%)	Anthracycline-treated patients
N (%)	Untreated patients
N (%)	P1	
Age						
<= 40 years	164 (31)	110 (34)	28 (28)	26 (25)	0.212	
41-55 years	361 (69)	214 (66)	71 (72)	76 (75)		
	
Involved lymph nodes						
1-3	292 (56)	217 (67)	47 (47)	28 (27)	&#60;0.0012	
&#62;3	233 (44)	107 (33)	52 (53)	74 (73)		
	
Steroid hormone rec. status						
Positive	432 (82)	269 (83)	76 (77)	87 (85)	0.242	
",P1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",CMF,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Additionally, in the anthracycline-treated group high TIMP-1 was associated with a significantly shorter OS both when analyzed as a continuous variable (HR 3.52, 95% CI 1.54-8.06, P = 0.003) and as a dichotomized one (HR 2.53, 95% CI 1.19-5.39, P = 0.02) whereas no differences were observed among TIMP-1 high and low patients in the CMF-treated subgroup (Table 4, Figures 2B and 3B).

",HR,anthracycline,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,docetaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,vincristine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,ifosfamide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,oxaliplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cyclophosphamide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,everolimus,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,leucovorin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,docetaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,adriamycin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,capecitabine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,fluorouracil,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,oxaliplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,docetaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,vincristine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,ifosfamide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,oxaliplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cyclophosphamide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,everolimus,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,leucovorin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,docetaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,adriamycin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,capecitabine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,fluorouracil,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,oxaliplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",RAD001,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,docetaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,vincristine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,ifosfamide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,oxaliplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cyclophosphamide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,everolimus,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,leucovorin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,docetaxel,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,adriamycin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,capecitabine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,fluorouracil,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,oxaliplatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",EP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FU,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CAV,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",CI,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",XELOX,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TC,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TTP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",TP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",IP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FOLFOX,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",FP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,Dacarbazine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,Sunitinib,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",DC,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,vincristine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,ifosfamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,leucovorin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,docetaxel,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,adriamycin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,Dacarbazine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,capecitabine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,carboplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,fluorouracil,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,cisplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,oxaliplatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 4 Drugs which were used in the 1st line

Drugs	Number	
Interferon	15	
Somatostatin-analogues	2	
EP, EC	16	
CAV	3	
TC, TP, DP, DC	4	
VIP	6	
Adriamycin+streptozotocin	2	
FOLFOX, XELOX	2	
FP, FC	4	
IP	1	
5-FU+adriamycin+streptozocin	2	
Dacarbazine	1	
Sunitinib	5	
RAD001	3	
Total	66	
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

The median TTP after 1st-line systemic treatment was 6.0 months (95% CI, 3.3-8.7).",VIP,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The formulation and dose of selenium used in the SELECT study have also been hot topics of debate.,SELECT,selenium,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
",AMD: AMD3100; inf: infliximab.,AMD3100,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
",AMD: AMD3100; inf: infliximab.,AMD,infliximab,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In a similar comparison nuclear YB-1 protein was not detectable in most progesterone receptor positive breast tumours (Figure 7C), while there was prominent nuclear YB-1 staining in most tumors with negative progesterone receptor status (D).

",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In a similar comparison nuclear YB-1 protein was not detectable in most progesterone receptor positive breast tumours (Figure 7C), while there was prominent nuclear YB-1 staining in most tumors with negative progesterone receptor status (D).

",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In a similar comparison nuclear YB-1 protein was not detectable in most progesterone receptor positive breast tumours (Figure 7C), while there was prominent nuclear YB-1 staining in most tumors with negative progesterone receptor status (D).

",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In a similar comparison nuclear YB-1 protein was not detectable in most progesterone receptor positive breast tumours (Figure 7C), while there was prominent nuclear YB-1 staining in most tumors with negative progesterone receptor status (D).

",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The membrane was immersed in 5% nonfat dry milk in PBS-Tween for 30 min, and probed with tissue inhibitor of metalloproteinase 1 (TIMP1) antibody (1:500; MAB3300, Millipore, Temecula, CA) or CD90 antibody (1:500; 5E10, BD-PharMingen, San Diego, CA) for 60 min, followed by horseradish peroxidase conjugated anti-mouse IgG.",PBS,BD,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The membrane was immersed in 5% nonfat dry milk in PBS-Tween for 30 min, and probed with tissue inhibitor of metalloproteinase 1 (TIMP1) antibody (1:500; MAB3300, Millipore, Temecula, CA) or CD90 antibody (1:500; 5E10, BD-PharMingen, San Diego, CA) for 60 min, followed by horseradish peroxidase conjugated anti-mouse IgG.",CD90,BD,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The membrane was immersed in 5% nonfat dry milk in PBS-Tween for 30 min, and probed with tissue inhibitor of metalloproteinase 1 (TIMP1) antibody (1:500; MAB3300, Millipore, Temecula, CA) or CD90 antibody (1:500; 5E10, BD-PharMingen, San Diego, CA) for 60 min, followed by horseradish peroxidase conjugated anti-mouse IgG.",MAB3300,BD,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The membrane was immersed in 5% nonfat dry milk in PBS-Tween for 30 min, and probed with tissue inhibitor of metalloproteinase 1 (TIMP1) antibody (1:500; MAB3300, Millipore, Temecula, CA) or CD90 antibody (1:500; 5E10, BD-PharMingen, San Diego, CA) for 60 min, followed by horseradish peroxidase conjugated anti-mouse IgG.",San,BD,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The membrane was immersed in 5% nonfat dry milk in PBS-Tween for 30 min, and probed with tissue inhibitor of metalloproteinase 1 (TIMP1) antibody (1:500; MAB3300, Millipore, Temecula, CA) or CD90 antibody (1:500; 5E10, BD-PharMingen, San Diego, CA) for 60 min, followed by horseradish peroxidase conjugated anti-mouse IgG.",TIMP1,BD,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","It has been postulated that the anti-neoplastic effects of statins could be attributed to their ability to increase HMG-CoAR activity in tumour cells, thus leading to the production of non-sterol bi-products of the mevalonate pathway [2].",HMG,sterol,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Tandem mass spectra of proteotypic peptides, most commonly generated on quadrupole or 3D ion trap instruments, have been collected so far in databases such as PeptideAtlas [32], GPM [33] and PRIDE [34].",GPM,Tandem,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Tandem mass spectra of proteotypic peptides, most commonly generated on quadrupole or 3D ion trap instruments, have been collected so far in databases such as PeptideAtlas [32], GPM [33] and PRIDE [34].",PRIDE,Tandem,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",EDTA,deoxycholic acid,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",EDTA,bestatin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",EDTA,aprotinin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",EDTA,pepstatin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",AEBSF,deoxycholic acid,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",AEBSF,bestatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",AEBSF,aprotinin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",AEBSF,pepstatin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",E-64,deoxycholic acid,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",E-64,bestatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",E-64,aprotinin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",E-64,pepstatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",PBS,deoxycholic acid,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",PBS,bestatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",PBS,aprotinin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",PBS,pepstatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",RIPA,deoxycholic acid,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",RIPA,bestatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",RIPA,aprotinin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",RIPA,pepstatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",NP-40,deoxycholic acid,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",NP-40,bestatin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",NP-40,aprotinin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","At 70% confluence the cells were harvested, rinsed three times with phosphate buffer saline (PBS), and lysed by rocking at 4degC (2 h) with a lysis solution prepared from 1 mL RIPA buffer (500 mM TrisHCl pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid, 10 mM EDTA), 100 mL protease inhibitor cocktail (104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), phosphatase inhibitors [100 mL NaF (~100 mM) and 50 mL Na3VO4 (~200 mM)], and 8.75 mL of ice cold water.",NP-40,pepstatin,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In each TMA block, 7 cores in total, from thyroid, skin and tonsil tissue were included as controls of immunostaining, block orientation and alignment.

",TMA,thyroid,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In comparison to the results of NSABP B-27 as reported by Bear et al. [26], the VE regimen in our study reached a higher pCR rate than the AC regimen (12.6%), and a lower rate than AC following docetaxel treatment(26.1%).",AC,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In comparison to the results of NSABP B-27 as reported by Bear et al. [26], the VE regimen in our study reached a higher pCR rate than the AC regimen (12.6%), and a lower rate than AC following docetaxel treatment(26.1%).",NSABP,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In comparison to the results of NSABP B-27 as reported by Bear et al. [26], the VE regimen in our study reached a higher pCR rate than the AC regimen (12.6%), and a lower rate than AC following docetaxel treatment(26.1%).",AC,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In comparison to the results of NSABP B-27 as reported by Bear et al. [26], the VE regimen in our study reached a higher pCR rate than the AC regimen (12.6%), and a lower rate than AC following docetaxel treatment(26.1%).",B-27,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In comparison to the results of NSABP B-27 as reported by Bear et al. [26], the VE regimen in our study reached a higher pCR rate than the AC regimen (12.6%), and a lower rate than AC following docetaxel treatment(26.1%).",pCR,docetaxel,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",pACC,Rapamycin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",pACC,Adenosine,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",mTOR,Rapamycin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",mTOR,Adenosine,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",LCFA,Rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",LCFA,Adenosine,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",NCRI,Rapamycin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",NCRI,Adenosine,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",TBS,Rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",TBS,Adenosine,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",IHC,Rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",IHC,Adenosine,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",pAMPK,Rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.

",pAMPK,Adenosine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,cytarabine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,etoposide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,etoposide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,melphalan,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BEAM,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,cytarabine,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,melphalan,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,cytarabine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,etoposide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,etoposide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,melphalan,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",BCNU,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,cytarabine,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,melphalan,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",CBV,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,cytarabine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,etoposide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,melphalan,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,carmustine,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",PBSCT,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,cytarabine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,etoposide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,melphalan,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,carmustine,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,cytarabine,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,etoposide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,carmustine,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,melphalan,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,carmustine,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CBV: cyclophosphamide (1500 mg/m2) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU - 450 mg/m2) given only 1 day before the transplantation (day minus 6) + etoposide (VP-16 - 250 mg/m2) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU - 300 mg/m2) given only 1 day before the transplantation (day minus 7) + etoposide (VP-16 - 200 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m2) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m2) given only 1 day before the transplantation (day minus 6) for Hodgkin and non-Hodgkin lymphomas in autologous PBSCT.",VP-16,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","FluCy: fludarabine (30 mg/m2) + cyclophosphamide (300 mg/m2), both given 3 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2) for Hodgkin and non-Hodgkin lymphomas in allogeneic BMT.",BMT,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","FluCy: fludarabine (30 mg/m2) + cyclophosphamide (300 mg/m2), both given 3 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2) for Hodgkin and non-Hodgkin lymphomas in allogeneic BMT.",BMT,fludarabine,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","qRT-PCR was also used as classifier to distinguish between a set of few genes [26,30] and gene trios [29], which were able to classify thyroid nodules correctly in between 83 and 96,7%.",PCR,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","qRT-PCR was also used as classifier to distinguish between a set of few genes [26,30] and gene trios [29], which were able to classify thyroid nodules correctly in between 83 and 96,7%.",qRT,thyroid,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","BuCy200: busulphan (1 mg/kg), given 3 consecutive days four times a day, starting 9 days before the transplantation (days minus 9 to minus 7) + cyclophosphamide (50 mg/m2), given 4 consecutive days, starting 6 days before the transplantation (days minus 6 to minus 3) for aplastic anemia in allogeneic BMT.",BMT,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","BuCy200: busulphan (1 mg/kg), given 3 consecutive days four times a day, starting 9 days before the transplantation (days minus 9 to minus 7) + cyclophosphamide (50 mg/m2), given 4 consecutive days, starting 6 days before the transplantation (days minus 6 to minus 3) for aplastic anemia in allogeneic BMT.",BuCy200,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CyTBI: cyclophosphamide (60 mg/m2), given 2 consecutive days, starting 7 days before the transplantation (days minus 7 to minus 6) + total body irradiation, carried out on 4 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2, three times a day and day minus 1, two times a day) for acute and chronic lymphoid leukemia in autologous PBSCT or allogeneic BMT.",BMT,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","CyTBI: cyclophosphamide (60 mg/m2), given 2 consecutive days, starting 7 days before the transplantation (days minus 7 to minus 6) + total body irradiation, carried out on 4 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2, three times a day and day minus 1, two times a day) for acute and chronic lymphoid leukemia in autologous PBSCT or allogeneic BMT.",PBSCT,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT.,PBSCT,melphalan,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT.,M-200,melphalan,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT.,BMT,melphalan,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Finally, patients were included in the present study based on the availability of information about TIMP-1 concentration in the primary tissue, originally measured in stored cytosolic extracts after estrogen and progesterone receptor (ER/PgR) determination and used for a previous study [14].

",TIMP-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Finally, patients were included in the present study based on the availability of information about TIMP-1 concentration in the primary tissue, originally measured in stored cytosolic extracts after estrogen and progesterone receptor (ER/PgR) determination and used for a previous study [14].

",ER,progesterone,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C is a powerful reducing agent and an important water-soluble vitamin for humans and it can scavenge O2*-, H2O2, OH*, aqueous peroxy radicals and singlet oxygen.",H2O2,Vitamin C,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","We then performed separate multivariable survival analyses in anthracycline-treated and in CMF-treated patients, respectively (Table 5 and 6).",CMF,anthracycline,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",CXCR4,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",CXCR4,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",HGC27,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",HGC27,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",PAI-,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",MKN45,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Other results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after infection with H. pylori 26695 (cag PAI+ ) or Tx30a (cag PAI- ); The induction of CXCR4 expression by H. pylori was inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45 cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27 cells after transfection with TNF-a RNAi plasmid.",MKN45,infliximab,1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Coro"": Ana Isabel de la Torre, Sandra Aguilar; Gyneco-obstetric Hospital ""America Arias"": Juan M. Ariosa; National Center for Toxicology: Dianci Medina, Felix Valdez, Orlando Perez; ""Cerro Pediatric Hospital"": Teresita la Pena, Ibis Capiro; Gyneco-obstetric Teaching Hospital 10 de Octubre: Iris Amores, Isabel Mendez Hernandez, Beatriz Lora Tellez; Gyneco-obstetric Teaching Hospital ""Eusebio Hernandez"": Kenia Aguilar; General Hospital ""Julio Trigo"": Elena Gutierrez; General Hospital ""Carlos Manuel de Cespedes"", Bayamo: Leonardo Gonzalez, Yarine Fajardo; Maternity Hospital of Sancti Spiritus: Rafael Perez; Ministry of Public Health of Cuba (MINSAP): Maria Cecilia Santana, Evelio Cabezas, Blanca Manzano; Center for Genetic Engineer and Biotechnology (CIGB): Alberto Cintado, Dunia Gomez, Osvaldo Reyes, Hilda Garay, Dania Bacardi, Karelia Cosme, Marisol Cruz, Elizeth Garcia, Silvia Barcelona, Ernesto Lopez.

",MINSAP,Maternity,-1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Coro"": Ana Isabel de la Torre, Sandra Aguilar; Gyneco-obstetric Hospital ""America Arias"": Juan M. Ariosa; National Center for Toxicology: Dianci Medina, Felix Valdez, Orlando Perez; ""Cerro Pediatric Hospital"": Teresita la Pena, Ibis Capiro; Gyneco-obstetric Teaching Hospital 10 de Octubre: Iris Amores, Isabel Mendez Hernandez, Beatriz Lora Tellez; Gyneco-obstetric Teaching Hospital ""Eusebio Hernandez"": Kenia Aguilar; General Hospital ""Julio Trigo"": Elena Gutierrez; General Hospital ""Carlos Manuel de Cespedes"", Bayamo: Leonardo Gonzalez, Yarine Fajardo; Maternity Hospital of Sancti Spiritus: Rafael Perez; Ministry of Public Health of Cuba (MINSAP): Maria Cecilia Santana, Evelio Cabezas, Blanca Manzano; Center for Genetic Engineer and Biotechnology (CIGB): Alberto Cintado, Dunia Gomez, Osvaldo Reyes, Hilda Garay, Dania Bacardi, Karelia Cosme, Marisol Cruz, Elizeth Garcia, Silvia Barcelona, Ernesto Lopez.

",CIGB,Maternity,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Sarcosine dehydrogenase (SARDH), involved in the conversion of betaine to glycine, also had significantly higher expression levels in the basal-like model.

",SARDH,betaine,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the irinotecan-treated subgroup, those patients who expressed Topo I had a better OS (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).

",HR,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the irinotecan-treated subgroup, those patients who expressed Topo I had a better OS (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).

",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the irinotecan-treated subgroup, those patients who expressed Topo I had a better OS (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).

",OS,irinotecan,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","To further define the HCCR-1 signaling pathway in pancreatic cancer cells, either PI3-kinase inhibitor (LY294002) or mTOR inhibitor (rapamycin) was pre-treated on PANC-1 cells and then they were re-stimulated with EGF.",PANC-1,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","To further define the HCCR-1 signaling pathway in pancreatic cancer cells, either PI3-kinase inhibitor (LY294002) or mTOR inhibitor (rapamycin) was pre-treated on PANC-1 cells and then they were re-stimulated with EGF.",mTOR,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","To further define the HCCR-1 signaling pathway in pancreatic cancer cells, either PI3-kinase inhibitor (LY294002) or mTOR inhibitor (rapamycin) was pre-treated on PANC-1 cells and then they were re-stimulated with EGF.",EGF,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","To further define the HCCR-1 signaling pathway in pancreatic cancer cells, either PI3-kinase inhibitor (LY294002) or mTOR inhibitor (rapamycin) was pre-treated on PANC-1 cells and then they were re-stimulated with EGF.",LY294002,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","To further define the HCCR-1 signaling pathway in pancreatic cancer cells, either PI3-kinase inhibitor (LY294002) or mTOR inhibitor (rapamycin) was pre-treated on PANC-1 cells and then they were re-stimulated with EGF.",HCCR-1,rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, in analyses of OS there was a statistically significant interaction between TIMP-1 and anthracycline treatment both in a model including only adjuvant therapy and TIMP-1 (HR 3.60, 95% CI 1.38-9.38, P = 0.009) and in the model including age, tumor size and malignancy grade (HR 3.20, 95% CI 1.26-8.12, P = 0.014).

",CI,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The interaction analysis which showed a statistically significant association between TIMP-1 and anthracycline therapy in the analyses of OS further suggests that high levels of tumor tissue TIMP-1 are predictive of reduced benefit from adjuvant anthracycline-based therapy.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The interaction analysis which showed a statistically significant association between TIMP-1 and anthracycline therapy in the analyses of OS further suggests that high levels of tumor tissue TIMP-1 are predictive of reduced benefit from adjuvant anthracycline-based therapy.

",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The interaction analysis which showed a statistically significant association between TIMP-1 and anthracycline therapy in the analyses of OS further suggests that high levels of tumor tissue TIMP-1 are predictive of reduced benefit from adjuvant anthracycline-based therapy.

",OS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The interaction analysis which showed a statistically significant association between TIMP-1 and anthracycline therapy in the analyses of OS further suggests that high levels of tumor tissue TIMP-1 are predictive of reduced benefit from adjuvant anthracycline-based therapy.

",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The interaction analysis which showed a statistically significant association between TIMP-1 and anthracycline therapy in the analyses of OS further suggests that high levels of tumor tissue TIMP-1 are predictive of reduced benefit from adjuvant anthracycline-based therapy.

",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The interaction analysis which showed a statistically significant association between TIMP-1 and anthracycline therapy in the analyses of OS further suggests that high levels of tumor tissue TIMP-1 are predictive of reduced benefit from adjuvant anthracycline-based therapy.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","While heparanase expression was not found in normal bladder tissue, low HYAL-1 hyaluronidase expression was found in normal bladder tissue compared to tumor tissue [8,9].",HYAL-1,hyaluronidase,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Statistical analysis
Time to disease progression (TTP) on the second trastuzumab-based regimen for metastatic disease was defined as primary study endpoint.",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The objective of this study is to investigate whether survivin gene silencing in conjunction with selenium treatment could enhance the therapeutic efficacy for prostate cancer and to elucidate the underlying mechanisms.

",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Other genes related to the degradation of PtdCho, such as lecithin-cholesterol acetyltransferase (LCAT) and phosphatidylserine synthase 1 (PTDSS1) also had significantly higher expression levels in the basal-like than in the luminal-like model.",PTDSS1,lecithin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Other genes related to the degradation of PtdCho, such as lecithin-cholesterol acetyltransferase (LCAT) and phosphatidylserine synthase 1 (PTDSS1) also had significantly higher expression levels in the basal-like than in the luminal-like model.",PTDSS1,cholesterol,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Other genes related to the degradation of PtdCho, such as lecithin-cholesterol acetyltransferase (LCAT) and phosphatidylserine synthase 1 (PTDSS1) also had significantly higher expression levels in the basal-like than in the luminal-like model.",LCAT,lecithin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Other genes related to the degradation of PtdCho, such as lecithin-cholesterol acetyltransferase (LCAT) and phosphatidylserine synthase 1 (PTDSS1) also had significantly higher expression levels in the basal-like than in the luminal-like model.",LCAT,cholesterol,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","We have recently shown that automated quantitation of estrogen receptor (ER) immunostaining yields results that do not differ from human scoring against dextran-coated charcoal biochemical assay and the most important clinico-pathologic correlate, patient outcome [28].",ER,charcoal,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Furthermore, enzyme inhibition can lead to accumulation of its substrate, 5-aminolevulinate (ALA), in the blood, which in turn can intensify oxidative stress by generating carbon-centered reactive species or by releasing iron from proteins such as ferritin [28].

",ALA,iron,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","HBME-1, galectin-3 and CK19 were the markers most frequently referred to in literature and most commonly used for differentiating benign from malignant thyroid tumours.",HBME-1,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","HBME-1, galectin-3 and CK19 were the markers most frequently referred to in literature and most commonly used for differentiating benign from malignant thyroid tumours.",CK19,thyroid,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","101 patients had concomitant CIS during follow-up and of these 38 patients received BCG immunotherapy.

",CIS,BCG,-1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
","Long term use of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) has been found to confer protection against CRC [43,44].",NSAID,aspirin,-1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
","Long term use of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) has been found to confer protection against CRC [43,44].",CRC,aspirin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F-12,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F-12,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F-12,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",SCC-4,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",SCC-4,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",SCC-4,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",AMOL,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",AMOL,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",AMOL,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",NEAA,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",NEAA,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",NEAA,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",FBS,streptomycin,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",FBS,penicillin,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",FBS,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",HSC2,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",HSC2,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",HSC2,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F12,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F12,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F12,glutamine,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",NCIC,doxorubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",NCIC,doxorubicin,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",NCIC,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",III,doxorubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",III,doxorubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",III,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",MA8,doxorubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",MA8,doxorubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Only one phase III randomized trial of MA8, conducted by the National Cancer Institute of Canada (NCIC) in 2000, compared single-agent doxorubicin with the combination of vinorelbine plus doxorubicin in metastatic breast cancer, and failed to show any added effect for the combination[9].",MA8,vinorelbine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Sections were then incubated with a mixture of terminal deoxynucleotidyl transferase (TdT) solution and biotin-dUTP solution in a humidified chamber at 37degC for 60 min, followed by washing with PBS and incubation with peroxidase-conjugated streptavidin in a humidified chamber for 30 min at room temperature.",PBS,biotin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Sections were then incubated with a mixture of terminal deoxynucleotidyl transferase (TdT) solution and biotin-dUTP solution in a humidified chamber at 37degC for 60 min, followed by washing with PBS and incubation with peroxidase-conjugated streptavidin in a humidified chamber for 30 min at room temperature.",dUTP,biotin,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Reversal of 14-3-3s silencing following demethylation of CpG island
To further investigate whether CpG island methylation is the principal mechanism leading to 14-3-3s silencing in NHEM and melanoma cell lines, we treated NHEM, LOX and WM266-4 with the demethylating agent, 5-aza-2'-deoxycytidine (DAC), alone or combined with the histone deacetylase inhibitor (HDACi), Trichostatin A (TSA).",NHEM,Trichostatin,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Reversal of 14-3-3s silencing following demethylation of CpG island
To further investigate whether CpG island methylation is the principal mechanism leading to 14-3-3s silencing in NHEM and melanoma cell lines, we treated NHEM, LOX and WM266-4 with the demethylating agent, 5-aza-2'-deoxycytidine (DAC), alone or combined with the histone deacetylase inhibitor (HDACi), Trichostatin A (TSA).",DAC,Trichostatin,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Reversal of 14-3-3s silencing following demethylation of CpG island
To further investigate whether CpG island methylation is the principal mechanism leading to 14-3-3s silencing in NHEM and melanoma cell lines, we treated NHEM, LOX and WM266-4 with the demethylating agent, 5-aza-2'-deoxycytidine (DAC), alone or combined with the histone deacetylase inhibitor (HDACi), Trichostatin A (TSA).",WM266,Trichostatin,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Reversal of 14-3-3s silencing following demethylation of CpG island
To further investigate whether CpG island methylation is the principal mechanism leading to 14-3-3s silencing in NHEM and melanoma cell lines, we treated NHEM, LOX and WM266-4 with the demethylating agent, 5-aza-2'-deoxycytidine (DAC), alone or combined with the histone deacetylase inhibitor (HDACi), Trichostatin A (TSA).",NHEM,Trichostatin,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Reversal of 14-3-3s silencing following demethylation of CpG island
To further investigate whether CpG island methylation is the principal mechanism leading to 14-3-3s silencing in NHEM and melanoma cell lines, we treated NHEM, LOX and WM266-4 with the demethylating agent, 5-aza-2'-deoxycytidine (DAC), alone or combined with the histone deacetylase inhibitor (HDACi), Trichostatin A (TSA).",TSA,Trichostatin,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Reversal of 14-3-3s silencing following demethylation of CpG island
To further investigate whether CpG island methylation is the principal mechanism leading to 14-3-3s silencing in NHEM and melanoma cell lines, we treated NHEM, LOX and WM266-4 with the demethylating agent, 5-aza-2'-deoxycytidine (DAC), alone or combined with the histone deacetylase inhibitor (HDACi), Trichostatin A (TSA).",LOX,Trichostatin,-1
"PMC 
BMC_Cancer_2010_Apr_8_10_133.txt
","Immunohistochemistry (IHC)
IHC studies were performed using a standard streptavidin-biotin-peroxidase complex method [22].",IHC,biotin,1
"PMC 
BMC_Cancer_2010_Apr_8_10_133.txt
","Immunohistochemistry (IHC)
IHC studies were performed using a standard streptavidin-biotin-peroxidase complex method [22].",IHC,biotin,1
"PMC 
BMC_Cancer_2010_Apr_13_10_138.txt
","PCR products were loaded on 2.5% agarose gel and 6% poly-acrylamide gel, stained with silver nitrate dyes and visualized under UV illumination.

",PCR,acrylamide,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Tumor tissue, normal matched mucosa and saliva were obtained from 74 patients consecutively diagnosed with primary untreated HNSCC between April 2005 and April 2007 in our institution.",HNSCC,April,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Tumor tissue, normal matched mucosa and saliva were obtained from 74 patients consecutively diagnosed with primary untreated HNSCC between April 2005 and April 2007 in our institution.",HNSCC,April,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",VNTR,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1B,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1RN,progesterone,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1A,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1RN,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",VNTR,progesterone,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In general, the apoptosis data are in agreement with the MTT results, showing that survivin gene knockdown greatly enhances the anticancer effect of selenium in prostate cancer cells.

",MTT,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In general, the apoptosis data are in agreement with the MTT results, showing that survivin gene knockdown greatly enhances the anticancer effect of selenium in prostate cancer cells.

",survivin,selenium,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
",Figure 1 Selenium speciation of the SeSp extract using HPLC/ICP-MS.,HPLC,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
",Figure 1 Selenium speciation of the SeSp extract using HPLC/ICP-MS.,ICP,Selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","These results demonstrate a strong inhibitory effect on tumor growth in vivo by the combination of survivin knockdown and selenium treatment.

",survivin,selenium,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1B,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1B,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",pT2,progesterone,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1RN,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",E1,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",VNTR,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1A,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",pT1,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Secondary endpoints consisted of response rate, time to progression on first-line trastuzumab-based therapy, cardiac toxicity, incidence of brain-metastases, and overall survival (OS).",OS,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1B,progesterone,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1RN,progesterone,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1B,progesterone,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1A,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
","The lifestyle questionnaire included this question regarding use of NSAID: ""Have you taken more than one pain relieving pill per month during the last year?"" If the answer was yes, the participant was asked to record how frequently they took each of the following medications: ""Aspirin"", ""Paracetamol"", ""Ibuprofen"", or ""Other pain relievers"".",NSAID,Ibuprofen,1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
","The lifestyle questionnaire included this question regarding use of NSAID: ""Have you taken more than one pain relieving pill per month during the last year?"" If the answer was yes, the participant was asked to record how frequently they took each of the following medications: ""Aspirin"", ""Paracetamol"", ""Ibuprofen"", or ""Other pain relievers"".",NSAID,Aspirin,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Until now QPRT has not been described in human thyroid tissue.

",QPRT,thyroid,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",PC-3,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",PC-3,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",PC-3,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",CO2,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",CO2,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",CO2,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",FBS,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",FBS,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",FBS,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",C4,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",C4,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",C4,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",RPMI,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",RPMI,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 unit/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM of L-glutamine and incubated at 37degC in 5% CO2.",RPMI,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",Different techniques such as global gene expression analysis and SAGE-analysis have been used to define follicular thyroid carcinoma (see Additional file 2). [25-30] The authors cited above validated the established gene expression or SAGE-results by qRT-PCR.,SAGE,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",Different techniques such as global gene expression analysis and SAGE-analysis have been used to define follicular thyroid carcinoma (see Additional file 2). [25-30] The authors cited above validated the established gene expression or SAGE-results by qRT-PCR.,qRT,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",Different techniques such as global gene expression analysis and SAGE-analysis have been used to define follicular thyroid carcinoma (see Additional file 2). [25-30] The authors cited above validated the established gene expression or SAGE-results by qRT-PCR.,SAGE,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",Different techniques such as global gene expression analysis and SAGE-analysis have been used to define follicular thyroid carcinoma (see Additional file 2). [25-30] The authors cited above validated the established gene expression or SAGE-results by qRT-PCR.,PCR,thyroid,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Inhibition of tumor growth in vivo by survivin knockdown and selenium
A xenograft nude mouse tumor model with subcutaneously implanted PC-3M cells was used to investigate the effects of survivin knockdown and selenium in vivo.",survivin,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Inhibition of tumor growth in vivo by survivin knockdown and selenium
A xenograft nude mouse tumor model with subcutaneously implanted PC-3M cells was used to investigate the effects of survivin knockdown and selenium in vivo.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Inhibition of tumor growth in vivo by survivin knockdown and selenium
A xenograft nude mouse tumor model with subcutaneously implanted PC-3M cells was used to investigate the effects of survivin knockdown and selenium in vivo.",PC-3,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Inhibition of tumor growth in vivo by survivin knockdown and selenium
A xenograft nude mouse tumor model with subcutaneously implanted PC-3M cells was used to investigate the effects of survivin knockdown and selenium in vivo.",PC-3,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Inhibition of tumor growth in vivo by survivin knockdown and selenium
A xenograft nude mouse tumor model with subcutaneously implanted PC-3M cells was used to investigate the effects of survivin knockdown and selenium in vivo.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Inhibition of tumor growth in vivo by survivin knockdown and selenium
A xenograft nude mouse tumor model with subcutaneously implanted PC-3M cells was used to investigate the effects of survivin knockdown and selenium in vivo.",survivin,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","As shown in Figure 3, choline dehydrogenase (CHDH) mediates the irreversible conversion of choline to betaine, which is a key precursor in the synthesis of glycine.",CHDH,betaine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Consistent with the in vitro results, selenium by itself has a modest inhibitory effect on the growth of PC-3M xenografts, but the combination with survivin knockdown achieved a robust growth inhibition.",PC-3,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Consistent with the in vitro results, selenium by itself has a modest inhibitory effect on the growth of PC-3M xenografts, but the combination with survivin knockdown achieved a robust growth inhibition.",survivin,selenium,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses whether oxidative stress was responsible for the DNA damage observed in the etoposide-treated non-stimulated cells, we used the SCGE assay in combination with Exo III, an enzyme that recognizes AP sites in DNA.",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses whether oxidative stress was responsible for the DNA damage observed in the etoposide-treated non-stimulated cells, we used the SCGE assay in combination with Exo III, an enzyme that recognizes AP sites in DNA.",III,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses whether oxidative stress was responsible for the DNA damage observed in the etoposide-treated non-stimulated cells, we used the SCGE assay in combination with Exo III, an enzyme that recognizes AP sites in DNA.",SCGE,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses whether oxidative stress was responsible for the DNA damage observed in the etoposide-treated non-stimulated cells, we used the SCGE assay in combination with Exo III, an enzyme that recognizes AP sites in DNA.",DNA,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In the study by Azrak et al which showed MSA did not inhibit survivin expression in skov3 ovarian cancer cells, survivin knockdown greatly enhanced the efficacy of combination therapy by MSA and paclitaxel, converting the interaction between these two agents from antagonistic to synergistic [34].

",MSA,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In the study by Azrak et al which showed MSA did not inhibit survivin expression in skov3 ovarian cancer cells, survivin knockdown greatly enhanced the efficacy of combination therapy by MSA and paclitaxel, converting the interaction between these two agents from antagonistic to synergistic [34].

",survivin,paclitaxel,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In the study by Azrak et al which showed MSA did not inhibit survivin expression in skov3 ovarian cancer cells, survivin knockdown greatly enhanced the efficacy of combination therapy by MSA and paclitaxel, converting the interaction between these two agents from antagonistic to synergistic [34].

",MSA,paclitaxel,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In the study by Azrak et al which showed MSA did not inhibit survivin expression in skov3 ovarian cancer cells, survivin knockdown greatly enhanced the efficacy of combination therapy by MSA and paclitaxel, converting the interaction between these two agents from antagonistic to synergistic [34].

",survivin,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",The 5-year DFS and OS were inferior to AC or AC following docetaxel arm in the Bear study.,AC,docetaxel,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",The 5-year DFS and OS were inferior to AC or AC following docetaxel arm in the Bear study.,AC,docetaxel,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",The 5-year DFS and OS were inferior to AC or AC following docetaxel arm in the Bear study.,OS,docetaxel,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",The 5-year DFS and OS were inferior to AC or AC following docetaxel arm in the Bear study.,DFS,docetaxel,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) was estimated as described by Galley et al.",VIT,Vitamin C,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","DNA was isolated from primary fresh-frozen tumor tissue by guanidine thiocyanate extraction using the commercially available IsoQuick kit (MicroProbe, Garden Grove, CA) as we have described previously [20].",DNA,guanidine,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","FACS and cell counting
Cells (grown with 0.1 mg/ml G418) were washed 3 times with PBS without calcium or magnesium (Invitrogen), counted with a Beckman Coulter Vi-Cell XR2.02, and seeded at 50,000 viable cells/well in 6 well dishes in 3 ml of medium without G418.",G418,magnesium,-1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","FACS and cell counting
Cells (grown with 0.1 mg/ml G418) were washed 3 times with PBS without calcium or magnesium (Invitrogen), counted with a Beckman Coulter Vi-Cell XR2.02, and seeded at 50,000 viable cells/well in 6 well dishes in 3 ml of medium without G418.",G418,magnesium,-1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","FACS and cell counting
Cells (grown with 0.1 mg/ml G418) were washed 3 times with PBS without calcium or magnesium (Invitrogen), counted with a Beckman Coulter Vi-Cell XR2.02, and seeded at 50,000 viable cells/well in 6 well dishes in 3 ml of medium without G418.",FACS,magnesium,-1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","FACS and cell counting
Cells (grown with 0.1 mg/ml G418) were washed 3 times with PBS without calcium or magnesium (Invitrogen), counted with a Beckman Coulter Vi-Cell XR2.02, and seeded at 50,000 viable cells/well in 6 well dishes in 3 ml of medium without G418.",PBS,magnesium,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Conclusion
These data suggest that the 180-gene GEPR will be a valuable clinical tool in determining who should receive cetuximab therapy in metastatic colorectal cancer, perhaps best used in combination with KRAS status.",GEPR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Conclusion
These data suggest that the 180-gene GEPR will be a valuable clinical tool in determining who should receive cetuximab therapy in metastatic colorectal cancer, perhaps best used in combination with KRAS status.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Although the interim analysis of the Selenium and Vitamin E Chemoprevention Trial (SELECT) indicated no reduction in prostate cancer risk associated with selenium supplementation [11], the finding should not be simply interpreted as selenium is ineffective against prostate cancer.",SELECT,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Although the interim analysis of the Selenium and Vitamin E Chemoprevention Trial (SELECT) indicated no reduction in prostate cancer risk associated with selenium supplementation [11], the finding should not be simply interpreted as selenium is ineffective against prostate cancer.",SELECT,Vitamin E,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Although the interim analysis of the Selenium and Vitamin E Chemoprevention Trial (SELECT) indicated no reduction in prostate cancer risk associated with selenium supplementation [11], the finding should not be simply interpreted as selenium is ineffective against prostate cancer.",SELECT,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Although the interim analysis of the Selenium and Vitamin E Chemoprevention Trial (SELECT) indicated no reduction in prostate cancer risk associated with selenium supplementation [11], the finding should not be simply interpreted as selenium is ineffective against prostate cancer.",SELECT,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 3 Percentage of ALS relative to controls after 2-h and 24-h of etoposide treatment for both non-stimulated and PHA stimulated blood cells.,ALS,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 3 Percentage of ALS relative to controls after 2-h and 24-h of etoposide treatment for both non-stimulated and PHA stimulated blood cells.,PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",F3,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",SCGE,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",SCGE,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",ANOVA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",ANOVA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Control cells differed from etoposide-treated cells in all conditions except in PHA-stimulated cells treated for 24 h. The ANOVA analysis showed that there was a significant effect of etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of ALS in all treatments: 2 h non-stimulated (F3 = 442.97, P &#60; 0.0000), 24 h non-stimulated (F3 = 246.66, P &#60; 0.0000) 2 h stimulated (F3 = 50.35,&#62; P &#60; 0000) 24 h stimulated (F3 = 9.52, P &#60; 0.01).; these findings were consistent with the SCGE data (Figure 3).

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative regions of the blocks were identified on the H&E-stained sections and cylindrical tissue cores (1 mm in diameter) were prepared using a tissue microarray constructor (Beecher Instruments MTA-1, Silver Spring, MD, USA).",MTA-1,Silver,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative regions of the blocks were identified on the H&E-stained sections and cylindrical tissue cores (1 mm in diameter) were prepared using a tissue microarray constructor (Beecher Instruments MTA-1, Silver Spring, MD, USA).",USA,Silver,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,III,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in Figure 3, non-stimulated whole blood cells had higher ALS index values than PHA-stimulated cells treated with etoposide.",ALS,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in Figure 3, non-stimulated whole blood cells had higher ALS index values than PHA-stimulated cells treated with etoposide.",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",III,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",DCR,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",DCR,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",ORR,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",ORR,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,Somatostatin,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","All patients received adjuvant 5-FU-based chemotherapy, 38% irinotecan-containing.",FU,irinotecan,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","The base medium for hFOB1.19 was a 1:1 mixture of Ham's F12 Medium Dulbecco's Modified Eagle's Medium, with 2.5 mM L-glutamine (without phenol red).",F12,glutamine,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","The transrectal ultrasound guided biopsies (TRUS) of the prostate were performed under local anesthesia with xilocaine gel using the biopsy system ASAP(tm) with Channel Cut(tm) 18 GA needles (length 21 cm with a cutting channel of 17 mm); at least six cylinders were obtained from each patient, this number corresponds to the sextant technique, a standard method practiced in Mexico.",TRUS,xilocaine,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","The transrectal ultrasound guided biopsies (TRUS) of the prostate were performed under local anesthesia with xilocaine gel using the biopsy system ASAP(tm) with Channel Cut(tm) 18 GA needles (length 21 cm with a cutting channel of 17 mm); at least six cylinders were obtained from each patient, this number corresponds to the sextant technique, a standard method practiced in Mexico.",GA,xilocaine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","To our surprise, selenium treatment did not affect survivin expression in these cells.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",TIMP-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",MCP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",COX-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",HCC,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",MMP-9,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",TIMP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",NOS-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","To confirm this, we evaluated the expression of some key angiogenic factors, including activator molecules (VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1), inhibitor molecules (endostatin, TIMP-1, TIMP-2), and the transcript factors (COX-2, NOS-2), in AT and TT using HCC tissue arrays.

",TSP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The effect of selenium on survivin expression was analyzed by Western blotting and semi-quantitative RT-PCR.,PCR,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The effect of selenium on survivin expression was analyzed by Western blotting and semi-quantitative RT-PCR.,survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Western blot analysis
Proteins were detected using a standard Western blot procedure after separation by SDS-polyacrylamide electrophoresis.",SDS,polyacrylamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
",Only few trials had a sufficiently large sample to explore the efficacy of fluorouracil-based adjuvant chemotherapy according to TS expression.,TS,fluorouracil,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Surprisingly, the unaltered 180-gene model had a high capacity to stratify KRAS-wildtype CRC patients who demonstrated disease control or response to cetuximab treatment.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Surprisingly, the unaltered 180-gene model had a high capacity to stratify KRAS-wildtype CRC patients who demonstrated disease control or response to cetuximab treatment.",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",TKI,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",TKI,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",GEPR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",GEPR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",mCRC,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",mCRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",KRAS,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",EGFR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",EGFR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",mAB,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","In this study, we utilized a GEPR for erlotinib, an EGFR-TKI, which was generated in lung cancer cell lines, to test its predictive capacity in KRAS-wildtype mCRC patients treated with the anti-EGFR mAB cetuximab.",mAB,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",NPV,panitumumab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",NPV,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",KRAS,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",PPV,panitumumab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",PPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",PPV,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",PPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",KRAS,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",CRC,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",NPV,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",NPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",EGFR,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",EGFR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",GEPR,panitumumab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.74	0.71	0.78	
Sensitivity	0.80	0.80	1.00	
PPV	0.76	0.63	0.33	
NPV	0.78	0.86	1.00	
NPV: negative predictive value; PPV positive predictive value

Discussion
The anti-EGFR monoclonal antibodies cetuximab and panitumumab are frequently used in metastatic CRC and improve overall survival when used in unselected populations [15-19].",GEPR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To determine whether the biological effect(s) of MP470 plus Erlotinib are correlated to its ability to inhibit Akt activation, Akt phosphorylation in tumor tissue at the end of treatment from the different treatment groups was analyzed by immunohistochemistry.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Figure 8 showed Akt phosphorylation was abolished in the combination arm (MP470 plus Erlotinib) compared to control or individual therapies.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","As shown in figure 7B, TGI in the group receiving 10 mg/kg MP470 + 80 mg/kg Erlotinib was not significantly different from the control group.",TGI,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","As shown in figure 7B, TGI in the group receiving 10 mg/kg MP470 + 80 mg/kg Erlotinib was not significantly different from the control group.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Figure 7 The MP470-Erlotinib combination causes TGI in an LNCaP xenograft mouse model.,TGI,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, mice receiving 20 mg/kg MP470 + 80 mg/kg Erlotinib had a significant TGI compared to the control group (p = 0.01).",TGI,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, mice receiving 20 mg/kg MP470 + 80 mg/kg Erlotinib had a significant TGI compared to the control group (p = 0.01).",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Also the HYAL-1 hyaluronidase expression in bladder cancer has been suggested to be regulated by binding of Egr-1 to the methylated promoter of HYAL-1 hyaluronidase [9].

",Egr-1,hyaluronidase,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Also the HYAL-1 hyaluronidase expression in bladder cancer has been suggested to be regulated by binding of Egr-1 to the methylated promoter of HYAL-1 hyaluronidase [9].

",Egr-1,hyaluronidase,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Also the HYAL-1 hyaluronidase expression in bladder cancer has been suggested to be regulated by binding of Egr-1 to the methylated promoter of HYAL-1 hyaluronidase [9].

",HYAL-1,hyaluronidase,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Also the HYAL-1 hyaluronidase expression in bladder cancer has been suggested to be regulated by binding of Egr-1 to the methylated promoter of HYAL-1 hyaluronidase [9].

",HYAL-1,hyaluronidase,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Also the HYAL-1 hyaluronidase expression in bladder cancer has been suggested to be regulated by binding of Egr-1 to the methylated promoter of HYAL-1 hyaluronidase [9].

",HYAL-1,hyaluronidase,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Also the HYAL-1 hyaluronidase expression in bladder cancer has been suggested to be regulated by binding of Egr-1 to the methylated promoter of HYAL-1 hyaluronidase [9].

",HYAL-1,hyaluronidase,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",TGI,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",TGI,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",TGI,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI), while MP470 plus Erlotinib had a marked effect on TGI (45-65%).",TGI,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Four LNCaP xenograft arms each with 12 mice were dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days (Fig.,MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Four LNCaP xenograft arms each with 12 mice were dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days (Fig.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Four LNCaP xenograft arms each with 12 mice were dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days (Fig.,DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Four LNCaP xenograft arms each with 12 mice were dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days (Fig.,DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Four LNCaP xenograft arms each with 12 mice were dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days (Fig.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Four LNCaP xenograft arms each with 12 mice were dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days (Fig.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",IP,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",IP,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",SEM,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume +- SEM are graphed.",SEM,Erlotinib,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The results are consistent with other reports for the vinorelbine-containing neoadjuvant chemotherapy, where the clinical response rate varies from 42% to 98%, and the pCR ranges from 4.2% to 32% [20-25].",pCR,vinorelbine,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In the entire course of the disease, 66 patients received systemic treatment (IFN, somatostatin analogues, and chemotherapy), 64 patients received local treatment to the metastatic/recurrent site (TACE, RFA, metastasectomy, endoscopic removal, and radiotherapy).",TACE,somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In the entire course of the disease, 66 patients received systemic treatment (IFN, somatostatin analogues, and chemotherapy), 64 patients received local treatment to the metastatic/recurrent site (TACE, RFA, metastasectomy, endoscopic removal, and radiotherapy).",IFN,somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In the entire course of the disease, 66 patients received systemic treatment (IFN, somatostatin analogues, and chemotherapy), 64 patients received local treatment to the metastatic/recurrent site (TACE, RFA, metastasectomy, endoscopic removal, and radiotherapy).",RFA,somatostatin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Treatment of LNCaP cells with either Erlotinib (10 mM) or MP470 (10 mM) induced 9% or 21% apoptosis respectively, while apoptosis with the combination, increased to 36%.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with the indicated doses of Erlotinib or MP470 alone or in combination for 48 hr, and apoptosis was detected as morphologic change by fluorescent microscopy.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","After incubation with the primary antibody for 60 min, the slides were incubated with the biotinylated goat anti-rabbit IgG (H+L) (DAKO, Carpinteria, CA) at 37degC for 30 min, followed by incubation with a 1:200 streptavidin-biotin-peroxidase complex (Sigma, St. Louis) for 30 min.",DAKO,biotin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",IM had an IC50 of ~12 mM in LNCaP cells [35] similar to that observed for Erlotinib alone.,IC50,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 or MP470-Erlotinib but not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.

",PARP,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 or MP470-Erlotinib but not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.

",PARP,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 or MP470-Erlotinib but not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.

",PARP,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 or MP470-Erlotinib but not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.

",MP470,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 or MP470-Erlotinib but not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 or MP470-Erlotinib but not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with the indicated doses of Erlotinib or MP470 or IM alone or the combinations for 48 hr, and PARP cleavage was determined by immunoblotting with anti-PARP antibody.",PARP,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with the indicated doses of Erlotinib or MP470 or IM alone or the combinations for 48 hr, and PARP cleavage was determined by immunoblotting with anti-PARP antibody.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with the indicated doses of Erlotinib or MP470 or IM alone or the combinations for 48 hr, and PARP cleavage was determined by immunoblotting with anti-PARP antibody.",PARP,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Additive effects on both cytotoxicity and induction of apoptosis were observed when LNCaP were treated with MP470 in combination with Erlotinib.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In a stratified univariate analysis, the prognostic value of nuclear YB-1 detection became even more pronounced in the clinically important subgroup of stage pT1/T2 tumors, representing ~80% of all diagnosed carcinomas, and breast tumors with negative progesterone receptor status (Figures 6 and 7).",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","In a stratified univariate analysis, the prognostic value of nuclear YB-1 detection became even more pronounced in the clinically important subgroup of stage pT1/T2 tumors, representing ~80% of all diagnosed carcinomas, and breast tumors with negative progesterone receptor status (Figures 6 and 7).",T2,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Hormonal receptor status including estrogen receptor (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (HER2) have been shown to predict treatment response and survival [1].,PR,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Hormonal receptor status including estrogen receptor (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (HER2) have been shown to predict treatment response and survival [1].,ER,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Hormonal receptor status including estrogen receptor (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (HER2) have been shown to predict treatment response and survival [1].,HER2,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 2 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH = 12.3.,DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 2 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH = 12.3.,PHA,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_13_10_423.txt
","Secondly, Kaplan-Meier's method with a log-rank test was used to compare SREs (pathological fracture, spinal cord paralysis, hypercalcemia, radiation therapy for osseous metastasis, orthopedic surgery for bone metastasis, and the use of morphine for pain) and survival (cause-specific death, CSD) in patients with and without pain at diagnosis of skeletal metastasis.",CSD,morphine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In nude mice bearing PC-3M xenografts, survivin knockdown synergizes with selenium in inhibiting tumor growth.

",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In nude mice bearing PC-3M xenografts, survivin knockdown synergizes with selenium in inhibiting tumor growth.

",PC-3,selenium,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","Total protein lysates (50 mg/lane), as determined by BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL), were separated by 10% SDS-polyacrylamide gels and transferred to membranes.",SDS,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","Total protein lysates (50 mg/lane), as determined by BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL), were separated by 10% SDS-polyacrylamide gels and transferred to membranes.",BCA,polyacrylamide,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","A significant drop in LVEF was observed in three patients (3.1%); in one patient, trastuzumab had to be stopped temporarily and in another discontinued permanently due to symptomatic congestive heart failure (Table 2).

",LVEF,trastuzumab,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",IC50,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",IC50,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",TKI,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",TKI,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",EGFR,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",EGFR,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",HER,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",HER,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",HER1,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",HER1,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",IC50,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Since growing evidence implicates the HER family in prostate cancer progression, we evaluated the cytotoxic effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor (TKI)] on LNCaP cells and demonstrated a cytotoxic effect with an IC50 of &#62;10 mM. However, when Erlotinib (10 mM) was combined with varying doses of MP470, the IC50 of MP470 decreased to 2 mM (Fig.",IC50,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, Erlotinib, an EGFR tyrosine kinase inhibitor, has less effect on proliferation and apoptosis in prostate cancer cell lines.",EGFR,Erlotinib,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","In contrast to papillary carcinoma, which usually can be easily diagnosed by its characteristic growth pattern und nuclear features, FTC can appear cytologically identical to follicular thyroid adenoma (FTA).",FTA,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","In contrast to papillary carcinoma, which usually can be easily diagnosed by its characteristic growth pattern und nuclear features, FTC can appear cytologically identical to follicular thyroid adenoma (FTA).",FTC,thyroid,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In this study, we evaluate whether MP470, a novel receptor tyrosine kinase inhibitor alone or in combination with Erlotinib has inhibitory effect on prostate cancer in vitro and in vivo.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Results
MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis
MP470, a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines.",RTK,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Results
MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis
MP470, a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Results
MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis
MP470, a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Of these 149 nodules, 75 were FTA, 51 nodular goiter, 9 oxyphilic FTA, 7 minimal invasive FTC and 7 others (Graves' disease, papillary thyroid carcinoma, diffuse goiter, or no nodule).

",FTA,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Of these 149 nodules, 75 were FTA, 51 nodular goiter, 9 oxyphilic FTA, 7 minimal invasive FTC and 7 others (Graves' disease, papillary thyroid carcinoma, diffuse goiter, or no nodule).

",FTC,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Of these 149 nodules, 75 were FTA, 51 nodular goiter, 9 oxyphilic FTA, 7 minimal invasive FTC and 7 others (Graves' disease, papillary thyroid carcinoma, diffuse goiter, or no nodule).

",FTA,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Moreover, a prospective study of QPRT-expression with staining of 149 solitary thyroid nodules was undertalen.",QPRT,thyroid,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","This indicates that Erlotinib has an additive effect on the cytotoxicity of MP470.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The content of creatine, choline, PCho, GPC, taurine and glycine in the xenografts as well as human breast cancer tissue samples was determined using HR MAS MRS.",GPC,creatine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The content of creatine, choline, PCho, GPC, taurine and glycine in the xenografts as well as human breast cancer tissue samples was determined using HR MAS MRS.",MAS,creatine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The content of creatine, choline, PCho, GPC, taurine and glycine in the xenografts as well as human breast cancer tissue samples was determined using HR MAS MRS.",HR,creatine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The content of creatine, choline, PCho, GPC, taurine and glycine in the xenografts as well as human breast cancer tissue samples was determined using HR MAS MRS.",MRS,creatine,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In a recent post hoc analysis from a randomized phase III trial comparing zoledronic acid and pamidronate in patients with bone metastasis, Lipton et al. demonstrated that early normalization of elevated baseline urinary N-telopeptide of type 1 collagen (NTX) levels was associated with longer event-free and overall survival (OS) times in BC patients receiving zoledronic acid[6,7].",III,pamidronate,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In a recent post hoc analysis from a randomized phase III trial comparing zoledronic acid and pamidronate in patients with bone metastasis, Lipton et al. demonstrated that early normalization of elevated baseline urinary N-telopeptide of type 1 collagen (NTX) levels was associated with longer event-free and overall survival (OS) times in BC patients receiving zoledronic acid[6,7].",III,zoledronic acid,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In a recent post hoc analysis from a randomized phase III trial comparing zoledronic acid and pamidronate in patients with bone metastasis, Lipton et al. demonstrated that early normalization of elevated baseline urinary N-telopeptide of type 1 collagen (NTX) levels was associated with longer event-free and overall survival (OS) times in BC patients receiving zoledronic acid[6,7].",OS,pamidronate,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In a recent post hoc analysis from a randomized phase III trial comparing zoledronic acid and pamidronate in patients with bone metastasis, Lipton et al. demonstrated that early normalization of elevated baseline urinary N-telopeptide of type 1 collagen (NTX) levels was associated with longer event-free and overall survival (OS) times in BC patients receiving zoledronic acid[6,7].",OS,zoledronic acid,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In a recent post hoc analysis from a randomized phase III trial comparing zoledronic acid and pamidronate in patients with bone metastasis, Lipton et al. demonstrated that early normalization of elevated baseline urinary N-telopeptide of type 1 collagen (NTX) levels was associated with longer event-free and overall survival (OS) times in BC patients receiving zoledronic acid[6,7].",NTX,pamidronate,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In a recent post hoc analysis from a randomized phase III trial comparing zoledronic acid and pamidronate in patients with bone metastasis, Lipton et al. demonstrated that early normalization of elevated baseline urinary N-telopeptide of type 1 collagen (NTX) levels was associated with longer event-free and overall survival (OS) times in BC patients receiving zoledronic acid[6,7].",NTX,zoledronic acid,1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",Yes,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",PR,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",BMI,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",ER,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",TCF7L2,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",BMI,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",CI,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",PR,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",HER2,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",HER2,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",ER,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",T,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Table 1 TCF7L2 rs12255372 and risk of breast cancer

		N	N	Ordinal OR (95% CI)	Co-Dominant ORs (95% CI)	
					
		Cases	Controls	Per T-allele	P (trend)	GT v GG	TT v GG	P (2 d.f.)	
Total	---	779	830	1.04 (0.89-1.22)	0.62	1.16 (0.93-1.43)	0.92 (0.62-1.36)	0.31	
Menopausal	Pre	268	213	1.28 (0.94-1.75)	0.12	1.51 (1.01-2.26)	1.21 (0.56-2.61)	0.14	
status	Post	467	573	0.95 (0.77-1.16)	0.59	1.03 (0.78-1.34)	0.79 (0.49-1.29)	0.60	
BMI	<= 25.9	341	394	1.07 (0.84-1.37)	0.59	1.25 (0.90-1.73)	0.91 (0.50-1.64)	0.34	
	&#62; 25.9	406	393	1.03 (0.82-1.30)	0.78	1.13 (0.83-1.54)	0.92 (0.52-1.63)	0.66	
Family	No	424	480	1.04 (0.84-1.30)	0.70	1.09 (0.81-1.46)	1.02 (0.60-1.73)	0.85	
history	Yes	336	312	0.99 (0.77-1.28)	0.95	1.25 (0.89-1.76)	0.68 (0.36-1.28)	0.14	
Estrogen	Positive	472	830	1.09 (0.91-1.31)	0.34	1.16 (0.90-1.49)	1.10 (0.70-1.71)	0.50	
Receptor (ER)	Negative	107	830	1.11 (0.81-1.52)	0.52	1.41 (0.92-2.17)	0.84 (0.36-1.96)	0.21	
Progesterone	Positive	429	830	1.21 (0.93-1.35)	0.23	1.19 (0.92-1.54)	1.15 (0.73-1.81)	0.39	
Receptor (PR)	Negative	147	830	1.00 (0.76-1.32)	0.99	1.19 (0.82-1.71)	0.74 (0.35-1.56)	0.40	
HER2 status	Positive	122	830	1.14 (0.83-1.55)	0.42	1.68 (1.12-2.53)	0.49 (0.17-1.45)	0.01	
	Negative	269	830	1.02 (0.82-1.27)	0.85	1.04 (0.78-1.40)	1.01 (0.60-1.70)	0.96	
ER, PR, HER2	All Negative	51	842	1.47 (0.95-2.26)	0.08	2.16 (1.16-4.01)	1.36 (0.43-4.30)	0.05	
BMI, body mass index, categorized by median value; family history, first-degree or second-degree family history; analyses adjusted for age, region of residence, oral contraceptive use, hormone therapy use, age at first birth, age at menarche, menopausal status (unless used as stratifiying variable), and pack years of smoking; n.a., not estimatable, bold indicates p &#60; 0.05.

",CI,Progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the third randomized trial, in which enrollment took place between October 1999 and December 2007, patients with rectal cancer received radiotherapy and adjuvant 5-FU/LV chemotherapy with or without the addition of irinotecan (CPT-11).",FU,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the third randomized trial, in which enrollment took place between October 1999 and December 2007, patients with rectal cancer received radiotherapy and adjuvant 5-FU/LV chemotherapy with or without the addition of irinotecan (CPT-11).",CPT-11,irinotecan,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Inostamycin caused decrease in the cellular levels of cyclins D1 and E [25] and suppressed the invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line [30].

",HSC-4,Inostamycin,-1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Inostamycin caused decrease in the cellular levels of cyclins D1 and E [25] and suppressed the invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line [30].

",D1,Inostamycin,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","OS was defined as the interval from the first day of trastuzumab application until death of any cause.

",OS,trastuzumab,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",HR,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",MRS,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",SD,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",MAS,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",ERETIC,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",HR,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",MRS,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",HR,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",MAS,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",MAS,Glycine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 3 Metabolite concentrations

	MAS98.12 (n = 10)	MAS98.06 (n = 9)	
Creatine	4.1 +- 1.4	3.4 +- 1.7	
Choline	1.2 +- 0.7	0.9 +- 0.6	
Phosphocholine *	4.5 +- 2.1	9.1 +- 4.4	
Glycerophosphocholine **	9.8 +- 2.5	2.7 +- 1.7	
Taurine	14.7 +- 4.1	19.1 +- 9.1	
Glycine *	8.2 +- 3.0	4.0 +- 1.8	
Metabolite concentrations in basal-like (MAS98.12) and luminal-like (MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC method (mmol/g, mean +- SD, * p &#60; 0.01, ** p &#60; 0.001)

HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples were retrieved from our internal database, and mean spectra from the two groups are shown in Figure 1.",MRS,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",NGS,biotin,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",NGS,citrate,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",PBS,biotin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",PBS,citrate,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",PBS,biotin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",PBS,citrate,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",BSA,biotin,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",BSA,citrate,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",BSA,biotin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",BSA,citrate,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",PBS,biotin,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",PBS,citrate,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",NGS,biotin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","In all cases initial antigen retrieval was carried out in citrate buffer [40], biotin conjugates were diluted in NGS/PBS/BSA, fluorescent conjugates were diluted in PBS, primary antibodies were diluted in NGS/PBS/BSA and incubated overnight at 4degC.",NGS,citrate,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To confirm these, co-immunoprecipitation and immunoblotting were performed and the results showed that phosphorylation of HER1, 2 and 3, binding of HER3 to PI3K p85, as well as downstream Akt activity were dramatically suppressed by MP470 plus Erlotinib in LNCaP (Fig.",HER1,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To confirm these, co-immunoprecipitation and immunoblotting were performed and the results showed that phosphorylation of HER1, 2 and 3, binding of HER3 to PI3K p85, as well as downstream Akt activity were dramatically suppressed by MP470 plus Erlotinib in LNCaP (Fig.",PI3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To confirm these, co-immunoprecipitation and immunoblotting were performed and the results showed that phosphorylation of HER1, 2 and 3, binding of HER3 to PI3K p85, as well as downstream Akt activity were dramatically suppressed by MP470 plus Erlotinib in LNCaP (Fig.",HER3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To confirm these, co-immunoprecipitation and immunoblotting were performed and the results showed that phosphorylation of HER1, 2 and 3, binding of HER3 to PI3K p85, as well as downstream Akt activity were dramatically suppressed by MP470 plus Erlotinib in LNCaP (Fig.",p85,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To confirm these, co-immunoprecipitation and immunoblotting were performed and the results showed that phosphorylation of HER1, 2 and 3, binding of HER3 to PI3K p85, as well as downstream Akt activity were dramatically suppressed by MP470 plus Erlotinib in LNCaP (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","One month after inoculation, when tumors reached a volume of ~100 mm3, animals were divided randomly (pair-matched) into four test groups each with 12 mice: control group (DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg) group and Erlotinib plus MP470 group.",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","One month after inoculation, when tumors reached a volume of ~100 mm3, animals were divided randomly (pair-matched) into four test groups each with 12 mice: control group (DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg) group and Erlotinib plus MP470 group.",DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","One month after inoculation, when tumors reached a volume of ~100 mm3, animals were divided randomly (pair-matched) into four test groups each with 12 mice: control group (DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg) group and Erlotinib plus MP470 group.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","One month after inoculation, when tumors reached a volume of ~100 mm3, animals were divided randomly (pair-matched) into four test groups each with 12 mice: control group (DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg) group and Erlotinib plus MP470 group.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","One month after inoculation, when tumors reached a volume of ~100 mm3, animals were divided randomly (pair-matched) into four test groups each with 12 mice: control group (DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg) group and Erlotinib plus MP470 group.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","One month after inoculation, when tumors reached a volume of ~100 mm3, animals were divided randomly (pair-matched) into four test groups each with 12 mice: control group (DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg) group and Erlotinib plus MP470 group.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
The efficacy of MP470 or MP470 plus Erlotinib was evaluated in vitro using three prostate cancer cell lines by MTS and apoptosis assays.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
The efficacy of MP470 or MP470 plus Erlotinib was evaluated in vitro using three prostate cancer cell lines by MTS and apoptosis assays.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
The efficacy of MP470 or MP470 plus Erlotinib was evaluated in vitro using three prostate cancer cell lines by MTS and apoptosis assays.",MTS,Erlotinib,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Blocking PI3K or mTOR signaling with either C) LY294002 (50 mg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells.",PI3,rapamycin,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Blocking PI3K or mTOR signaling with either C) LY294002 (50 mg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells.",PANC-1,rapamycin,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Blocking PI3K or mTOR signaling with either C) LY294002 (50 mg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells.",EGF,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Blocking PI3K or mTOR signaling with either C) LY294002 (50 mg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells.",LY294002,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Blocking PI3K or mTOR signaling with either C) LY294002 (50 mg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells.",mTOR,rapamycin,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Blocking PI3K or mTOR signaling with either C) LY294002 (50 mg/mL) or D) rapamycin (10 ng/ml), respectively, suppresses the EGF (100 ng/mL)-mediated HCCR-1 expression in PANC-1 cells.",HCCR-1,rapamycin,-1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Table 3 Frequency and distribution of the systemic events occurred at each dose level

Systemic Events	Group I
(14 mg)	Group II
(70 mg)	Group III
(245 mg)	Group IV
(490 mg)		
Itching	8 (14.6%)	18 (25.0%)	29 (25.9%)	29 (32.3%)	84	
Hot flashes	12 (21.8%)	14 (11.7%)	8 (7.1%)	8 (8.9%)	42	
Localized rash	3 (5.4%)	21 (17.5%)	6 (5.4%)	8 (8.9%)	38	
Localized facial edema	9 (16.4%)	6 (5.0%)	8 (7.1%)	13 (14.4%)	36	
Bumps	0	12 (10.0%)	17 (15.2%)	6 (6.7%)	35	
Extensive rash	2 (3.6%)	0	21 (18.8%)	5 (5.6%)	28	
Cramps	3 (5.4%)	2 (1.7%)	11 (9.0%)	6 (6.7%)	22	
Headache	3 (5.4%)	2 (1.7%)	4 (3.6%)	2 (2.2%)	11	
Metallic flavor	4 (7.3%)	6 (5.0%)	1 (0.9%)	0	11	
Tickling or tingling	5 (9.1%)	6 (5.0%)	0	0	11	
Tachycardia	0	7 (5.8%)	3 (2.7%)	0	10	
Tinnitus	0	7 (5.8%)	0	0	7	
Nausea	0	3 (2.5%)	1 (0.9%)	3 (3.3%)	7	
Facial erythema	0	7 (5.8%)	0	0	7	
Palpitations	0	2 (1.7%)	1 (0.9%)	2 (2.2%)	5	
Hypertension	3 (5.4%)	1 (0.8%)	0	1 (1.1%)	5	
Vasovagal syndrome	0	g2: 2 (1.7%)		g3: 2 (2.2%)	4	
Dizziness	1 (1.8%)	2 (1.7%)	0	0	3	
Tremors	0	0	0	3 (3.3%)	3	
Vomiting	0	2 (1.7%)	0	0	2	
Fast breathing	1 (1.8%)	0	0	0	1	
Abdominal pain	1 (1.8%)	0	0	0	1	
Arrhythmia	0	0	0	1 (1.1%)	1	
Hypotension	0	0	1 (0.9%)	0	1	
Posture-related tremor in lower limbs	0	0	0	1 (1.1%)	1	
Red eyes	0	0	1 (0.9%)	0	1	
	
Total	55	120	112	90		
There were no differences between baseline and post-treatment blood counts, serum chemistry results, coagulation parameters and electrocardiograms (data not shown).

Efficacy analysis
Individual efficacy results are shown in Table 1 and summarized in Table 4.",III,Posture,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In order to estimate the hazard ratios of TS or Topo I status for OS and DFS, univariate Cox regression analyses were performed both unadjusted and adjusted for irinotecan chemotherapy.

",OS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In order to estimate the hazard ratios of TS or Topo I status for OS and DFS, univariate Cox regression analyses were performed both unadjusted and adjusted for irinotecan chemotherapy.

",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In order to estimate the hazard ratios of TS or Topo I status for OS and DFS, univariate Cox regression analyses were performed both unadjusted and adjusted for irinotecan chemotherapy.

",DFS,irinotecan,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Figure 6 Effects of MP470-Erlotinib combination on tyrosine phosphorylation of the HER family and PI3K/Akt.,PI3K,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Figure 6 Effects of MP470-Erlotinib combination on tyrosine phosphorylation of the HER family and PI3K/Akt.,HER,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In prostate cancer cells where selenium had no effect on survivin expression, growth inhibition and apoptosis induction effects of selenium were modest.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In prostate cancer cells where selenium had no effect on survivin expression, growth inhibition and apoptosis induction effects of selenium were modest.",survivin,selenium,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","With the purpose to quantified apurinic or apyrimidine (AP) sites we employed a specific restriction enzyme. Etoposide effects were determined on whole blood cells cultured in absence or presence of phytohemagglutinin (PHA) treated during 2 and 24 hours of cultured.

",PHA,Etoposide,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO (control), Erlotinib (80 mg/kg) plus MP470 (10 mg/kg or 20 mg/kg, respectively) by IP daily for 22 days (starting day 27 and ending day 49), and the mean tumor volume +- SEM are graphed. *",IP,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO (control), Erlotinib (80 mg/kg) plus MP470 (10 mg/kg or 20 mg/kg, respectively) by IP daily for 22 days (starting day 27 and ending day 49), and the mean tumor volume +- SEM are graphed. *",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO (control), Erlotinib (80 mg/kg) plus MP470 (10 mg/kg or 20 mg/kg, respectively) by IP daily for 22 days (starting day 27 and ending day 49), and the mean tumor volume +- SEM are graphed. *",SEM,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The mice were treated with DMSO (control), Erlotinib (80 mg/kg) plus MP470 (10 mg/kg or 20 mg/kg, respectively) by IP daily for 22 days (starting day 27 and ending day 49), and the mean tumor volume +- SEM are graphed. *",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cl (pH 7.4), 0.15 M NaCl, 0.5% NP-40, 1 mM DTT, 50 mM Sodium Fluoride, and 2 ml/ml Protease inhibitor cocktail (Sigma, St. Louis, MO).",DTT,Fluoride,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cl (pH 7.4), 0.15 M NaCl, 0.5% NP-40, 1 mM DTT, 50 mM Sodium Fluoride, and 2 ml/ml Protease inhibitor cocktail (Sigma, St. Louis, MO).",NP-40,Fluoride,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","These results confirmed our in vitro observations and showed survivin knockdown greatly enhanced the efficacy of selenium in inhibiting the growth of prostate cancer cells in vivo.

",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to a report that selenium suppresses survivin expression in a number of PCa cell lines, including the parental PC-3 and LNCaP lines [18], our in vitro and in vivo data both showed that MSA treatment had little or no effect on survivin expression in PC-3M, C4-2B, and 22Rv1 cells.",MSA,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to a report that selenium suppresses survivin expression in a number of PCa cell lines, including the parental PC-3 and LNCaP lines [18], our in vitro and in vivo data both showed that MSA treatment had little or no effect on survivin expression in PC-3M, C4-2B, and 22Rv1 cells.",PC-3,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to a report that selenium suppresses survivin expression in a number of PCa cell lines, including the parental PC-3 and LNCaP lines [18], our in vitro and in vivo data both showed that MSA treatment had little or no effect on survivin expression in PC-3M, C4-2B, and 22Rv1 cells.",C4,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to a report that selenium suppresses survivin expression in a number of PCa cell lines, including the parental PC-3 and LNCaP lines [18], our in vitro and in vivo data both showed that MSA treatment had little or no effect on survivin expression in PC-3M, C4-2B, and 22Rv1 cells.",PC-3,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to a report that selenium suppresses survivin expression in a number of PCa cell lines, including the parental PC-3 and LNCaP lines [18], our in vitro and in vivo data both showed that MSA treatment had little or no effect on survivin expression in PC-3M, C4-2B, and 22Rv1 cells.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to a report that selenium suppresses survivin expression in a number of PCa cell lines, including the parental PC-3 and LNCaP lines [18], our in vitro and in vivo data both showed that MSA treatment had little or no effect on survivin expression in PC-3M, C4-2B, and 22Rv1 cells.",survivin,selenium,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Moreover, MP470 plus Erlotinib significantly suppressed tumor growth in an LNCaP mouse xenograft model, suggesting it could be used as a new combination for prostate cancer treatment.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",GIST,Sunitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",GIST,Dasatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",GIST,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",EGFR,Sunitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",EGFR,Dasatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",EGFR,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",GBM,Sunitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",GBM,Dasatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",GBM,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",CML,Sunitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",CML,Dasatinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",CML,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",PDGFR,Sunitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",PDGFR,Dasatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",PDGFR,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",NSCLC,Sunitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",NSCLC,Dasatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Discussion
Single agent therapy with small molecule TKIs is effective in malignancies dependent on mutated constitutively activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib), EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs such as, Bcr-Abl in CML (IM, Dasatinib).",NSCLC,Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, inclusion of TIMP-1 as a continuous variable, in particular in analyses of patients treated with anthracycline-based therapy, showed a stronger association between TIMP-1 and outcome than those employing the dichotomized variable.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","However, inclusion of TIMP-1 as a continuous variable, in particular in analyses of patients treated with anthracycline-based therapy, showed a stronger association between TIMP-1 and outcome than those employing the dichotomized variable.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","After 4 hr pre-treatment with MP470, Erlotinib, IM or combinations at the appropriate concentrations, the cells were stimulated by pervanadate (100 mM) for 10 min and then lysed for protein analysis.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The endpoint of DFS is uninfluenced by therapy given in the metastatic setting; yet, the results in the present analyses of OS are stronger in terms of showing statistically significant associations, including a significant interaction between anthracycline treatment and TIMP-1.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The endpoint of DFS is uninfluenced by therapy given in the metastatic setting; yet, the results in the present analyses of OS are stronger in terms of showing statistically significant associations, including a significant interaction between anthracycline treatment and TIMP-1.",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The endpoint of DFS is uninfluenced by therapy given in the metastatic setting; yet, the results in the present analyses of OS are stronger in terms of showing statistically significant associations, including a significant interaction between anthracycline treatment and TIMP-1.",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Immunohistochemistry
Immunohistochemistry was performed using the labeled streptavidin biotin (LSAB) method.",LSAB,biotin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",Figure 2 Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high anthracycline-treated patients.,OS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",Figure 2 Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high anthracycline-treated patients.,DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
",Figure 2 Kaplan-Meier plot showing the DFS (A) and OS (B) of TIMP-1 low and high anthracycline-treated patients.,TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","In the early nineties eight-drugs-in-one -protocol and later vincristine, lomustine and prednisolon were widely used also for MB and PNETs [35].",MB,vincristine,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","In the early nineties eight-drugs-in-one -protocol and later vincristine, lomustine and prednisolon were widely used also for MB and PNETs [35].",MB,lomustine,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In none of the patients switched to lapatinib, a significant drop in LVEF or congestive heart failure was observed.

",LVEF,lapatinib,1
"PMC 
BMC_Cancer_2010_Aug_11_10_420.txt
","CYP1B1 is primarily involved in the hydroxylation of 17b-estradiol at the 2-OH and 4-OH positions, which can then be oxidized to semiquinones and quinines [1].",CYP1B1,estradiol,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",CO2,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",CO2,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",RPMI,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",RPMI,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",HepG2,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",HepG2,streptomycin,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","IFNa	286 (57)	
 5FU/LV/Oxaliplatin	17 (3)	
 Other	5 (1)	
The patients included in the analysis had a significantly higher percentage of Dukes' stage B2 at diagnosis (49% vs. 43%, kh2 test, p = 0.034) than the protocol patients excluded due to inability to obtain tissue for IHC evaluation.",B2,Oxaliplatin,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","IFNa	286 (57)	
 5FU/LV/Oxaliplatin	17 (3)	
 Other	5 (1)	
The patients included in the analysis had a significantly higher percentage of Dukes' stage B2 at diagnosis (49% vs. 43%, kh2 test, p = 0.034) than the protocol patients excluded due to inability to obtain tissue for IHC evaluation.",IHC,Oxaliplatin,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Sigmoid	137 (27)	
 Cecum	69 (14)	
 Ascending	57 (11)	
 Descending	37 (7)	
 Transverse	35 (7)	
 Unknown	2 (0.4)	
Stage at diagnosis		
 Dukes' B	246 (49)	
 Dukes' C	252 (51)	
Differentiation Grade		
 Good	67 (14)	
 Moderate	357 (72)	
 Poor	62 (12)	
 Undifferentiated	3 (1)	
 Unknown	9 (2)	
Adjuvant radiotherapy		
 No	325 (65)	
 Yes	143 (29)	
 Unknown	30 (6)	
Adjuvant chemotherapy		
 5FU/LV/Irinotecan	190 (38)	
 5FU/LV +-",Yes,Irinotecan,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3751984594410.1186/1471-2407-9-375Research ArticleRetrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months Huang Ou 12ou_huang@medmail.com.cnChen CanMing 2canmingchen@126.comWu JiaYi 1jiayiwu9@126.comChen ShuJie 2shujiechen9@126.comChen XiaoSong 1xiaosongchen9@126.comLiu GuangYu 2guangyuliu9@126.comHu",BMC,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3751984594410.1186/1471-2407-9-375Research ArticleRetrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months Huang Ou 12ou_huang@medmail.com.cnChen CanMing 2canmingchen@126.comWu JiaYi 1jiayiwu9@126.comChen ShuJie 2shujiechen9@126.comChen XiaoSong 1xiaosongchen9@126.comLiu GuangYu 2guangyuliu9@126.comHu",BMC,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3751984594410.1186/1471-2407-9-375Research ArticleRetrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months Huang Ou 12ou_huang@medmail.com.cnChen CanMing 2canmingchen@126.comWu JiaYi 1jiayiwu9@126.comChen ShuJie 2shujiechen9@126.comChen XiaoSong 1xiaosongchen9@126.comLiu GuangYu 2guangyuliu9@126.comHu",Cancer1471,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3751984594410.1186/1471-2407-9-375Research ArticleRetrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months Huang Ou 12ou_huang@medmail.com.cnChen CanMing 2canmingchen@126.comWu JiaYi 1jiayiwu9@126.comChen ShuJie 2shujiechen9@126.comChen XiaoSong 1xiaosongchen9@126.comLiu GuangYu 2guangyuliu9@126.comHu",Cancer1471,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Results
Significant differential modulation of 151 genes were found at 4 h after start of induction therapy with cytarabine and anthracycline, including significant overexpression of 31 genes associated with p53 regulation.",p53,cytarabine,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Results
Significant differential modulation of 151 genes were found at 4 h after start of induction therapy with cytarabine and anthracycline, including significant overexpression of 31 genes associated with p53 regulation.",p53,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Conclusion
In the subgroup of patients receiving adjuvant chemotherapy we found an association between shorter survival after treatment in TIMP-1 high patients compared with TIMP-1 low patients, especially in patients receiving anthracycline-based therapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Conclusion
In the subgroup of patients receiving adjuvant chemotherapy we found an association between shorter survival after treatment in TIMP-1 high patients compared with TIMP-1 low patients, especially in patients receiving anthracycline-based therapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",USA2,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",LLC,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",SAR,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",TP,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",China4,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",PR,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",PR,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",BMC,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",China5,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",Cancer1471,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",SAR,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",China3,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",Singapore2009,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",PR,Nikki,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3891988698910.1186/1471-2407-9-389Research ArticlePredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters Hao Ke 1ke_hao@merck.comLuk John M 25jmluk@nus.edu.sgLee Nikki PY 2nikkilee@hkucc.hku.hkMao Mao 1mao_mao@merck.comZhang Chunsheng 1Chunsheng_Zhang@merck.comFerguson Mark D 1Mark_Ferguson@merck.comLamb John 1John_Lamb3@merck.comDai Hongyue 1hongyue_dai@merck.comNg Irene O 3iolng@hkusua.hku.hkSham Pak C 4pcsham@hkucc.hku.hkPoon Ronnie TP 2poontp@hkucc.hku.hk1 Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA2 Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, PR China3 Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China4 Department of Psychiatry and Genome Research Center, The University of Hong Kong, Pokfulam, Hong Kong SAR, PR China5 Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore2009 3 11 2009 9 389 389 1 12 2008 3 11 2009 Copyright (c)2009 Hao et al; licensee BioMed Central Ltd.2009Hao et al; licensee BioMed Central Ltd.",SAR,Nikki,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Cardiorespiratory fitness, as measured by an objective exercise tolerance test, reflects the integrative capacity of components in the oxygen (O2) cascade to supply adequate O2 for adenosine triphosphate (ATP) resynthesis.",O2,adenosine,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Cardiorespiratory fitness, as measured by an objective exercise tolerance test, reflects the integrative capacity of components in the oxygen (O2) cascade to supply adequate O2 for adenosine triphosphate (ATP) resynthesis.",ATP,adenosine,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Cardiorespiratory fitness, as measured by an objective exercise tolerance test, reflects the integrative capacity of components in the oxygen (O2) cascade to supply adequate O2 for adenosine triphosphate (ATP) resynthesis.",O2,adenosine,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","At 18-24 h after chemotherapy, the gene expression of p53 target genes was attenuated, while genes involved in chemoresistance, cytarabine detoxification, chemokine networks and T cell receptor were prominent.",T,cytarabine,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","At 18-24 h after chemotherapy, the gene expression of p53 target genes was attenuated, while genes involved in chemoresistance, cytarabine detoxification, chemokine networks and T cell receptor were prominent.",p53,cytarabine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The negative SELECT finding makes it more important and imperative to study the efficacy of new selenium compounds [12-14], including the compounds used in the study, methylseleninic acid (MSA) and methylselenocysteine (MSC), for prostate cancer intervention.

",MSA,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The negative SELECT finding makes it more important and imperative to study the efficacy of new selenium compounds [12-14], including the compounds used in the study, methylseleninic acid (MSA) and methylselenocysteine (MSC), for prostate cancer intervention.

",SELECT,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The negative SELECT finding makes it more important and imperative to study the efficacy of new selenium compounds [12-14], including the compounds used in the study, methylseleninic acid (MSA) and methylselenocysteine (MSC), for prostate cancer intervention.

",MSC,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Sixty-six patients received systemic treatment (interferon, somatostatin analogues or chemotherapy), 64 patients received local treatment (TACE, radiofrequency ablation, metastasectomy, etc.).",TACE,somatostatin,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in figure 6, we found that a 2-h treatment course with the antioxidant AA (200 mM) concurrent with the 2-h etoposide treatment reduced the DNA damage induced by etoposide in non-stimulated whole blood cells.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in figure 6, we found that a 2-h treatment course with the antioxidant AA (200 mM) concurrent with the 2-h etoposide treatment reduced the DNA damage induced by etoposide in non-stimulated whole blood cells.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Tissue sections cut from formalin-fixed paraffin-embedded blocks from biopsy specimens and postoperative tumor tissues were stained for the presence of estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor receptor-2), and MIB-1(Ki-67).

",ER,progesterone,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Tissue sections cut from formalin-fixed paraffin-embedded blocks from biopsy specimens and postoperative tumor tissues were stained for the presence of estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor receptor-2), and MIB-1(Ki-67).

",HER-2,progesterone,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Most importantly, we found that the CpG induced invasion could be blocked with chloroquine, which is an inhibitor of TLR9 signaling pathway.",TLR9,chloroquine,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The gradient-purified stromal cell fraction was resuspended in 100 ml 0.1% bovine serum albumin (BSA)-HBSS, and CD90-Phycoerythrin (PE) mouse monoclonal antibody (1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15, BD-PharMingen) added for 15 min at room temperature in the dark.",WM15,BD,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The gradient-purified stromal cell fraction was resuspended in 100 ml 0.1% bovine serum albumin (BSA)-HBSS, and CD90-Phycoerythrin (PE) mouse monoclonal antibody (1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15, BD-PharMingen) added for 15 min at room temperature in the dark.",WM15,BD,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The gradient-purified stromal cell fraction was resuspended in 100 ml 0.1% bovine serum albumin (BSA)-HBSS, and CD90-Phycoerythrin (PE) mouse monoclonal antibody (1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15, BD-PharMingen) added for 15 min at room temperature in the dark.",CD13-PE,BD,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The gradient-purified stromal cell fraction was resuspended in 100 ml 0.1% bovine serum albumin (BSA)-HBSS, and CD90-Phycoerythrin (PE) mouse monoclonal antibody (1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15, BD-PharMingen) added for 15 min at room temperature in the dark.",CD13-PE,BD,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay
Apoptotic cells in tissues were determined by using the TUNEL assay (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions.",TUNEL,biotin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay
Apoptotic cells in tissues were determined by using the TUNEL assay (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions.",dUTP,biotin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay
Apoptotic cells in tissues were determined by using the TUNEL assay (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions.",TUNEL,biotin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay
Apoptotic cells in tissues were determined by using the TUNEL assay (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions.",IN,biotin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Slides were rinsed with PBS and incubated with 3% H2O2 in methanol for 10 min at room temperature to block endogenous peroxidase activity, followed by PBS washing and incubation in 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice.",H2O2,citrate,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Slides were rinsed with PBS and incubated with 3% H2O2 in methanol for 10 min at room temperature to block endogenous peroxidase activity, followed by PBS washing and incubation in 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice.",PBS,citrate,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Slides were rinsed with PBS and incubated with 3% H2O2 in methanol for 10 min at room temperature to block endogenous peroxidase activity, followed by PBS washing and incubation in 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice.",PBS,citrate,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Slides were rinsed with PBS and incubated with 3% H2O2 in methanol for 10 min at room temperature to block endogenous peroxidase activity, followed by PBS washing and incubation in 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice.",X-100,citrate,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","SF participated rationally in the project design, and with LJ and CAP verified TMA staining and scoring.",TMA,SF,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","SF participated rationally in the project design, and with LJ and CAP verified TMA staining and scoring.",CAP,SF,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Methods
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >= 10 each group) using qRTPCR, single and double immunohistochemistry.",PR,progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Methods
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >= 10 each group) using qRTPCR, single and double immunohistochemistry.",G1,progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Methods
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >= 10 each group) using qRTPCR, single and double immunohistochemistry.",qRTPCR,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Methods
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >= 10 each group) using qRTPCR, single and double immunohistochemistry.",G3,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Methods
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >= 10 each group) using qRTPCR, single and double immunohistochemistry.",G2,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Methods
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >= 10 each group) using qRTPCR, single and double immunohistochemistry.",COX-2,progesterone,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
",Trastuzumab inhibits downstream signalling pathways and blocks the shedding of Her2's extracellular domain.,Her2,Trastuzumab,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","In addition to this, for the first time, we showed that chloroquine was able to inhibit the TLR9 induced invasiveness of glioma cells(Fig.",TLR9,chloroquine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Reactions were loaded into a native 4% polyacrylamide gel (pre-ran for 60 minutes) in 0.5 x Tris borate/EDTA, ran at 100 V and transferred onto a positively charged nylon membrane (Hybond-N+) in 0.5 x Tris borate/EDTA at 100 V for 30 minutes.",EDTA,polyacrylamide,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Reactions were loaded into a native 4% polyacrylamide gel (pre-ran for 60 minutes) in 0.5 x Tris borate/EDTA, ran at 100 V and transferred onto a positively charged nylon membrane (Hybond-N+) in 0.5 x Tris borate/EDTA at 100 V for 30 minutes.",EDTA,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.

",III,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.

",SCGE,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.

",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Both strategies are supported by data from prospective randomized phase III trials [17,18], although a continuation of trastuzumab is potentially less well established, as the trial conducted by the German Breast Group (GBG-26) had to be closed early due to poor accrual [17].",III,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Both strategies are supported by data from prospective randomized phase III trials [17,18], although a continuation of trastuzumab is potentially less well established, as the trial conducted by the German Breast Group (GBG-26) had to be closed early due to poor accrual [17].",GBG-26,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
Our results indicate that etoposide induces DNA damage specifically at DNA-AP sites in quiescent blood cells.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
Our results indicate that etoposide induces DNA damage specifically at DNA-AP sites in quiescent blood cells.",DNA,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","4), and thus may be used as an adjuvant for the GBM therapy, this was confirmed by Briceno et al[39,40], who showed that chloroquine may improve mid-term survival when given in addition to conventional therapy for GBM.",GBM,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","4), and thus may be used as an adjuvant for the GBM therapy, this was confirmed by Briceno et al[39,40], who showed that chloroquine may improve mid-term survival when given in addition to conventional therapy for GBM.",GBM,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",S100A4,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",DAKO,progesterone,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",L-0303,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",ER,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",M0877,progesterone,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",SP1,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",SP2,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were immunostained ON with the following antibodies: ER (NeoMarker clone SP1, 1:500 dilution), progesterone receptor (PgR) (NeoMarker clone SP2, 1:500 dilution), Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin (NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb [23] 1:2000 dilution, F4/80 (Accurate Chemicals clone A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO #M0877, 1:400 dilutions).",A3,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",GFP,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",ER,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",PR,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",AKT,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",ELISA,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",Y,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Abbreviations
AKT: protein kinase B; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbant assay; ER: estrogen receptor; GFP: green fluorescent protein; Mab: monoclonal antibody; PR: progesterone receptor; YB-1: Y-box binding protein-1.

",EGF,progesterone,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum starved for 24 hr, pretreated with DMSO (control), Erlotinib (10 mM), MP470 (10 mM), or MP470-Erlotinib (10 mM each) for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum starved for 24 hr, pretreated with DMSO (control), Erlotinib (10 mM), MP470 (10 mM), or MP470-Erlotinib (10 mM each) for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",DMSO,MP470-Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum starved for 24 hr, pretreated with DMSO (control), Erlotinib (10 mM), MP470 (10 mM), or MP470-Erlotinib (10 mM each) for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum starved for 24 hr, pretreated with DMSO (control), Erlotinib (10 mM), MP470 (10 mM), or MP470-Erlotinib (10 mM each) for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",MP470,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 100 U penicillin, streptomycin and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at 37degC in 5% CO2.",CO2,penicillin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 100 U penicillin, streptomycin and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at 37degC in 5% CO2.",CO2,streptomycin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 100 U penicillin, streptomycin and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at 37degC in 5% CO2.",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 100 U penicillin, streptomycin and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at 37degC in 5% CO2.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 100 U penicillin, streptomycin and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at 37degC in 5% CO2.",FBS,penicillin,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 100 U penicillin, streptomycin and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at 37degC in 5% CO2.",FBS,streptomycin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",CO2,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",CO2,streptomycin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",USA,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",USA,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",USA,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",USA,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",FBS,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Glioma cells were grown in Dulbecco's modified essential medium (DMEM, Gibcol, Gaithersburg, MD, USA) supplemented with 10% FBS (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37degC with 5% CO2 in humidified air.

",FBS,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","The ex vivo response to anthracycline included increased stabilization of p53 followed by regulation of p53 target gene expression in concordance with in vivo observations.

",p53,anthracycline,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","The ex vivo response to anthracycline included increased stabilization of p53 followed by regulation of p53 target gene expression in concordance with in vivo observations.

",p53,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Comparison of TIMP-1 low- and high patients within treatment subgroups
We then compared the outcome after therapy and the association with increasing tumor tissue TIMP-1 separately within each treatment subgroup (anthracycline-treated, CMF).",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Comparison of TIMP-1 low- and high patients within treatment subgroups
We then compared the outcome after therapy and the association with increasing tumor tissue TIMP-1 separately within each treatment subgroup (anthracycline-treated, CMF).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Comparison of TIMP-1 low- and high patients within treatment subgroups
We then compared the outcome after therapy and the association with increasing tumor tissue TIMP-1 separately within each treatment subgroup (anthracycline-treated, CMF).",CMF,anthracycline,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","The difference in the Kaplan-Meier survival curves retained significance in the entire cohort, supporting the secondary hypothesis that the GEPR was an independent predictor of cetuximab benefit (Figure 2B, right).",GEPR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","Positive	563	46.5	
	Unknown	4	0.3	
	
Histological diagnosis	Ductal	1149	94.8	
	Lobular	48	4	
	Other	15	1.2	
	
Systemic therapy	No adjuvant systemic therapy	484	39.9	
	Tamoxifen, no chemotherapy	398	32.8	
	Chemotherapy, no Tamoxifen	228	18.8	
	Chemotherapy and Tamoxifen	100	8.3	
	Ovarian ablation or hormono-therapy other than Tamoxifen, no chemotherapy	1	0.1	
	Ovarian ablation or hormono-therapy other than Tamoxifen, and chemotherapy	1	0.1	
Kaplan-Meier survival analysis of cases stratified based on the HER2 status, as determined by visual or machine scoring of the immunostained slides, is shown in Figure 2.",HER2,Tamoxifen,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","Positive	563	46.5	
	Unknown	4	0.3	
	
Histological diagnosis	Ductal	1149	94.8	
	Lobular	48	4	
	Other	15	1.2	
	
Systemic therapy	No adjuvant systemic therapy	484	39.9	
	Tamoxifen, no chemotherapy	398	32.8	
	Chemotherapy, no Tamoxifen	228	18.8	
	Chemotherapy and Tamoxifen	100	8.3	
	Ovarian ablation or hormono-therapy other than Tamoxifen, no chemotherapy	1	0.1	
	Ovarian ablation or hormono-therapy other than Tamoxifen, and chemotherapy	1	0.1	
Kaplan-Meier survival analysis of cases stratified based on the HER2 status, as determined by visual or machine scoring of the immunostained slides, is shown in Figure 2.",HER2,Tamoxifen,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","Positive	563	46.5	
	Unknown	4	0.3	
	
Histological diagnosis	Ductal	1149	94.8	
	Lobular	48	4	
	Other	15	1.2	
	
Systemic therapy	No adjuvant systemic therapy	484	39.9	
	Tamoxifen, no chemotherapy	398	32.8	
	Chemotherapy, no Tamoxifen	228	18.8	
	Chemotherapy and Tamoxifen	100	8.3	
	Ovarian ablation or hormono-therapy other than Tamoxifen, no chemotherapy	1	0.1	
	Ovarian ablation or hormono-therapy other than Tamoxifen, and chemotherapy	1	0.1	
Kaplan-Meier survival analysis of cases stratified based on the HER2 status, as determined by visual or machine scoring of the immunostained slides, is shown in Figure 2.",HER2,Tamoxifen,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","Positive	563	46.5	
	Unknown	4	0.3	
	
Histological diagnosis	Ductal	1149	94.8	
	Lobular	48	4	
	Other	15	1.2	
	
Systemic therapy	No adjuvant systemic therapy	484	39.9	
	Tamoxifen, no chemotherapy	398	32.8	
	Chemotherapy, no Tamoxifen	228	18.8	
	Chemotherapy and Tamoxifen	100	8.3	
	Ovarian ablation or hormono-therapy other than Tamoxifen, no chemotherapy	1	0.1	
	Ovarian ablation or hormono-therapy other than Tamoxifen, and chemotherapy	1	0.1	
Kaplan-Meier survival analysis of cases stratified based on the HER2 status, as determined by visual or machine scoring of the immunostained slides, is shown in Figure 2.",HER2,Tamoxifen,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","Positive	563	46.5	
	Unknown	4	0.3	
	
Histological diagnosis	Ductal	1149	94.8	
	Lobular	48	4	
	Other	15	1.2	
	
Systemic therapy	No adjuvant systemic therapy	484	39.9	
	Tamoxifen, no chemotherapy	398	32.8	
	Chemotherapy, no Tamoxifen	228	18.8	
	Chemotherapy and Tamoxifen	100	8.3	
	Ovarian ablation or hormono-therapy other than Tamoxifen, no chemotherapy	1	0.1	
	Ovarian ablation or hormono-therapy other than Tamoxifen, and chemotherapy	1	0.1	
Kaplan-Meier survival analysis of cases stratified based on the HER2 status, as determined by visual or machine scoring of the immunostained slides, is shown in Figure 2.",HER2,Tamoxifen,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","In the betaine synthesis pathway, choline is oxidized to betaine through the action of choline dehydrogenase (CHDH).",CHDH,betaine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","In the betaine synthesis pathway, choline is oxidized to betaine through the action of choline dehydrogenase (CHDH).",CHDH,betaine,1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",ERBB2,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",AB-14,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",TP53,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",D0,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",ER,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",PR,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",TP53,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",SP3,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_24_10_455.txt
","Immunohistochemistry: Presence of ER, PR, ERBB2 (HER2/neu) and TP53 was determined by immunohistochemistry staining using the antibodies: estrogen receptor AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25 (Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako).",PR-1,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","The antimetabolite, 5-Fluorouracil (5-FU), remains the mainstay of chemotherapy for colorectal cancer (CRC).",CRC,Fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","The antimetabolite, 5-Fluorouracil (5-FU), remains the mainstay of chemotherapy for colorectal cancer (CRC).",FU,Fluorouracil,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","The purpose of this study was to determine if this predictor could identify KRAS-wildtype CRC patients who will benefit from cetuximab therapy.

",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","The purpose of this study was to determine if this predictor could identify KRAS-wildtype CRC patients who will benefit from cetuximab therapy.

",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Methods
Microarray data from 80 metastatic CRC patients subsequently treated with cetuximab were extracted from the study by Khambata-Ford et al.",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given that cetuximab yields an overall benefit in PFS of 1.5 months as monotherapy in CRC as well as the high cost of treatment, these findings should be considered clinically important [20].

",PFS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given that cetuximab yields an overall benefit in PFS of 1.5 months as monotherapy in CRC as well as the high cost of treatment, these findings should be considered clinically important [20].

",CRC,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","We previously published a gene expression predictor of sensitivity to erlotinib, an EGFR inhibitor.",EGFR,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","However, many KRAS-wildtype patients do not benefit from cetuximab.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Background
The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of therapy.",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Background
The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of therapy.",EGFR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1451943907710.1186/1471-2407-9-145Research ArticleA gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer Balko Justin M 1jmbalk2@email.uky.eduBlack Esther P 1Penni.Black@uky.edu1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA2009 13 5 2009 9 145 145 28 1 2009 13 5 2009 Copyright (c)2009 Balko and Black; licensee BioMed Central Ltd.2009Balko and Black; licensee BioMed Central Ltd.",Cancer1471,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1451943907710.1186/1471-2407-9-145Research ArticleA gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer Balko Justin M 1jmbalk2@email.uky.eduBlack Esther P 1Penni.Black@uky.edu1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA2009 13 5 2009 9 145 145 28 1 2009 13 5 2009 Copyright (c)2009 Balko and Black; licensee BioMed Central Ltd.2009Balko and Black; licensee BioMed Central Ltd.",EGFR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1451943907710.1186/1471-2407-9-145Research ArticleA gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer Balko Justin M 1jmbalk2@email.uky.eduBlack Esther P 1Penni.Black@uky.edu1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA2009 13 5 2009 9 145 145 28 1 2009 13 5 2009 Copyright (c)2009 Balko and Black; licensee BioMed Central Ltd.2009Balko and Black; licensee BioMed Central Ltd.",USA2009,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1451943907710.1186/1471-2407-9-145Research ArticleA gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer Balko Justin M 1jmbalk2@email.uky.eduBlack Esther P 1Penni.Black@uky.edu1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA2009 13 5 2009 9 145 145 28 1 2009 13 5 2009 Copyright (c)2009 Balko and Black; licensee BioMed Central Ltd.2009Balko and Black; licensee BioMed Central Ltd.",BMC,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1451943907710.1186/1471-2407-9-145Research ArticleA gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer Balko Justin M 1jmbalk2@email.uky.eduBlack Esther P 1Penni.Black@uky.edu1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA2009 13 5 2009 9 145 145 28 1 2009 13 5 2009 Copyright (c)2009 Balko and Black; licensee BioMed Central Ltd.2009Balko and Black; licensee BioMed Central Ltd.",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",Mutations in the KRAS gene occur in ~40% of CRC and are a negative predictor of response to cetuximab.,KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",Mutations in the KRAS gene occur in ~40% of CRC and are a negative predictor of response to cetuximab.,CRC,cetuximab,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",FBS,glutamine,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",FBS,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",FBS,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",RPMI,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",RPMI,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",RPMI,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",CO2,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",CO2,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",CO2,streptomycin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","Previously frozen breast cancer tissue samples were fixed in 10% neutral buffered formalin, embedded in paraffin and used to construct TMAs consisting of 0.6 mm tissue cores using a manual arrayer (Beecher Instruments, Inc., Silver Springs, Maryland, USA) as previously described [35,36].

",USA,Silver,1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Stratified analyses were performed on sub-groups of menopausal status, BMI, family history, and estrogen, progesterone, and HER2 receptor status (breast cancer) and age, family history, BMI, stage, grade, histology, and tumor behavior (ovarian cancer).

",BMI,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Stratified analyses were performed on sub-groups of menopausal status, BMI, family history, and estrogen, progesterone, and HER2 receptor status (breast cancer) and age, family history, BMI, stage, grade, histology, and tumor behavior (ovarian cancer).

",HER2,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Stratified analyses were performed on sub-groups of menopausal status, BMI, family history, and estrogen, progesterone, and HER2 receptor status (breast cancer) and age, family history, BMI, stage, grade, histology, and tumor behavior (ovarian cancer).

",BMI,progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Scoring
Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1.",E600,SF,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Scoring
Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1.",TMA,SF,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Scoring
Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1.",CAP,SF,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Scoring
Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1.",DXM,SF,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Scoring
Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1.",SMH,SF,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Scoring
Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1.",TMA,SF,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Identification of p53-associated gene expression in AML cells after induction therapy with anthracycline and cytarabine
Samples from all treated patients were analyzed using Agilent 44 k oligonucleotide microarrays and comparing gene expression before and after induction therapy with anthracycline and cytarabine.",AML,cytarabine,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Identification of p53-associated gene expression in AML cells after induction therapy with anthracycline and cytarabine
Samples from all treated patients were analyzed using Agilent 44 k oligonucleotide microarrays and comparing gene expression before and after induction therapy with anthracycline and cytarabine.",AML,anthracycline,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Identification of p53-associated gene expression in AML cells after induction therapy with anthracycline and cytarabine
Samples from all treated patients were analyzed using Agilent 44 k oligonucleotide microarrays and comparing gene expression before and after induction therapy with anthracycline and cytarabine.",AML,cytarabine,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Identification of p53-associated gene expression in AML cells after induction therapy with anthracycline and cytarabine
Samples from all treated patients were analyzed using Agilent 44 k oligonucleotide microarrays and comparing gene expression before and after induction therapy with anthracycline and cytarabine.",AML,anthracycline,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In contrast to what have been observed in other cell lines, selenium treatment had little or no effect on survivin expression in several androgen-independent prostate cancer cell lines.",survivin,selenium,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",AML cells obtained from one patient (P8) prior to chemotherapy were also treated ex vivo with 8.0 mM daunorubicin for 4 h in order to compare with in vivo changes of gene expression.,AML,daunorubicin,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",AML cells obtained from one patient (P8) prior to chemotherapy were also treated ex vivo with 8.0 mM daunorubicin for 4 h in order to compare with in vivo changes of gene expression.,P8,daunorubicin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","The fused cells were resuspended in DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM hypoxanthine, 160 mM thymidine, and 400 nM aminopterin.",BRL,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","The fused cells were resuspended in DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM hypoxanthine, 160 mM thymidine, and 400 nM aminopterin.",BRL,penicillin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","The fused cells were resuspended in DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM hypoxanthine, 160 mM thymidine, and 400 nM aminopterin.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","The fused cells were resuspended in DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM hypoxanthine, 160 mM thymidine, and 400 nM aminopterin.",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",Equivalent volumes of lysates containing 20 ug of total protein were loaded and size-fractionated using 10% SDS-polyacrylamide gels.,SDS,polyacrylamide,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Negative	
	
Intrinsic molecular subtype	Basal-like	Basal-like	Luminal-like	Luminal-like	
	
TP53 status	Wildtype	Mutated	Mutated	Mutated	
	
Volume doubling time	NA	1-2 days	NA	7 days	
	
Proliferation index (Ki67)	Missing	28%	Missing	35%	
Summary of characteristics related to genotype and phenotype of the xenograft models

",Ki67,Luminal,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Negative	
	
Intrinsic molecular subtype	Basal-like	Basal-like	Luminal-like	Luminal-like	
	
TP53 status	Wildtype	Mutated	Mutated	Mutated	
	
Volume doubling time	NA	1-2 days	NA	7 days	
	
Proliferation index (Ki67)	Missing	28%	Missing	35%	
Summary of characteristics related to genotype and phenotype of the xenograft models

",Ki67,Luminal,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Negative	
	
Intrinsic molecular subtype	Basal-like	Basal-like	Luminal-like	Luminal-like	
	
TP53 status	Wildtype	Mutated	Mutated	Mutated	
	
Volume doubling time	NA	1-2 days	NA	7 days	
	
Proliferation index (Ki67)	Missing	28%	Missing	35%	
Summary of characteristics related to genotype and phenotype of the xenograft models

",TP53,Luminal,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Negative	
	
Intrinsic molecular subtype	Basal-like	Basal-like	Luminal-like	Luminal-like	
	
TP53 status	Wildtype	Mutated	Mutated	Mutated	
	
Volume doubling time	NA	1-2 days	NA	7 days	
	
Proliferation index (Ki67)	Missing	28%	Missing	35%	
Summary of characteristics related to genotype and phenotype of the xenograft models

",TP53,Luminal,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In the analysis of the anthracycline-treated subgroup, TIMP-1 analyzed as a continuous variable showed a strong tendency for higher levels to be associated with a shorter DFS (HR 1.75, 95% CI 1.00-3.07, P = 0.05).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In the analysis of the anthracycline-treated subgroup, TIMP-1 analyzed as a continuous variable showed a strong tendency for higher levels to be associated with a shorter DFS (HR 1.75, 95% CI 1.00-3.07, P = 0.05).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In the analysis of the anthracycline-treated subgroup, TIMP-1 analyzed as a continuous variable showed a strong tendency for higher levels to be associated with a shorter DFS (HR 1.75, 95% CI 1.00-3.07, P = 0.05).",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In the analysis of the anthracycline-treated subgroup, TIMP-1 analyzed as a continuous variable showed a strong tendency for higher levels to be associated with a shorter DFS (HR 1.75, 95% CI 1.00-3.07, P = 0.05).",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In the latest report of a 16-year follow-up of the NSABP B27 study[26], the addition of neoadjuvant docetaxel to the AC regimen resulted in a doubled pCR rate but not in an increased survival rate, suggesting that pCR of the breast may not completely take the place of OS as the surrogate end point for neoadjuvant chemotherapy studies.",B27,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In the latest report of a 16-year follow-up of the NSABP B27 study[26], the addition of neoadjuvant docetaxel to the AC regimen resulted in a doubled pCR rate but not in an increased survival rate, suggesting that pCR of the breast may not completely take the place of OS as the surrogate end point for neoadjuvant chemotherapy studies.",OS,docetaxel,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In the latest report of a 16-year follow-up of the NSABP B27 study[26], the addition of neoadjuvant docetaxel to the AC regimen resulted in a doubled pCR rate but not in an increased survival rate, suggesting that pCR of the breast may not completely take the place of OS as the surrogate end point for neoadjuvant chemotherapy studies.",pCR,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In the latest report of a 16-year follow-up of the NSABP B27 study[26], the addition of neoadjuvant docetaxel to the AC regimen resulted in a doubled pCR rate but not in an increased survival rate, suggesting that pCR of the breast may not completely take the place of OS as the surrogate end point for neoadjuvant chemotherapy studies.",NSABP,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In the latest report of a 16-year follow-up of the NSABP B27 study[26], the addition of neoadjuvant docetaxel to the AC regimen resulted in a doubled pCR rate but not in an increased survival rate, suggesting that pCR of the breast may not completely take the place of OS as the surrogate end point for neoadjuvant chemotherapy studies.",AC,docetaxel,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","In the latest report of a 16-year follow-up of the NSABP B27 study[26], the addition of neoadjuvant docetaxel to the AC regimen resulted in a doubled pCR rate but not in an increased survival rate, suggesting that pCR of the breast may not completely take the place of OS as the surrogate end point for neoadjuvant chemotherapy studies.",pCR,docetaxel,-1
"PMC 
BMC_Cancer_2010_Apr_14_10_140.txt
","Three tissue cylinders with a diameter of 0.6 mm [38,39] from representative tumor areas identified on H&E stained slides, generally at the suprabasal areas of the primary tumors, were punched and mounted into a recipient paraffin block using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA).",USA,Silver,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",TTP,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",TTP,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",TTP,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",TTP,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",CR,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",CR,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",CR,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",CR,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",PR,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",PR,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",PR,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the univariate analysis of TTP, the following variables were included: age &#62; 65 years; age &#60; 35 years; tumour stage at primary diagnosis (localized versus metastatic); grading (1,2 versus 3); histological subtype (ductal versus lobular carcinoma); hormone receptor status (oestrogen and/or progesterone receptor positive versus negative); metastatic sites (non-visceral only versus visceral involvement); number of metastatic sites (1 versus >= 2; <= 2 versus &#62; 2); time to disease recurrence &#60; 12 months following primary treatment; trastuzumab from diagnosis of metastatic disease; response (CR + PR) to first-line trastuzumab treatment; and appearance of new metastatic sites upon progression on first-line trastuzumab.",PR,trastuzumab,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",Cancer1471,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",PI3K,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",USA2,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",UK3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",ArticleMP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",HER,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",USA2009,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1421943298710.1186/1471-2407-9-142Research ArticleMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer Qi Wenqing 1wenqing@email.arizona.eduCooke Larry S 1lcooke@azcc.arizona.eduStejskal Amy 1stejskal@email.arizona.eduRiley Christopher 1cjriley@email.arizona.eduCroce Kimiko Della 1kimiko@email.arizona.eduSaldanha Jose W 2jsaldan@nimr.mrc.ac.ukBearss David 3David.Bearss@supergen.comMahadevan Daruka 1dmahadevan@azcc.arizona.edu1 Arizona Cancer Center, the University of Arizona, Tucson, AZ 85724, USA2 National Institute for Medical Research, Mill Hill, London, UK3 SuperGen, Inc, Dublin, CA 94568, USA2009 11 5 2009 9 142 142 8 1 2009 11 5 2009 Copyright (c)2009 Qi et al; licensee BioMed Central Ltd.2009Qi et al; licensee BioMed Central Ltd.",BMC,Erlotinib,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,DMEM,charcoal,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,MOI,charcoal,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,CSFCS,charcoal,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,ERE,charcoal,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Consistent with the idea that AMPK activation might inhibit growth of tumour cells were findings that the oral anti-diabetic drug, metformin, inhibits proliferation of epithelial cells derived from breast, prostate and ovarian cancers, an effect that requires both LKB1 and AMPK [34].",AMPK,metformin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Consistent with the idea that AMPK activation might inhibit growth of tumour cells were findings that the oral anti-diabetic drug, metformin, inhibits proliferation of epithelial cells derived from breast, prostate and ovarian cancers, an effect that requires both LKB1 and AMPK [34].",AMPK,metformin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","Consistent with the idea that AMPK activation might inhibit growth of tumour cells were findings that the oral anti-diabetic drug, metformin, inhibits proliferation of epithelial cells derived from breast, prostate and ovarian cancers, an effect that requires both LKB1 and AMPK [34].",LKB1,metformin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","The formed cell aggregates were manually transferred to a layer of polymerized Matrigel(tm) (growth factor-reduced, BD) mixed 1:1 with serum-free DMEM prior to use.",DMEM,BD,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",It has yet to be shown whether AREG and EREG hold any external validity as predictors of cetuximab response.,EREG,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",It has yet to be shown whether AREG and EREG hold any external validity as predictors of cetuximab response.,AREG,cetuximab,1
"PMC 
BMC_Cancer_2010_Apr_7_10_129.txt
","Methods
A bladder cell line was engineered to express a doxycycline (dox) regulated shRNA against PSCA.",PSCA,doxycycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",HR,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In Cox univariate regression analyses, both in patients who received adjuvant anthracycline-based chemotherapy and in CMF-treated patients, we found no statistically significant associations between TIMP-1 and DFS (Table 4, Figures 2A and 3A); however, in anthracycline-treated patients, despite the non-significant results, there was a trend for TIMP-1 high patients to have a worse outcome than TIMP-1 low patients, especially when analyzing TIMP-1 as a continuous variable (HR 1.66, 95% CI 0.96-2.85, P = 0.07).",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2010_Aug_13_10_423.txt
","Factors at initial therapy
The following factors were used in a Cox proportional hazards mode: age at surgery (Age), menstruation state, breast tumor (T) with minor modification (T2 tumors were classed as small (2.1-3.0 cm) or large (3.1-5.0 cm)), clinical and pathological lymph node state (N and pN), histopathology, and estrogen receptor and progesterone receptor status.",T,progesterone,-1
"PMC 
BMC_Cancer_2010_Aug_13_10_423.txt
","Factors at initial therapy
The following factors were used in a Cox proportional hazards mode: age at surgery (Age), menstruation state, breast tumor (T) with minor modification (T2 tumors were classed as small (2.1-3.0 cm) or large (3.1-5.0 cm)), clinical and pathological lymph node state (N and pN), histopathology, and estrogen receptor and progesterone receptor status.",T2,progesterone,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
",A Cox proportional hazard model was applied as multivariate analysis to evaluate factors associated with OS and TTP on second-line trastuzumab-based therapy.,OS,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
",A Cox proportional hazard model was applied as multivariate analysis to evaluate factors associated with OS and TTP on second-line trastuzumab-based therapy.,TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","DNA AP-sites detection
To test the hypothesis that ALSs generated by etoposide-oxidative stress could develop into DNA-AP sites, we used the enzyme Exo III, which recognizes this kind of DNA lesions.",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","DNA AP-sites detection
To test the hypothesis that ALSs generated by etoposide-oxidative stress could develop into DNA-AP sites, we used the enzyme Exo III, which recognizes this kind of DNA lesions.",III,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","DNA AP-sites detection
To test the hypothesis that ALSs generated by etoposide-oxidative stress could develop into DNA-AP sites, we used the enzyme Exo III, which recognizes this kind of DNA lesions.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","DNA AP-sites detection
To test the hypothesis that ALSs generated by etoposide-oxidative stress could develop into DNA-AP sites, we used the enzyme Exo III, which recognizes this kind of DNA lesions.",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Click here for file

 Additional file 3
IC50 concentration of Sulforaphane (SF) and Se-methylselenocysteine (Se-MSC) in CSp and SeSp on LNCaP, PC-3, DU-145, and CHEK-1 cells.",DU-145,SF,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Click here for file

 Additional file 3
IC50 concentration of Sulforaphane (SF) and Se-methylselenocysteine (Se-MSC) in CSp and SeSp on LNCaP, PC-3, DU-145, and CHEK-1 cells.",IC50,SF,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Click here for file

 Additional file 3
IC50 concentration of Sulforaphane (SF) and Se-methylselenocysteine (Se-MSC) in CSp and SeSp on LNCaP, PC-3, DU-145, and CHEK-1 cells.",PC-3,SF,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Click here for file

 Additional file 3
IC50 concentration of Sulforaphane (SF) and Se-methylselenocysteine (Se-MSC) in CSp and SeSp on LNCaP, PC-3, DU-145, and CHEK-1 cells.",MSC,SF,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Click here for file

 Additional file 3
IC50 concentration of Sulforaphane (SF) and Se-methylselenocysteine (Se-MSC) in CSp and SeSp on LNCaP, PC-3, DU-145, and CHEK-1 cells.",CHEK-1,SF,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3981991708510.1186/1471-2407-9-398Research ArticleDNA-AP sites generation by Etoposide in whole blood cells Rojas Emilio 1emilior@servidor.unam.mxMussali Patricia 1pmussali@yahoo.com.mxTovar Efrain 2etovar@yahoo.mxValverde Mahara 1mahara@biomedicas.unam.mx1 Departamento de Medicina Genomica y Toxicologia Ambiental Instituto de Investigaciones Biomedicas.",Cancer1471,Etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3981991708510.1186/1471-2407-9-398Research ArticleDNA-AP sites generation by Etoposide in whole blood cells Rojas Emilio 1emilior@servidor.unam.mxMussali Patricia 1pmussali@yahoo.com.mxTovar Efrain 2etovar@yahoo.mxValverde Mahara 1mahara@biomedicas.unam.mx1 Departamento de Medicina Genomica y Toxicologia Ambiental Instituto de Investigaciones Biomedicas.",BMC,Etoposide,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Nonetheless, 2/2 KRAS-mutant patients demonstrating stable disease to cetuximab were captured in the sensitive group (Figure 1C).",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","However, in the absence of a genomic data to predict response, most wildtype KRAS mCRC patients could be considered candidates for cetuximab therapy.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","However, in the absence of a genomic data to predict response, most wildtype KRAS mCRC patients could be considered candidates for cetuximab therapy.",mCRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",mCRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",mCRC,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",GEPR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",GEPR,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",PPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",PPV,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",PPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",PPV,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",KRAS,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",NPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",NPV,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",KRAS,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",NPV,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",NPV,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Table 1 Calculated parameters for the ability of the GEPR to predict disease control

Parameter	KRAS-wildtype	All patients	KRAS-mutant	
Specificity	0.32	0.4	0.5	
Sensitivity	0.85	0.8	1	
PPV	0.57	0.43	0.18	
NPV	0.66	0.77	1	
NPV: negative predictive value; PPV positive predictive value

The gene expression predictor of response to erlotinib stratifies cetuximab-treated mCRC patients based on progression-free survival
We next determined whether KRAS-wildtype patients identified by the model as 'sensitive' would exhibit true clinical benefit when compared to those classified as 'resistant'.",KRAS,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",Figure 2 The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progression-free survival in metastatic CRC patients treated with cetuximab.,EGFR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",Figure 2 The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progression-free survival in metastatic CRC patients treated with cetuximab.,GEPR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",Figure 2 The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progression-free survival in metastatic CRC patients treated with cetuximab.,CRC,cetuximab,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Previous studies [25,28,29] have shown that inhibitors of PI Synthase, inostamycin and d-hexachloro-cyclohexane inhibit PI synthesis and blocked cell cycle progression in the G1 or S phase respectively.",G1,inostamycin,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To further determine whether MP470 or combination with Erlotinib continues to inhibit Akt activity after androgen deprivation, LNCaP cells were cultured in androgen-free medium for 10 days and then treated with MP470, IM and Erlotinib alone or in combination.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To further determine whether MP470 or combination with Erlotinib continues to inhibit Akt activity after androgen deprivation, LNCaP cells were cultured in androgen-free medium for 10 days and then treated with MP470, IM and Erlotinib alone or in combination.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To further determine whether MP470 or combination with Erlotinib continues to inhibit Akt activity after androgen deprivation, LNCaP cells were cultured in androgen-free medium for 10 days and then treated with MP470, IM and Erlotinib alone or in combination.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","To further determine whether MP470 or combination with Erlotinib continues to inhibit Akt activity after androgen deprivation, LNCaP cells were cultured in androgen-free medium for 10 days and then treated with MP470, IM and Erlotinib alone or in combination.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","It has been shown that selenium decreased survivin expression in several prostate cancer cell lines, including LNCaP, PC-3, and C4-2 [18].",PC-3,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","It has been shown that selenium decreased survivin expression in several prostate cancer cell lines, including LNCaP, PC-3, and C4-2 [18].",C4,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","It has been shown that selenium decreased survivin expression in several prostate cancer cell lines, including LNCaP, PC-3, and C4-2 [18].",survivin,selenium,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A combination of MP470 and Erlotinib causes a further decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP cell survival, we evaluated whether MP470 or MP470 plus Erlotinib could inhibit Akt activation.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",PC-3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",PC-3,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",A549,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",A549,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",DMSO,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A549, LNCaP and PC-3 cells were treated with DMSO, 10 mM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr.",MP470,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO or different doses of Erlotinib, MP470, IM or combinations as indicated for 30 hr. Phospho(Ser473)-Akt and total Akt",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO or different doses of Erlotinib, MP470, IM or combinations as indicated for 30 hr. Phospho(Ser473)-Akt and total Akt",DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment generates the production of reactive oxygen species, principally phenoxyl radicals, in non-stimulated whole blood cells, then exposure to an antioxidant should reduce the extent of DNA damage induced.

",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","In this study, we used the alkaline SCGE assay at pH 12.3 and pH &#62;13 in non-stimulated and PHA-stimulated human blood cells to assess the genotoxicity associated with etoposide-induced oxidative stress in non-transformed cells.",SCGE,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","In this study, we used the alkaline SCGE assay at pH 12.3 and pH &#62;13 in non-stimulated and PHA-stimulated human blood cells to assess the genotoxicity associated with etoposide-induced oxidative stress in non-transformed cells.",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were exposed to varying concentrations of Erlotinib (Tarceva), MP470 or Erlotinib (10 mM) plus MP470 (varied concentrations) for 4 days.",MP470,Tarceva,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were exposed to varying concentrations of Erlotinib (Tarceva), MP470 or Erlotinib (10 mM) plus MP470 (varied concentrations) for 4 days.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were exposed to varying concentrations of Erlotinib (Tarceva), MP470 or Erlotinib (10 mM) plus MP470 (varied concentrations) for 4 days.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were exposed to varying concentrations of Erlotinib (Tarceva), MP470 or Erlotinib (10 mM) plus MP470 (varied concentrations) for 4 days.",MP470,Tarceva,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were exposed to varying concentrations of Erlotinib (Tarceva), MP470 or Erlotinib (10 mM) plus MP470 (varied concentrations) for 4 days.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were exposed to varying concentrations of Erlotinib (Tarceva), MP470 or Erlotinib (10 mM) plus MP470 (varied concentrations) for 4 days.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Transwell assay
The invasion assay was done in 24 well cell culture chambers using transwell inserts (Corning life sciences, NY, Bioscience, San Jose, CA, USA) with 8 um Pore membrane precotated with matrigel (BD biosciense, San Jose, CA, USA).",USA,BD,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Transwell assay
The invasion assay was done in 24 well cell culture chambers using transwell inserts (Corning life sciences, NY, Bioscience, San Jose, CA, USA) with 8 um Pore membrane precotated with matrigel (BD biosciense, San Jose, CA, USA).",USA,BD,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Transwell assay
The invasion assay was done in 24 well cell culture chambers using transwell inserts (Corning life sciences, NY, Bioscience, San Jose, CA, USA) with 8 um Pore membrane precotated with matrigel (BD biosciense, San Jose, CA, USA).",San,BD,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Transwell assay
The invasion assay was done in 24 well cell culture chambers using transwell inserts (Corning life sciences, NY, Bioscience, San Jose, CA, USA) with 8 um Pore membrane precotated with matrigel (BD biosciense, San Jose, CA, USA).",San,BD,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","ODN 2006 (10 uM), ODN 2006 control (10 uM), same volume of the control medium, or Chloroquine (10 uM) was added to both upper and lower well.",ODN,Chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","ODN 2006 (10 uM), ODN 2006 control (10 uM), same volume of the control medium, or Chloroquine (10 uM) was added to both upper and lower well.",ODN,Chloroquine,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
",Figure 7 Representative tissue microarray staining results illustrating YB-1 expression in relation to tumor stage (A and B) and progesterone receptor status (C and D). A and B,YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","A further finding of our study is the highly significant correlation between nuclear YB-1 expression and negativity of the progesterone receptor status (p = 0.002), which has not been described so far.",YB-1,progesterone,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Somatostatin analogues have been considered mainly an antisecretory drug for symptom control in NET and its ability to control the growth of NET has been a matter of debate [22].,NET,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Somatostatin analogues have been considered mainly an antisecretory drug for symptom control in NET and its ability to control the growth of NET has been a matter of debate [22].,NET,Somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Due to the role of survivin in conferring cytoprotection against apoptosis in cancer cells, we set out to examine the effect of selenium on the expression of survivin in several hormone refractory prostate cancer cell lines.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Due to the role of survivin in conferring cytoprotection against apoptosis in cancer cells, we set out to examine the effect of selenium on the expression of survivin in several hormone refractory prostate cancer cell lines.",survivin,selenium,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Together, these observations indicate that the combination of MP470 and Erlotinib inhibits Akt with an associated TGI.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Together, these observations indicate that the combination of MP470 and Erlotinib inhibits Akt with an associated TGI.

",TGI,Erlotinib,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Figure 6 A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.

",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Figure 6 A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.

",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Figure 6 A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.

",pT1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Figure 6 A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.

",pT1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Figure 6 A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.

",pT3,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Figure 6 A -- D: Distribution of time (months) to tumor-related death among the various subgroups (A, pT1-2; B, pT3-4; C, negative progesterone receptor status; D; positive progesterone receptor status) of breast cancer patients with negative and positive YB-1 immunoreactivity as estimated by the method of Kaplan and Meier.

",pT3,progesterone,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","In order to ensure that TLR9 is responsible for the invasion effects induced by CpG ODN, glioma cells were treated with CpG ODN in the presence of chloroquine, which is an inhibitor of endosomal acidification resulting in inhibition of TLR9 signaling[21].",ODN,chloroquine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","In order to ensure that TLR9 is responsible for the invasion effects induced by CpG ODN, glioma cells were treated with CpG ODN in the presence of chloroquine, which is an inhibitor of endosomal acidification resulting in inhibition of TLR9 signaling[21].",TLR9,chloroquine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","In order to ensure that TLR9 is responsible for the invasion effects induced by CpG ODN, glioma cells were treated with CpG ODN in the presence of chloroquine, which is an inhibitor of endosomal acidification resulting in inhibition of TLR9 signaling[21].",ODN,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","In order to ensure that TLR9 is responsible for the invasion effects induced by CpG ODN, glioma cells were treated with CpG ODN in the presence of chloroquine, which is an inhibitor of endosomal acidification resulting in inhibition of TLR9 signaling[21].",TLR9,chloroquine,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","We observed a close correlation between nuclear YB-1 detection and absence of progesterone receptor expression (p = 0.002), indicating that nuclear YB-1 detection marks a specific subgroup of breast cancer.",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","We observed a close correlation between nuclear YB-1 detection and absence of progesterone receptor expression (p = 0.002), indicating that nuclear YB-1 detection marks a specific subgroup of breast cancer.",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",HR,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In a similar multivariable analysis of OS, a more pronounced difference was found in benefit from anthracycline-based therapy in TIMP-1 low and high patients, when compared with untreated patients (TIMP-1 low patients: HR 0.54, 95% CI 0.26-1.11, P = 0.094; TIMP-1 high patients: HR 1.20, 95% CI 0.64-2.26, P = 0.58); none of the groups, though, had a significantly better outcome than patients who received no adjuvant chemotherapy.",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median time to progression first-line trastuzumab-based therapy (months)	8 (95% CI 6.26-9.74)	
	
",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Furthermore, patients younger than 35 years derived less benefit from a second trastuzumab-based treatment line (TTP median 3 months [95% CI 0.23-5.77] versus 7 [95% CI 5.67-8.33]; 0.026) (Table 3).",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Furthermore, patients younger than 35 years derived less benefit from a second trastuzumab-based treatment line (TTP median 3 months [95% CI 0.23-5.77] versus 7 [95% CI 5.67-8.33]; 0.026) (Table 3).",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Furthermore, patients younger than 35 years derived less benefit from a second trastuzumab-based treatment line (TTP median 3 months [95% CI 0.23-5.77] versus 7 [95% CI 5.67-8.33]; 0.026) (Table 3).",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","The mRNA levels of most of these genes except for BAX decreased at the end of the first cytarabine infusion, 18-24 h after start of treatment.",mRNA,cytarabine,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","The mRNA levels of most of these genes except for BAX decreased at the end of the first cytarabine infusion, 18-24 h after start of treatment.",BAX,cytarabine,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",CMF,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",HR,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",TIMP-1,Anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",CMF,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",DFS,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",CI,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 3 Multivariable analysis of DFS after adjuvant chemotherapy with CMF or anthracyclines vs. no adjuvant treatment*

		HR (95% CI)	P	
Anthracycline-treatment	TIMP-1 low vs. all untreated	0.71 (0.42-1.19)	0.19	
		
	TIMP-1 high vs. all untreated	0.97 (0.60-1.57)	0.90	
	
CMF-treatment	TIMP-1 low vs. all untreated	0.48 (0.33-0.69)	&#60;0.001	
		
	TIMP-1 high vs. all untreated	0.57 (0.41-0.81)	0.001	
	
Age	41-55 years vs. <= 40 years	0.63 (0.49-0.81)	&#60;0.001	
	
Tumor size	Stage 2 (&#62; 2 cm) vs. stage 1 (<= 2 cm)	1.80 (1.33-2.45)	&#60;0.001	
			
	Stage 3 (&#62;5",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
",Scores were entered into a standardized Excel worksheet with a sector map matching each TMA section.,TMA,Excel,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","For all tumour specimens analyzed, full histopathological and clinical follow-up data were available, allowing uni- and multivariate analyses of nuclear YB-1 expression in correlation to well-established factors of breast cancer prognosis (grade, nodal status, HER2, estrogen receptor (ER) status, progesterone receptor (PR) status).",PR,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","For all tumour specimens analyzed, full histopathological and clinical follow-up data were available, allowing uni- and multivariate analyses of nuclear YB-1 expression in correlation to well-established factors of breast cancer prognosis (grade, nodal status, HER2, estrogen receptor (ER) status, progesterone receptor (PR) status).",ER,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","For all tumour specimens analyzed, full histopathological and clinical follow-up data were available, allowing uni- and multivariate analyses of nuclear YB-1 expression in correlation to well-established factors of breast cancer prognosis (grade, nodal status, HER2, estrogen receptor (ER) status, progesterone receptor (PR) status).",HER2,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","For all tumour specimens analyzed, full histopathological and clinical follow-up data were available, allowing uni- and multivariate analyses of nuclear YB-1 expression in correlation to well-established factors of breast cancer prognosis (grade, nodal status, HER2, estrogen receptor (ER) status, progesterone receptor (PR) status).",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Overall survival (months)	43 (95% CI 37,92-48.09)	
	
Response rate second-line trastuzumab-based therapy (%)	30.9%	
	
Complete response (%)	7.2%	
	
Partial response (%)	23.7%	
	
Response rate first-line trastuzumab-based therapy (%)	44.3%	
	
Complete response (%)	9.3%	
	
Partial response (%)	35.1%	
	
Clinical Benefit second-line trastuzumab-based therapy (%)	66%	
	
Clinical Benefit first-line trastuzumab-based therapy (%)	83.5%	
	
Time to development of brain metastases (months)	21 (95% CI 13.86-28.14)	
	
",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Therefore, one versus more than one metastatic site appeared superior in prediction for TTP on second-line trastuzumab-based therapy and was included into the multivariate model.",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlotinib and MP470 plus Erlotinib in a mouse LNCaP xenograft model based on the cell culture mechanism of action studies.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",IDC,Luminal,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",III,Luminal,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",III,Luminal,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",ERBB2,Luminal,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",IDC,Luminal,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The primary endpoint of our study was to test the ability of our predictive algorithm to segregate cetuximab responders from non-responders in the KRAS-wildtype population included in the Khambata-Ford study.,KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Conclusion
Our model of sensitivity to EGFR inhibition stratified PFS following cetuximab in KRAS-wildtype CRC patients.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Conclusion
Our model of sensitivity to EGFR inhibition stratified PFS following cetuximab in KRAS-wildtype CRC patients.",PFS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Conclusion
Our model of sensitivity to EGFR inhibition stratified PFS following cetuximab in KRAS-wildtype CRC patients.",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Conclusion
Our model of sensitivity to EGFR inhibition stratified PFS following cetuximab in KRAS-wildtype CRC patients.",EGFR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The publication of these data presented an excellent opportunity to test our hypothesis that the 180-gene GEPR to erlotinib generated in lung adenocarcinoma cell lines was portable to KRAS-wildtype CRC in predicting response to cetuximab.,KRAS,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The publication of these data presented an excellent opportunity to test our hypothesis that the 180-gene GEPR to erlotinib generated in lung adenocarcinoma cell lines was portable to KRAS-wildtype CRC in predicting response to cetuximab.,KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The publication of these data presented an excellent opportunity to test our hypothesis that the 180-gene GEPR to erlotinib generated in lung adenocarcinoma cell lines was portable to KRAS-wildtype CRC in predicting response to cetuximab.,CRC,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The publication of these data presented an excellent opportunity to test our hypothesis that the 180-gene GEPR to erlotinib generated in lung adenocarcinoma cell lines was portable to KRAS-wildtype CRC in predicting response to cetuximab.,CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The publication of these data presented an excellent opportunity to test our hypothesis that the 180-gene GEPR to erlotinib generated in lung adenocarcinoma cell lines was portable to KRAS-wildtype CRC in predicting response to cetuximab.,GEPR,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",The publication of these data presented an excellent opportunity to test our hypothesis that the 180-gene GEPR to erlotinib generated in lung adenocarcinoma cell lines was portable to KRAS-wildtype CRC in predicting response to cetuximab.,GEPR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",We found that our GEPR of erlotinib response was strongly predictive of cetuximab response with no gene-weighting adjustment or additional gene selection.,GEPR,erlotinib,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",We found that our GEPR of erlotinib response was strongly predictive of cetuximab response with no gene-weighting adjustment or additional gene selection.,GEPR,cetuximab,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the absence of irinotecan, Topo I expression has no effect on OS (HR = 0.86, 95% CI 0.55-1.32, wald p = 0.481).",OS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the absence of irinotecan, Topo I expression has no effect on OS (HR = 0.86, 95% CI 0.55-1.32, wald p = 0.481).",HR,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the absence of irinotecan, Topo I expression has no effect on OS (HR = 0.86, 95% CI 0.55-1.32, wald p = 0.481).",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",EGFR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",EGFR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",TKI,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",GEPR,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Given the correlation between KRAS mutational status and response to both EGFR-mAB and EGFR-TKI in lung and colorectal tumors, we hypothesized that our previously published GEPR is capable of predicting response to cetuximab in metastatic CRC.

",mAB,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",This study represents the first true external validation of a molecular predictor of response to cetuximab in KRAS-WT metastatic CRC.,KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",This study represents the first true external validation of a molecular predictor of response to cetuximab in KRAS-WT metastatic CRC.,CRC,cetuximab,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",RPMI,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",RPMI,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",RPMI,streptomycin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",FBS,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",FBS,glutamine,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",FBS,streptomycin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",USA,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",USA,glutamine,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","The cells concentration was adjusted to 3 x 104 cells/ml and suspended in RPMI 1640 medium without FBS, supplemented with 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin and 20% Alamar Blue cell assay (tm)(BioSource International Inc., Camarillo, CA, USA) to determine metabolic activity/cell viability of the cells.",USA,streptomycin,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",We have previously published a gene expression predictor of response (GEPR) to erlotinib in lung cancer [11].,GEPR,erlotinib,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","The other 7 cases included in this study were mostly negative (one oxyphilic FTC, two cases with Graves'disease, one papillary thyroid carcinoma, one diffuse goiter and one thyroid without nodules).",FTC,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","The other 7 cases included in this study were mostly negative (one oxyphilic FTC, two cases with Graves'disease, one papillary thyroid carcinoma, one diffuse goiter and one thyroid without nodules).",FTC,thyroid,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The insensitivity of PC-3M cells to selenium could be related to its inability to suppress survivin expression in these cells.,survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The insensitivity of PC-3M cells to selenium could be related to its inability to suppress survivin expression in these cells.,PC-3,selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplasmic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.

Cox regression models including factors possibly influencing tumor-related survival and recurrence-free survival in relation to nuclear YB-1 expression were applied.",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplasmic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.

Cox regression models including factors possibly influencing tumor-related survival and recurrence-free survival in relation to nuclear YB-1 expression were applied.",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplasmic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.

Cox regression models including factors possibly influencing tumor-related survival and recurrence-free survival in relation to nuclear YB-1 expression were applied.",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplasmic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.

Cox regression models including factors possibly influencing tumor-related survival and recurrence-free survival in relation to nuclear YB-1 expression were applied.",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplasmic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.

Cox regression models including factors possibly influencing tumor-related survival and recurrence-free survival in relation to nuclear YB-1 expression were applied.",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","C and D: In breast tumors with positive progesterone receptor status (C) YB-1 expression is predominantly cytoplasmic, while tumors that lost progesterone receptor expression (D) exhibit prominent nuclear YB-1 expression.

Cox regression models including factors possibly influencing tumor-related survival and recurrence-free survival in relation to nuclear YB-1 expression were applied.",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",EDTA,insulin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",USA,insulin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",MCF-7,insulin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",EMEM,insulin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",FBS,insulin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",ATCC,insulin,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",QPRT is a 34 kD [17] key enzyme in the catabolism of quinolinate in the tryptophan-nicotinamide adenine dinucleotide pathway.,QPRT,tryptophan,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",G3,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",G2,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",G1,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT4,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",TP53,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pN1,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT3,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT1,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT2,Progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",HER2,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Nuclear YB-1 detection also correlated with tumor stage (p = 0.004), higher (G2/G3) histological grade (p = 0.011) and negativity of progesterone receptor status (p = 0.002) (Table 1).",YB-1,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","Nuclear YB-1 detection also correlated with tumor stage (p = 0.004), higher (G2/G3) histological grade (p = 0.011) and negativity of progesterone receptor status (p = 0.002) (Table 1).",G3,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3671983562110.1186/1471-2407-9-367Research ArticlePredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer Bartsch Rupert 1rupert.bartsch@meduniwien.ac.atDe Vries Catharina 1catharina.wenzel@meduniwien.ac.atPluschnig Ursula 1ursula.pluschnig@meduniwien.ac.atDubsky Peter 2peter.dubsky@meduniwien.ac.atBago-Horvath Zsuzsanna 3zsuzsanna.horvath@meduniwien.ac.atGampenrieder Simon P 1simon.gampenrieder@meduniwien.ac.atRudas Margaretha 3margaretha.rudas@meduniwien.ac.atMader Robert M 1robert.mader@meduniwien.ac.atRottenfusser Andrea 4andrea.rottenfusser@meduniwien.ac.atWiltschke Christoph 1christoph.wiltschke@meduniwien.ac.atGnant Michael 2michael.gnant@meduniwien.ac.atZielinski Christoph C 1christoph.zielinski@meduniwien.ac.atSteger Guenther G 1guenther.steger@meduniwien.ac.at1 Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria2 Department of Surgery, Medical University of Vienna, Vienna, Austria3 Department of Pathology, Medical University of Vienna, Vienna, Austria4 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria2009 17 10 2009 9 367 367 30 5 2009 17 10 2009 Copyright (c)2009 Bartsch et al; licensee BioMed Central Ltd.2009Bartsch et al; licensee BioMed Central Ltd.",Austria4,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3671983562110.1186/1471-2407-9-367Research ArticlePredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer Bartsch Rupert 1rupert.bartsch@meduniwien.ac.atDe Vries Catharina 1catharina.wenzel@meduniwien.ac.atPluschnig Ursula 1ursula.pluschnig@meduniwien.ac.atDubsky Peter 2peter.dubsky@meduniwien.ac.atBago-Horvath Zsuzsanna 3zsuzsanna.horvath@meduniwien.ac.atGampenrieder Simon P 1simon.gampenrieder@meduniwien.ac.atRudas Margaretha 3margaretha.rudas@meduniwien.ac.atMader Robert M 1robert.mader@meduniwien.ac.atRottenfusser Andrea 4andrea.rottenfusser@meduniwien.ac.atWiltschke Christoph 1christoph.wiltschke@meduniwien.ac.atGnant Michael 2michael.gnant@meduniwien.ac.atZielinski Christoph C 1christoph.zielinski@meduniwien.ac.atSteger Guenther G 1guenther.steger@meduniwien.ac.at1 Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria2 Department of Surgery, Medical University of Vienna, Vienna, Austria3 Department of Pathology, Medical University of Vienna, Vienna, Austria4 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria2009 17 10 2009 9 367 367 30 5 2009 17 10 2009 Copyright (c)2009 Bartsch et al; licensee BioMed Central Ltd.2009Bartsch et al; licensee BioMed Central Ltd.",Austria2,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3671983562110.1186/1471-2407-9-367Research ArticlePredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer Bartsch Rupert 1rupert.bartsch@meduniwien.ac.atDe Vries Catharina 1catharina.wenzel@meduniwien.ac.atPluschnig Ursula 1ursula.pluschnig@meduniwien.ac.atDubsky Peter 2peter.dubsky@meduniwien.ac.atBago-Horvath Zsuzsanna 3zsuzsanna.horvath@meduniwien.ac.atGampenrieder Simon P 1simon.gampenrieder@meduniwien.ac.atRudas Margaretha 3margaretha.rudas@meduniwien.ac.atMader Robert M 1robert.mader@meduniwien.ac.atRottenfusser Andrea 4andrea.rottenfusser@meduniwien.ac.atWiltschke Christoph 1christoph.wiltschke@meduniwien.ac.atGnant Michael 2michael.gnant@meduniwien.ac.atZielinski Christoph C 1christoph.zielinski@meduniwien.ac.atSteger Guenther G 1guenther.steger@meduniwien.ac.at1 Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria2 Department of Surgery, Medical University of Vienna, Vienna, Austria3 Department of Pathology, Medical University of Vienna, Vienna, Austria4 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria2009 17 10 2009 9 367 367 30 5 2009 17 10 2009 Copyright (c)2009 Bartsch et al; licensee BioMed Central Ltd.2009Bartsch et al; licensee BioMed Central Ltd.",BMC,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3671983562110.1186/1471-2407-9-367Research ArticlePredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer Bartsch Rupert 1rupert.bartsch@meduniwien.ac.atDe Vries Catharina 1catharina.wenzel@meduniwien.ac.atPluschnig Ursula 1ursula.pluschnig@meduniwien.ac.atDubsky Peter 2peter.dubsky@meduniwien.ac.atBago-Horvath Zsuzsanna 3zsuzsanna.horvath@meduniwien.ac.atGampenrieder Simon P 1simon.gampenrieder@meduniwien.ac.atRudas Margaretha 3margaretha.rudas@meduniwien.ac.atMader Robert M 1robert.mader@meduniwien.ac.atRottenfusser Andrea 4andrea.rottenfusser@meduniwien.ac.atWiltschke Christoph 1christoph.wiltschke@meduniwien.ac.atGnant Michael 2michael.gnant@meduniwien.ac.atZielinski Christoph C 1christoph.zielinski@meduniwien.ac.atSteger Guenther G 1guenther.steger@meduniwien.ac.at1 Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria2 Department of Surgery, Medical University of Vienna, Vienna, Austria3 Department of Pathology, Medical University of Vienna, Vienna, Austria4 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria2009 17 10 2009 9 367 367 30 5 2009 17 10 2009 Copyright (c)2009 Bartsch et al; licensee BioMed Central Ltd.2009Bartsch et al; licensee BioMed Central Ltd.",Austria3,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3671983562110.1186/1471-2407-9-367Research ArticlePredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer Bartsch Rupert 1rupert.bartsch@meduniwien.ac.atDe Vries Catharina 1catharina.wenzel@meduniwien.ac.atPluschnig Ursula 1ursula.pluschnig@meduniwien.ac.atDubsky Peter 2peter.dubsky@meduniwien.ac.atBago-Horvath Zsuzsanna 3zsuzsanna.horvath@meduniwien.ac.atGampenrieder Simon P 1simon.gampenrieder@meduniwien.ac.atRudas Margaretha 3margaretha.rudas@meduniwien.ac.atMader Robert M 1robert.mader@meduniwien.ac.atRottenfusser Andrea 4andrea.rottenfusser@meduniwien.ac.atWiltschke Christoph 1christoph.wiltschke@meduniwien.ac.atGnant Michael 2michael.gnant@meduniwien.ac.atZielinski Christoph C 1christoph.zielinski@meduniwien.ac.atSteger Guenther G 1guenther.steger@meduniwien.ac.at1 Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria2 Department of Surgery, Medical University of Vienna, Vienna, Austria3 Department of Pathology, Medical University of Vienna, Vienna, Austria4 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria2009 17 10 2009 9 367 367 30 5 2009 17 10 2009 Copyright (c)2009 Bartsch et al; licensee BioMed Central Ltd.2009Bartsch et al; licensee BioMed Central Ltd.",Cancer1471,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3671983562110.1186/1471-2407-9-367Research ArticlePredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer Bartsch Rupert 1rupert.bartsch@meduniwien.ac.atDe Vries Catharina 1catharina.wenzel@meduniwien.ac.atPluschnig Ursula 1ursula.pluschnig@meduniwien.ac.atDubsky Peter 2peter.dubsky@meduniwien.ac.atBago-Horvath Zsuzsanna 3zsuzsanna.horvath@meduniwien.ac.atGampenrieder Simon P 1simon.gampenrieder@meduniwien.ac.atRudas Margaretha 3margaretha.rudas@meduniwien.ac.atMader Robert M 1robert.mader@meduniwien.ac.atRottenfusser Andrea 4andrea.rottenfusser@meduniwien.ac.atWiltschke Christoph 1christoph.wiltschke@meduniwien.ac.atGnant Michael 2michael.gnant@meduniwien.ac.atZielinski Christoph C 1christoph.zielinski@meduniwien.ac.atSteger Guenther G 1guenther.steger@meduniwien.ac.at1 Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria2 Department of Surgery, Medical University of Vienna, Vienna, Austria3 Department of Pathology, Medical University of Vienna, Vienna, Austria4 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria2009 17 10 2009 9 367 367 30 5 2009 17 10 2009 Copyright (c)2009 Bartsch et al; licensee BioMed Central Ltd.2009Bartsch et al; licensee BioMed Central Ltd.",Austria2009,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Discussion
We performed gene expression analysis of 12 follicular thyroid tumours (4 FTA, 4 minimal invasive FTC and 4 widely invasive FTC) resulting in a list of 25 genes which differed highly in their FTC and FTA expressions.",FTC,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Discussion
We performed gene expression analysis of 12 follicular thyroid tumours (4 FTA, 4 minimal invasive FTC and 4 widely invasive FTC) resulting in a list of 25 genes which differed highly in their FTC and FTA expressions.",FTA,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Discussion
We performed gene expression analysis of 12 follicular thyroid tumours (4 FTA, 4 minimal invasive FTC and 4 widely invasive FTC) resulting in a list of 25 genes which differed highly in their FTC and FTA expressions.",FTA,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Discussion
We performed gene expression analysis of 12 follicular thyroid tumours (4 FTA, 4 minimal invasive FTC and 4 widely invasive FTC) resulting in a list of 25 genes which differed highly in their FTC and FTA expressions.",FTC,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Discussion
We performed gene expression analysis of 12 follicular thyroid tumours (4 FTA, 4 minimal invasive FTC and 4 widely invasive FTC) resulting in a list of 25 genes which differed highly in their FTC and FTA expressions.",FTC,thyroid,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",RPMI,streptomycin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",RPMI,penicillin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",CO2,streptomycin,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",CO2,penicillin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",PC-3,streptomycin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",PC-3,penicillin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",DU145,streptomycin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",DU145,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In support of the notion, we found that the effect of selenium was greatly enhanced when survivin expression was silenced.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Immunohistochemistry for estrogen receptor (ER-alpha), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2/neu) and Ki-67 was performed in IELs and adjacent tumor tissues.

",ER,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Immunohistochemistry for estrogen receptor (ER-alpha), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2/neu) and Ki-67 was performed in IELs and adjacent tumor tissues.

",Ki-67,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Immunohistochemistry for estrogen receptor (ER-alpha), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2/neu) and Ki-67 was performed in IELs and adjacent tumor tissues.

",PR,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_29_9_348.txt
","Helium and nitrogen of purity 6.0 (i.e., 99.9999%) were purchased from Linde (Vienna, Austria) and 3 Lit Tedlar bags from SKC (Eighty Four, PA, USA).",PA,Helium,-1
"PMC 
BMC_Cancer_2009_Sep_29_9_348.txt
","Helium and nitrogen of purity 6.0 (i.e., 99.9999%) were purchased from Linde (Vienna, Austria) and 3 Lit Tedlar bags from SKC (Eighty Four, PA, USA).",USA,Helium,-1
"PMC 
BMC_Cancer_2009_Sep_29_9_348.txt
","Helium and nitrogen of purity 6.0 (i.e., 99.9999%) were purchased from Linde (Vienna, Austria) and 3 Lit Tedlar bags from SKC (Eighty Four, PA, USA).",SKC,Helium,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",HR,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",HR,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",DFS,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",CMF,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",OS,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",CI,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",CI,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",TIMP-1,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

		DFS		OS		
			
		HR (95% CI)	P	HR (95% CI)	P	
Anthracycline-treated patients	TIMP-1
(continuous variable)	1.66 (0.96-2.85)	0.07	3.52 (1.54-8.06)	0.003	
		
	TIMP-1
(high vs. low)	1.52 (0.88-2.63)	0.13	2.53 (1.19-5.39)	0.02	
	
CMF-treated patients	TIMP-1
(continuous variable)	1.12 (0.84-1.51)	0.44	1.22 (0.82-1.81)	0.32	
		
	TIMP-1
(high vs. low)	1.15 (0.82-1.61)	0.42	1.44 (0.91-2.29)	0.12	
* Analyses stratified for hormone receptor status, nodal status and RT on the axilla.

",CMF,Anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",CI,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",HR,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients neither TIMP-1 low nor TIMP-1 high patients had a significantly improved survival when using the untreated patients as a reference group (TIMP-1 low patients: HR 0.74, 95% CI 0.45-1.24, P = 0.26; TIMP-1 high patients: HR 1.03, 95% CI 0.63-1.67, P = 0.92).",HR,anthracycline,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",COX-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",TIMP-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",MMP-9,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",TIMP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",NOS-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",TSP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, MMP-9, TSP-1, TIMP-2, and endostatin was significantly higher in AT than in normal liver or TT (p &#60; 0.01 and 0.05, respectively), while no significant difference was found in the levels of TIMP-1, COX-2, and NOS-2 between TT and AT.",MCP-1,endostatin,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Before initiation of trastuzumab treatment, echocardiography was mandatory, and patients with left ventricular ejection fraction (LVEF) below 50% were excluded.

",LVEF,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This finding indicates that AA provided some level of protection for the non-stimulated blood cell DNA in the oxidative micro-environment generated by the etoposide.

",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","One possible explanation is that the predictive value of TS can only be detected in the non-irinotecan treated group, since there is no data available connecting TS expression with responsiveness to irinotecan.",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","One possible explanation is that the predictive value of TS can only be detected in the non-irinotecan treated group, since there is no data available connecting TS expression with responsiveness to irinotecan.",TS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","One possible explanation is that the predictive value of TS can only be detected in the non-irinotecan treated group, since there is no data available connecting TS expression with responsiveness to irinotecan.",TS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","One possible explanation is that the predictive value of TS can only be detected in the non-irinotecan treated group, since there is no data available connecting TS expression with responsiveness to irinotecan.",TS,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","This is important, especially in the context of the negative findings of the SELECT trial with regard to the anticancer activity of selenium.",SELECT,selenium,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
",Our finding of a significant association of high TS expression with shorter DFS in a subgroup of patients not treated with irinotecan adds to the controversy.,DFS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
",Our finding of a significant association of high TS expression with shorter DFS in a subgroup of patients not treated with irinotecan adds to the controversy.,TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","In vitro transcription was performed with biotinylated ribonucleotides, and the biotin-labeled cRNA was hybridized to the GeneChips.",cRNA,biotin,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
In summary, our data show that etoposide can produce differential forms of DNA damage in PHA-stimulated and non-stimulated blood cells.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
In summary, our data show that etoposide can produce differential forms of DNA damage in PHA-stimulated and non-stimulated blood cells.",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","While there are data regarding the prognostic role of TS in the adjuvant setting in patients with CRC, little is known about the possible role of Topo I. Topo I is the target of the active irinotecan metabolite SN 38 and may therefore be a plausible predictive marker for irinotecan containing chemotherapy[14].",SN,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","While there are data regarding the prognostic role of TS in the adjuvant setting in patients with CRC, little is known about the possible role of Topo I. Topo I is the target of the active irinotecan metabolite SN 38 and may therefore be a plausible predictive marker for irinotecan containing chemotherapy[14].",SN,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","While there are data regarding the prognostic role of TS in the adjuvant setting in patients with CRC, little is known about the possible role of Topo I. Topo I is the target of the active irinotecan metabolite SN 38 and may therefore be a plausible predictive marker for irinotecan containing chemotherapy[14].",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","While there are data regarding the prognostic role of TS in the adjuvant setting in patients with CRC, little is known about the possible role of Topo I. Topo I is the target of the active irinotecan metabolite SN 38 and may therefore be a plausible predictive marker for irinotecan containing chemotherapy[14].",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","While there are data regarding the prognostic role of TS in the adjuvant setting in patients with CRC, little is known about the possible role of Topo I. Topo I is the target of the active irinotecan metabolite SN 38 and may therefore be a plausible predictive marker for irinotecan containing chemotherapy[14].",CRC,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","While there are data regarding the prognostic role of TS in the adjuvant setting in patients with CRC, little is known about the possible role of Topo I. Topo I is the target of the active irinotecan metabolite SN 38 and may therefore be a plausible predictive marker for irinotecan containing chemotherapy[14].",CRC,irinotecan,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Thus as structural maintenance of DNA is most challenged during DNA replication, it is expected that cycling cells would be the most susceptible to damage in the presence of etoposide.",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Thus as structural maintenance of DNA is most challenged during DNA replication, it is expected that cycling cells would be the most susceptible to damage in the presence of etoposide.",DNA,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","A neutralizing TNF-a antibody, infliximab (4 mg/ml, Sigma), was then used to treat MKN45 and HGC27 cells after an infection by 26695, and the induction of CXCR4 was inhibited significantly (P &#60; 0.01, respectively, Figure 3A, B).",MKN45,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","A neutralizing TNF-a antibody, infliximab (4 mg/ml, Sigma), was then used to treat MKN45 and HGC27 cells after an infection by 26695, and the induction of CXCR4 was inhibited significantly (P &#60; 0.01, respectively, Figure 3A, B).",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","A neutralizing TNF-a antibody, infliximab (4 mg/ml, Sigma), was then used to treat MKN45 and HGC27 cells after an infection by 26695, and the induction of CXCR4 was inhibited significantly (P &#60; 0.01, respectively, Figure 3A, B).",HGC27,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","MSA and MSC can be easily converted to methylselenol, which is considered to be the critical metabolite for the anticancer activity of selenium [14,27].",MSA,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","MSA and MSC can be easily converted to methylselenol, which is considered to be the critical metabolite for the anticancer activity of selenium [14,27].",MSC,selenium,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After another wash Vectastain avidin-biotin complex (Vector Laboratories, California, USA) was added for 10 minutes.",USA,biotin,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
",TMA sections were microwave-treated twice in citrate buffer (PH 6.0) at 99degC for 6 min.,TMA,citrate,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
",TMA sections were microwave-treated twice in citrate buffer (PH 6.0) at 99degC for 6 min.,PH,citrate,1
"PMC 
BMC_Cancer_2010_Apr_14_10_140.txt
","Cdc6
Microwave antigen retrieval was performed in citrate buffer, followed by incubation overnight at 4degC with the monoclonal mouse Cdc6 antibody, catalogue # sc-9964 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1: 20.

",Cdc6,citrate,-1
"PMC 
BMC_Cancer_2010_Apr_14_10_140.txt
","Cdc6
Microwave antigen retrieval was performed in citrate buffer, followed by incubation overnight at 4degC with the monoclonal mouse Cdc6 antibody, catalogue # sc-9964 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1: 20.

",Cdc6,citrate,-1
"PMC 
BMC_Cancer_2010_Apr_14_10_140.txt
","Cdc6
Microwave antigen retrieval was performed in citrate buffer, followed by incubation overnight at 4degC with the monoclonal mouse Cdc6 antibody, catalogue # sc-9964 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1: 20.

",USA,citrate,-1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
",SDS-PAGE was performed in 12% polyacrylamide gel and proteins were transferred for 1 hr using a Bio-Rad Semi-Dry apparatus in a transfer buffer.,PAGE,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
",SDS-PAGE was performed in 12% polyacrylamide gel and proteins were transferred for 1 hr using a Bio-Rad Semi-Dry apparatus in a transfer buffer.,SDS,polyacrylamide,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","MMP detection by zymography
Zymography gels were produced from standard 12% SDS-acrylamide gels containing gelatine or b-casein protein at a concentration of 1.2 mg/ml.",SDS,acrylamide,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","MMP detection by zymography
Zymography gels were produced from standard 12% SDS-acrylamide gels containing gelatine or b-casein protein at a concentration of 1.2 mg/ml.",MMP,acrylamide,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After four washing steps with phosphate-buffered saline with 0.05% Tween-20 (50 mM sodium phosphate, 3 mM potassium phosphate, 150 mM sodium chloride [pH 7.4]), blocking with 2.5% low fat milk powder in PBS was performed at 37degC for 1 h. After four additional washing steps Mabs dissolved in washing buffer at 1:50 were added to each well (200 ml) and incubated another hour at 37degC and washed four times.",PBS,sodium chloride,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After four washing steps with phosphate-buffered saline with 0.05% Tween-20 (50 mM sodium phosphate, 3 mM potassium phosphate, 150 mM sodium chloride [pH 7.4]), blocking with 2.5% low fat milk powder in PBS was performed at 37degC for 1 h. After four additional washing steps Mabs dissolved in washing buffer at 1:50 were added to each well (200 ml) and incubated another hour at 37degC and washed four times.",PBS,potassium phosphate,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After four washing steps with phosphate-buffered saline with 0.05% Tween-20 (50 mM sodium phosphate, 3 mM potassium phosphate, 150 mM sodium chloride [pH 7.4]), blocking with 2.5% low fat milk powder in PBS was performed at 37degC for 1 h. After four additional washing steps Mabs dissolved in washing buffer at 1:50 were added to each well (200 ml) and incubated another hour at 37degC and washed four times.",Tween-20,sodium chloride,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After four washing steps with phosphate-buffered saline with 0.05% Tween-20 (50 mM sodium phosphate, 3 mM potassium phosphate, 150 mM sodium chloride [pH 7.4]), blocking with 2.5% low fat milk powder in PBS was performed at 37degC for 1 h. After four additional washing steps Mabs dissolved in washing buffer at 1:50 were added to each well (200 ml) and incubated another hour at 37degC and washed four times.",Tween-20,potassium phosphate,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
",Slides were incubated with a 1:25 dilution of monoclonal biotin-labeled YB-1 antibody in 2% milk powder dissolved in PBS in a humidified chamber overnight at 4degC.,YB-1,biotin,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
",Slides were incubated with a 1:25 dilution of monoclonal biotin-labeled YB-1 antibody in 2% milk powder dissolved in PBS in a humidified chamber overnight at 4degC.,PBS,biotin,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Alkaline (pH &#62; 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells.",SCGE,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Alkaline (pH &#62; 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells.",DNA,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",MCP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",bFGF,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",NOS-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",TIMP-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",TSP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",COX-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver tissue was weaker than that in AT or TT.",MMP-9,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Figure 2 Immunohistochemical staining of MMP-9, TIMP-1, TIMP-2, endostatin, COX-2, and NOS-2 in tissues.",COX-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Figure 2 Immunohistochemical staining of MMP-9, TIMP-1, TIMP-2, endostatin, COX-2, and NOS-2 in tissues.",NOS-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Figure 2 Immunohistochemical staining of MMP-9, TIMP-1, TIMP-2, endostatin, COX-2, and NOS-2 in tissues.",TIMP-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Figure 2 Immunohistochemical staining of MMP-9, TIMP-1, TIMP-2, endostatin, COX-2, and NOS-2 in tissues.",TIMP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Figure 2 Immunohistochemical staining of MMP-9, TIMP-1, TIMP-2, endostatin, COX-2, and NOS-2 in tissues.",MMP-9,endostatin,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Furthermore, selenium-enriched broccoli sprouts but, not normal broccoli sprouts, induced a downregulation of the survival Akt/mTOR pathway.

",mTOR,selenium,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The results corroborated the presence of DNA-AP sites in the genomes of the non-stimulated cells treated with etoposide.,DNA,etoposide,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",USA3,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",Italy2,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",Italy5,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",USA2010,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",Italy4,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",IN,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",IN,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",BMC,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",IN,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",Cancer1471,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1562041258610.1186/1471-2407-10-156Research ArticleSpontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions Burrai Giovanni P 12vanniburrai@tiscali.itMohammed Sulma I 256mohammes@purdue.eduMiller Margaret A 2mille188@purdue.eduMarras Vincenzo 3marrasv@gmail.comPirino Salvatore 1pirino@uniss.itAddis Maria F 4addis@portocontericerche.itUzzau Sergio 4uzzau@portocontericerche.itAntuofermo Elisabetta 1eantuofermo@uniss.it1 Department of Pathology and Veterinary Clinic, Faculty of Veterinary Medicine, Sassari University, Italy2 Department of Comparative Pathobiology and Animal Disease Diagnostic Laboratory, Purdue University, West Lafayette, IN 47907, USA3 Institute of Anatomy and Histopathology, Sassari University School of Medicine, Sardinia, Italy4 PortoConteRicerche Srl, Tramariglio, Alghero, Sassari, Italy5 Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA6 Bindley Bioscience, Discovery Park, Purdue University, West Lafayette, IN 47907, USA2010 22 4 2010 10 156 156 17 7 2009 22 4 2010 Copyright (c)2010 Burrai et al; licensee BioMed Central Ltd.2010Burrai et al; licensee BioMed Central Ltd.",USA6,progesterone,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","After washing of the primary antibody, the slides were incubated in a biotin-free detection system (HRP super sensitive non-biotin detection system, BioGenex) for a total of 40 minutes.",HRP,biotin,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","After washing of the primary antibody, the slides were incubated in a biotin-free detection system (HRP super sensitive non-biotin detection system, BioGenex) for a total of 40 minutes.",HRP,biotin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The regions from 0.20 to -0.20 ppm (TSP), -0.85 to -1.15 ppm (ERETIC) and 3.60 to 2.90 ppm (glycine, taurine, GPC, PCho, choline, and creatine) were selected for quantification in all spectra.",ERETIC,creatine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The regions from 0.20 to -0.20 ppm (TSP), -0.85 to -1.15 ppm (ERETIC) and 3.60 to 2.90 ppm (glycine, taurine, GPC, PCho, choline, and creatine) were selected for quantification in all spectra.",TSP,creatine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","The regions from 0.20 to -0.20 ppm (TSP), -0.85 to -1.15 ppm (ERETIC) and 3.60 to 2.90 ppm (glycine, taurine, GPC, PCho, choline, and creatine) were selected for quantification in all spectra.",GPC,creatine,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","The PCR products were analyzed by electrophoresis on a 10% TBE-urea polyacrylamide gel (Invitrogen Corp., Carlsbad, CA).",TBE,polyacrylamide,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","The PCR products were analyzed by electrophoresis on a 10% TBE-urea polyacrylamide gel (Invitrogen Corp., Carlsbad, CA).",PCR,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the assessment of the predictive value of TS and Topo I, the interaction of each of the biomarkers under study with the irinotecan adjuvant treatment was taken into account.",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",Y,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",Y,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",X,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO (control), 10 mM of Erlotinib or MP470 or in combination for 48 h. Flow cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively.",X,Erlotinib,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",HCC,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",TIMP-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",TSP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",TIMP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Immunoreactivity to VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, TIMP-1, TIMP-2, and endostatin was observed mainly in HCC cells and hepatocytes, showing a predominant cytoplasmic staining with positive liver cells distributed throughout the tumor tissue and the surrounding liver (Figures 1 and 2).",MCP-1,endostatin,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","After sensitivity prediction on each of the datasets, the results were imported into Excel (Microsoft, Redmond, WA) and cross referenced with response and progression free survival (PFS).

",PFS,Excel,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Since KRAS status is used to determine the CRC patients who should receive cetuximab, the primary endpoint of our study was to determine if the GEPR could correctly stratify KRAS-wildtype patients according to response/disease control.",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Since KRAS status is used to determine the CRC patients who should receive cetuximab, the primary endpoint of our study was to determine if the GEPR could correctly stratify KRAS-wildtype patients according to response/disease control.",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Since KRAS status is used to determine the CRC patients who should receive cetuximab, the primary endpoint of our study was to determine if the GEPR could correctly stratify KRAS-wildtype patients according to response/disease control.",GEPR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Since KRAS status is used to determine the CRC patients who should receive cetuximab, the primary endpoint of our study was to determine if the GEPR could correctly stratify KRAS-wildtype patients according to response/disease control.",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",PC-3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",PC-3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",PC-3,Nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",PC-3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 mM of Erlotinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus IM for 32 hr and then left unsynchronized or synchronized with 0.3 mg/ml Nocodazole (Sigma) for 16 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Meanwhile, constitutive expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in normal liver tissue was weaker than that in AT or TT tissues (Table 1, Figures 1 and 2).",TSP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Meanwhile, constitutive expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in normal liver tissue was weaker than that in AT or TT tissues (Table 1, Figures 1 and 2).",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Meanwhile, constitutive expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in normal liver tissue was weaker than that in AT or TT tissues (Table 1, Figures 1 and 2).",MMP-9,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Meanwhile, constitutive expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in normal liver tissue was weaker than that in AT or TT tissues (Table 1, Figures 1 and 2).",MCP-1,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Meanwhile, constitutive expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in normal liver tissue was weaker than that in AT or TT tissues (Table 1, Figures 1 and 2).",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Meanwhile, constitutive expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, and endostatin in normal liver tissue was weaker than that in AT or TT tissues (Table 1, Figures 1 and 2).",TIMP-2,endostatin,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO and increasing doses of MP470 (1, 2, 5, 10 mM) alone or in combination with Erlotinib for 48 hr.",DMSO,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were treated with DMSO and increasing doses of MP470 (1, 2, 5, 10 mM) alone or in combination with Erlotinib for 48 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Because MP470 inhibits c-Kit and PDGFR RTKs, we evaluated Imatinib Mesylate (IM), a well-established c-Kit and PDGFR TKI.",MP470,Imatinib Mesylate,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Because MP470 inhibits c-Kit and PDGFR RTKs, we evaluated Imatinib Mesylate (IM), a well-established c-Kit and PDGFR TKI.",TKI,Imatinib Mesylate,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Because MP470 inhibits c-Kit and PDGFR RTKs, we evaluated Imatinib Mesylate (IM), a well-established c-Kit and PDGFR TKI.",PDGFR,Imatinib Mesylate,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Because MP470 inhibits c-Kit and PDGFR RTKs, we evaluated Imatinib Mesylate (IM), a well-established c-Kit and PDGFR TKI.",PDGFR,Imatinib Mesylate,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Western blot analysis
Protein extracts were obtained from cell pellets utilizing standard procedures, fractionated on a 12% polyacrylamide gel, transferred to a nitrocellulose membrane and blocked for 1 h with 5% milk in Tris-buffered saline-T. 14-3-3s was detected using anti-14-3-3s monoclonal mouse antibody [1.N.6] (Abcam) in 5% milk in Tris-buffered saline-T incubated overnight at 4degC.",T,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Fix air dried cell samples with a freshly prepared solution (4% paraformaldehyde in PBS, pH 7.4) for 1 hr at 15-25degC and incubate in permeabilisation solution (0.1% Trixon X-100 in 0.1% sodium citrate) for 2 min on ice.",PBS,citrate,-1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Fix air dried cell samples with a freshly prepared solution (4% paraformaldehyde in PBS, pH 7.4) for 1 hr at 15-25degC and incubate in permeabilisation solution (0.1% Trixon X-100 in 0.1% sodium citrate) for 2 min on ice.",X-100,citrate,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","4, chloroquine significantly inhibited CpG ODN induced invasion in glioma cells, which suggest that TLR9 signaling is responsible for the enhanced invasion of U87 cells induced by CpG ODN.

",ODN,chloroquine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","4, chloroquine significantly inhibited CpG ODN induced invasion in glioma cells, which suggest that TLR9 signaling is responsible for the enhanced invasion of U87 cells induced by CpG ODN.

",ODN,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","4, chloroquine significantly inhibited CpG ODN induced invasion in glioma cells, which suggest that TLR9 signaling is responsible for the enhanced invasion of U87 cells induced by CpG ODN.

",TLR9,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","4, chloroquine significantly inhibited CpG ODN induced invasion in glioma cells, which suggest that TLR9 signaling is responsible for the enhanced invasion of U87 cells induced by CpG ODN.

",U87,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Antitumor effect of survivin siRNA and selenium in vivo
Five-week-old pathogen-free athymic nude mice were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (Beijing, China).",survivin,selenium,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","There is limited documentation that idarubicin has therapeutic advantages over daunorubicin, and we regard these anthracyclines as equal in therapy of AML.",AML,idarubicin,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","There is limited documentation that idarubicin has therapeutic advantages over daunorubicin, and we regard these anthracyclines as equal in therapy of AML.",AML,daunorubicin,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",III,Vitamin C,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",CR,Vitamin C,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",BMT,Vitamin C,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",CR,Vitamin C,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",VIT,Vitamin C,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Together, these data imply that MP470 plus Erlotinib exquisitely inhibits cell survival through the HER family/PI3K/Akt pathway.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Together, these data imply that MP470 plus Erlotinib exquisitely inhibits cell survival through the HER family/PI3K/Akt pathway.

",PI3K,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Together, these data imply that MP470 plus Erlotinib exquisitely inhibits cell survival through the HER family/PI3K/Akt pathway.

",HER,Erlotinib,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Results
Pre-apoptotic AML cells in peripheral circulation were without signs of apoptosis during the first 24 hours of chemotherapy
In this study we examined seven AML patients before (-30 min), at 2-4 h and at 18-24 h after start of first day standard induction therapy (for patient characteristics, see Additional File 1) [26], consisting of a 30 min infusion of anthracycline and a 24 h continuous infusion of cytarabine started concomitantly.",AML,cytarabine,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Results
Pre-apoptotic AML cells in peripheral circulation were without signs of apoptosis during the first 24 hours of chemotherapy
In this study we examined seven AML patients before (-30 min), at 2-4 h and at 18-24 h after start of first day standard induction therapy (for patient characteristics, see Additional File 1) [26], consisting of a 30 min infusion of anthracycline and a 24 h continuous infusion of cytarabine started concomitantly.",AML,anthracycline,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Results
Pre-apoptotic AML cells in peripheral circulation were without signs of apoptosis during the first 24 hours of chemotherapy
In this study we examined seven AML patients before (-30 min), at 2-4 h and at 18-24 h after start of first day standard induction therapy (for patient characteristics, see Additional File 1) [26], consisting of a 30 min infusion of anthracycline and a 24 h continuous infusion of cytarabine started concomitantly.",AML,cytarabine,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Results
Pre-apoptotic AML cells in peripheral circulation were without signs of apoptosis during the first 24 hours of chemotherapy
In this study we examined seven AML patients before (-30 min), at 2-4 h and at 18-24 h after start of first day standard induction therapy (for patient characteristics, see Additional File 1) [26], consisting of a 30 min infusion of anthracycline and a 24 h continuous infusion of cytarabine started concomitantly.",AML,anthracycline,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","SARDH, related to conversion of betaine to glycine, was also significantly higher expressed in the basal-like model.",SARDH,betaine,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",We believe that this model could be highly useful in predicting response to cetuximab in CRC in patients with KRAS-wildtype tumors.,CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
",We believe that this model could be highly useful in predicting response to cetuximab in CRC in patients with KRAS-wildtype tumors.,KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Methods
Gene expression predictor of response to EGFR-targeted agents
The GEPR to EGFR-targeted agents was built using lung cancer cell lines and sensitivity data to the EGFR-tyrosine kinase inhibitor erlotinib.",GEPR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Methods
Gene expression predictor of response to EGFR-targeted agents
The GEPR to EGFR-targeted agents was built using lung cancer cell lines and sensitivity data to the EGFR-tyrosine kinase inhibitor erlotinib.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Methods
Gene expression predictor of response to EGFR-targeted agents
The GEPR to EGFR-targeted agents was built using lung cancer cell lines and sensitivity data to the EGFR-tyrosine kinase inhibitor erlotinib.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Methods
Gene expression predictor of response to EGFR-targeted agents
The GEPR to EGFR-targeted agents was built using lung cancer cell lines and sensitivity data to the EGFR-tyrosine kinase inhibitor erlotinib.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","Treatment of MCF-7 cells with mevastatin resulted in a 10- to 15-fold induction of HMG-CoAR activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression [28], suggesting that treatment with statins may increase tumour specific HMG-CoAR expression in vivo, however this remains to be fully elucidated.",HMG,mevastatin,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","Treatment of MCF-7 cells with mevastatin resulted in a 10- to 15-fold induction of HMG-CoAR activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression [28], suggesting that treatment with statins may increase tumour specific HMG-CoAR expression in vivo, however this remains to be fully elucidated.",HMG,mevastatin,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","Treatment of MCF-7 cells with mevastatin resulted in a 10- to 15-fold induction of HMG-CoAR activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression [28], suggesting that treatment with statins may increase tumour specific HMG-CoAR expression in vivo, however this remains to be fully elucidated.",mRNA,mevastatin,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","Treatment of MCF-7 cells with mevastatin resulted in a 10- to 15-fold induction of HMG-CoAR activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression [28], suggesting that treatment with statins may increase tumour specific HMG-CoAR expression in vivo, however this remains to be fully elucidated.",HMG,mevastatin,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","Treatment of MCF-7 cells with mevastatin resulted in a 10- to 15-fold induction of HMG-CoAR activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression [28], suggesting that treatment with statins may increase tumour specific HMG-CoAR expression in vivo, however this remains to be fully elucidated.",MCF-7,mevastatin,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Click here for file

 Additional file 2
 Excel file comparing different published studies concerning the discrimination of FTC and FTA using gene expression analysis.

",FTC,Excel,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Click here for file

 Additional file 2
 Excel file comparing different published studies concerning the discrimination of FTC and FTA using gene expression analysis.

",FTA,Excel,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Indeed, Karapetis and colleagues reached the conclusion that additional biomarker approaches are needed to identify KRAS-wildtype patients who will receive benefit from cetuximab in one of the largest analyses to date of the association of KRAS status with clinical outcome to cetuximab in CRC [7].

",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Indeed, Karapetis and colleagues reached the conclusion that additional biomarker approaches are needed to identify KRAS-wildtype patients who will receive benefit from cetuximab in one of the largest analyses to date of the association of KRAS status with clinical outcome to cetuximab in CRC [7].

",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Indeed, Karapetis and colleagues reached the conclusion that additional biomarker approaches are needed to identify KRAS-wildtype patients who will receive benefit from cetuximab in one of the largest analyses to date of the association of KRAS status with clinical outcome to cetuximab in CRC [7].

",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Indeed, Karapetis and colleagues reached the conclusion that additional biomarker approaches are needed to identify KRAS-wildtype patients who will receive benefit from cetuximab in one of the largest analyses to date of the association of KRAS status with clinical outcome to cetuximab in CRC [7].

",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Indeed, Karapetis and colleagues reached the conclusion that additional biomarker approaches are needed to identify KRAS-wildtype patients who will receive benefit from cetuximab in one of the largest analyses to date of the association of KRAS status with clinical outcome to cetuximab in CRC [7].

",CRC,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Indeed, Karapetis and colleagues reached the conclusion that additional biomarker approaches are needed to identify KRAS-wildtype patients who will receive benefit from cetuximab in one of the largest analyses to date of the association of KRAS status with clinical outcome to cetuximab in CRC [7].

",CRC,cetuximab,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Table 1 Viability of non-stimulated and PHA-stimulated blood cells treated with etoposide as determined by dual-cell stain method.

",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","Consequently, QPRT is a potential new marker for the immunohistochemical screening of follicular thyroid nodules.
",QPRT,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","The specificity of the antibody was validated by western blot analysis

Results
In gene expression analysis QPRT was detected as differently expressed between follicular thyroid adenoma and follicular thyroid carcinoma.",QPRT,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","The specificity of the antibody was validated by western blot analysis

Results
In gene expression analysis QPRT was detected as differently expressed between follicular thyroid adenoma and follicular thyroid carcinoma.",QPRT,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","In the group of endocrine malignant tumours they form, however, the largest entity. Differentiated thyroid carcinomas are a heterogeneous group composed of papillary, follicular (FTC) and medullary thyroid carcinoma [2].",FTC,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","In the group of endocrine malignant tumours they form, however, the largest entity. Differentiated thyroid carcinomas are a heterogeneous group composed of papillary, follicular (FTC) and medullary thyroid carcinoma [2].",FTC,thyroid,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Recently, a result from a randomized controlled trial was reported which demonstrated favorable response and prolongation of TTP after use of somatostatin analogues in well-differentiated midgut NET [24].

",NET,somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Recently, a result from a randomized controlled trial was reported which demonstrated favorable response and prolongation of TTP after use of somatostatin analogues in well-differentiated midgut NET [24].

",TTP,somatostatin,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","QPRT protein could be detected by immunohistochemistry in 65% of follicular thyroid carcinomas including minimal invasive variant and only 22% of follicular adenomas.

",QPRT,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
",Overall evaluations show that FLLL-12 has the closest drug-likeness profile and has 86% similarity to propafenone and trimethobenzamide averaged over all fifty parameters.,FLLL-12,trimethobenzamide,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
",Overall evaluations show that FLLL-12 has the closest drug-likeness profile and has 86% similarity to propafenone and trimethobenzamide averaged over all fifty parameters.,FLLL-12,propafenone,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","However, application of LY294002 and rapamycin caused a dramatic reduction of epidermal growth factor-induced HCCR expression.",LY294002,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","However, application of LY294002 and rapamycin caused a dramatic reduction of epidermal growth factor-induced HCCR expression.",HCCR,rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Nevertheless, we were not able to show statistical benefit in DFS from the addition of irinotecan.",DFS,irinotecan,1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",HSTB,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",TBIS,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",APLIS,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",NCI,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",NAACCR,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",UPMC,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CPCTR,Air,1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",PHI,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CBCTR,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",SPORE,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",IRB,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",EMR,Air,1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",ADASP,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CPLIS,Air,1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CAE,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",AJCC,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",HIPAA,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",IATA,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CAP,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",NIH,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",MRS,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",UPITT,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",REP,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",ISO,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CRIS,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",CDE,Air,-1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",EDRN,Air,1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Abbreviations
ADASP: Association of Directors of Anatomic and Surgical Pathology; AJCC: American Joint Committee on Cancer; APLIS: Anatomic Pathology Lab Information System; caBIG: cancer Bioinformatics Grid; CAE: Clinical Annotation Engine; CRIS: Cancer Registry Information System; CAP: College of American Pathologist; CBCTR: Cooperative Breast Cancer Tissue Resource; CDE: Common data element; CPCTR: Cooperative Prostate Cancer Tissue Resource; CPLIS: Clinical Pathology Lab Information System; EDRN: Early Detection Research Network; EMR: Electronic Medical Record; HIPAA: Health Insurance Portability and Accountability Act; HSTB: Health Science Tissue Bank; IATA: International Air Transport Association; IRB: Institutional Review Board; ISO: International Organization for Standardization; MRS: Medical Registry System; NAACCR: North American Association of Central Cancer Registries; NCI: National Cancer Institute; NIH: National Institutes of Health; PCABC: Pennsylvania Cancer Alliance Bioinformatics Consortium; PHI: Protected Health Information; REP: Research Evaluation Panel; SPORE: Specialized Programs of Research Excellence; TBIS: Tissue Bank Information System; UPITT: University of Pittsburgh; UPMC: University of Pittsburgh Medical Center.

",PCABC,Air,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In our study we looked in retrospect, whether the immunohistochemical expression of TS and Topo I (which is the target of irinotecan) had any predictive significance in a large cohort of patients with colorectal cancer, who received several schedules of 5-FU-based adjuvant chemotherapy.

",FU,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In our study we looked in retrospect, whether the immunohistochemical expression of TS and Topo I (which is the target of irinotecan) had any predictive significance in a large cohort of patients with colorectal cancer, who received several schedules of 5-FU-based adjuvant chemotherapy.

",TS,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The Nutritional Prevention of Cancer (NPC) trial demonstrated that supplementation of selenium, in the form of selenized yeast, could reduce the incidence of prostate cancer by ~50%  [9,10].",NPC,selenium,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Sections containing representative tumor samples were assayed by immunohistochemistry for the presence of the estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor receptor-2), and MIB-1(Ki-67).",ER,progesterone,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Sections containing representative tumor samples were assayed by immunohistochemistry for the presence of the estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor receptor-2), and MIB-1(Ki-67).",HER-2,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",was offered to all ER or PR positive patients before exposure to NC or after surgery; this consisted of tamoxifen for premenopausal patients and aromatase inhibitors for postmenopausal patients.,PR,tamoxifen,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",was offered to all ER or PR positive patients before exposure to NC or after surgery; this consisted of tamoxifen for premenopausal patients and aromatase inhibitors for postmenopausal patients.,ER,tamoxifen,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",was offered to all ER or PR positive patients before exposure to NC or after surgery; this consisted of tamoxifen for premenopausal patients and aromatase inhibitors for postmenopausal patients.,aromatase,tamoxifen,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Specifically HER2 status did not contribute as a prognostic marker perhaps due to the use of trastuzumab in half of our patients.

",HER2,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Both double-and single-strand breaks (SSBs) in DNA can be produced by etoposide.

",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Specifically when etoposide interacts with topoisomerase IIa, it traps the enzyme in a covalently bound form with its DNA substrate [5,22].

",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","The topoisomeriase IIa-DNA complex is stabilized with the etoposide molecule by hydrogen bonds with the nucleic acid bases, and this stabilized complex thus prevents re-ligation of DNA by topoisomerase IIa [23,24].",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","It has been known for more than a decade that etoposide stabilizes topoisomerase II-associated DNA breaks, thereby abolishing the ability of the enzyme to ligate cleaved nucleic acid molecules [7,12,16,19-21].",DNA,etoposide,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The average baseline selenium level of the participants in SELECT was much higher than that observed in the NPC study.,SELECT,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The average baseline selenium level of the participants in SELECT was much higher than that observed in the NPC study.,NPC,selenium,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Rather than blocking the activity of this essential enzyme, etoposide kills cells by increasing the concentration of topoisomerase II-DNA cleavage complexes [7,12,14-16].",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","In the last decade, etoposide (also known as VP-16213) has been one of the most commonly used agents for treating a number of malignancies.",VP-16213,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",DFS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",DFS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",TS,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",CI,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",TS,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",HR,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",HR,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",HR,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In the subgroup of irinotecan treated patients the effect of TS expression was not statistically significant (HR = 1.02, 95% CI 0.59-1.77, wald p = 0.946), while in the absence of irinotecan, TS was associated with a worse DFS (HR = 1.50, 95% CI 1.03-2.19, wald p = 0.036) (Figure 5).

",HR,irinotecan,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In fact, 78% of men in SELECT had baseline selenium above the range that selenium provided protection in the NPC trial (&#60;121.6 ng/ml) [11].",SELECT,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In fact, 78% of men in SELECT had baseline selenium above the range that selenium provided protection in the NPC trial (&#60;121.6 ng/ml) [11].",SELECT,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In fact, 78% of men in SELECT had baseline selenium above the range that selenium provided protection in the NPC trial (&#60;121.6 ng/ml) [11].",NPC,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In fact, 78% of men in SELECT had baseline selenium above the range that selenium provided protection in the NPC trial (&#60;121.6 ng/ml) [11].",NPC,selenium,1
"PMC 
BMC_Cancer_2010_Apr_13_10_138.txt
","No significant association was found between the methylation status of the p16 gene and the factors studied, including age, sex, tumor histopathology, tumor site and size, and opium and tobacco use (cigarette and hookah smoking, Nass chewing) (Table 1).",p16,opium,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","When oxidized, hydroquinones give rise to hydroxyl radicals, which may ultimately contribute to etoposide-associated SSBs in DNA [28].",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","In addition, in a fifth randomized trial published in an abstract form, in which enrollment took place between January 1999 and September 2004, patients with colon cancer received adjuvant 5-FU/Folinic acid chemotherapy with or without the addition of irinotecan.",FU,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",BAY,BD,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",PDTC,BD,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",FITC,BD,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",Tca8113,BD,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",BAY,BD,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",FITC,BD,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Annexin V/PI staining
Tca8113 and TL cells (1x106) treated with TNFa (50 ng/ml), PDTC 100 mM and BAY 11-7085(10 mM) alone or with TNFa plus PDTC or plus BAY 11-7085 for 24 hours were labeled with FITC-conjugated Annexin V and propidium iodide (PI) using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's protocol.",PDTC,BD,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","The cell lines were cultured in RPMI-1640 medium (Sigma, MO, USA) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).

",USA,penicillin,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","The cell lines were cultured in RPMI-1640 medium (Sigma, MO, USA) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).

",USA,streptomycin,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","The cell lines were cultured in RPMI-1640 medium (Sigma, MO, USA) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).

",RPMI-1640,penicillin,-1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","The cell lines were cultured in RPMI-1640 medium (Sigma, MO, USA) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).

",RPMI-1640,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In view of the above information, we believe that the negative finding by SELECT should not be simply interpreted as selenium is ineffective against prostate cancer; instead, it raises the hypothesis of whether selenium might only be effective only in selected subsets of men with lower selenium levels at baseline.

",SELECT,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In view of the above information, we believe that the negative finding by SELECT should not be simply interpreted as selenium is ineffective against prostate cancer; instead, it raises the hypothesis of whether selenium might only be effective only in selected subsets of men with lower selenium levels at baseline.

",SELECT,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","In view of the above information, we believe that the negative finding by SELECT should not be simply interpreted as selenium is ineffective against prostate cancer; instead, it raises the hypothesis of whether selenium might only be effective only in selected subsets of men with lower selenium levels at baseline.

",SELECT,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The compounds used in the current study, MSA and MSC, are monomethylated forms of selenium and are considered second-generation selenium compounds.",MSA,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The compounds used in the current study, MSA and MSC, are monomethylated forms of selenium and are considered second-generation selenium compounds.",MSA,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The compounds used in the current study, MSA and MSC, are monomethylated forms of selenium and are considered second-generation selenium compounds.",MSC,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The compounds used in the current study, MSA and MSC, are monomethylated forms of selenium and are considered second-generation selenium compounds.",MSC,selenium,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Conclusion
Patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy.",CRC,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Survivin gene silencing enhances selenium's efficacy on apoptosis induction
Next, we analyzed the effect of apoptosis induction by sh-survivin and MSA in PC-3M cells by flow cytometry.",survivin,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Survivin gene silencing enhances selenium's efficacy on apoptosis induction
Next, we analyzed the effect of apoptosis induction by sh-survivin and MSA in PC-3M cells by flow cytometry.",PC-3,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Survivin gene silencing enhances selenium's efficacy on apoptosis induction
Next, we analyzed the effect of apoptosis induction by sh-survivin and MSA in PC-3M cells by flow cytometry.",MSA,selenium,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",RPMI,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",RPMI,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",RPMI,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",CO2,streptomycin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",CO2,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",CO2,glutamine,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",PHA,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",PHA,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",PHA,glutamine,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
",IHC score: 3+ (D3).,IHC,D3,1
"PMC 
BMC_Cancer_2009_Oct_2_9_351.txt
",Past studies using SWNT-antibody conjugates for specific photothermal ablation of cancer cells attached antibodies to SWNTs either noncovalently through adsorption [20] or indirectly via streptavidin-biotin interaction [21].,SWNT,biotin,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Other studies have reported no correlation between expression of ERb2 mRNA and response to tamoxifen [50,51].",mRNA,tamoxifen,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","tissue microarray was constructed with tissue microarrayer (Beecher Instruments, Silver Springs, MD, USA) as described previously[18].",USA,Silver,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The samples were heated to 70deg for 10 min, electrophoresed on 4-20% gradient SDS-polyacrylamide gel (BioRad), and electrotransferred to PVDF membrane (Hybond-P, Amersham).",PVDF,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The samples were heated to 70deg for 10 min, electrophoresed on 4-20% gradient SDS-polyacrylamide gel (BioRad), and electrotransferred to PVDF membrane (Hybond-P, Amersham).",SDS,polyacrylamide,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","This is consistent with results published by Azrak et al showing at similar doses, selenium treatment did not affect survivin expression in mouse prostate cancer cells or ovarian cancer cells [33,34].",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",OS,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",NSE,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",TTP,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",OS,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",IFN,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",OS,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",NSE,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",CI,Somatostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",IFN,Somatostatin,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","For electrophoresis, protein extracts from fresh-frozen mammary and liver specimens were subjected to SDS-PAGE in 8% polyacrylamide gels according to Laemmli [32].",PAGE,polyacrylamide,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","For electrophoresis, protein extracts from fresh-frozen mammary and liver specimens were subjected to SDS-PAGE in 8% polyacrylamide gels according to Laemmli [32].",SDS,polyacrylamide,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","For Western blotting, the following antibodies were used: anti-p-Tyr 4G10 (Upstate Biotechnology, Millipore Corporation, Billerica, MA); p-Neu (Tyr 1248)-R (Santa Cruz, Biothecnology, Santa Cruz, CA) for ERBB2 and anti-FAK (Transduction Laboratories, BD, Franklin Lakes, NJ).

",FAK,BD,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","For Western blotting, the following antibodies were used: anti-p-Tyr 4G10 (Upstate Biotechnology, Millipore Corporation, Billerica, MA); p-Neu (Tyr 1248)-R (Santa Cruz, Biothecnology, Santa Cruz, CA) for ERBB2 and anti-FAK (Transduction Laboratories, BD, Franklin Lakes, NJ).

",ERBB2,BD,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID3,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DEAD,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DEAD,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DEAD,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SOCS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SOCS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SOCS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FLJ20481,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FLJ20481,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FLJ20481,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",E1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",E1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",E1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IL13RA1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IL13RA1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IL13RA1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MDR,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MDR,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MDR,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A1S9,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A1S9,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A1S9,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POR,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POR,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POR,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CKLF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CKLF,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CKLF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BN75,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BN75,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BN75,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RALGPS1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RALGPS1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RALGPS1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POSTN,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POSTN,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POSTN,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DIP2B,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DIP2B,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DIP2B,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6GAL1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6GAL1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6GAL1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTMS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTMS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTMS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GEF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GEF,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GEF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",P450,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",P450,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",P450,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FARSB,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FARSB,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FARSB,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KIAA1463,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KIAA1463,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KIAA1463,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PH,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PH,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PH,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",STAT1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",STAT1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",STAT1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",tRNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",tRNA,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",tRNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SH3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SH3,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SH3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",HIST2H2BE,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",HIST2H2BE,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",HIST2H2BE,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FBP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FBP1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FBP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FANCG,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FANCG,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FANCG,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CALU,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CALU,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CALU,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MYO1C,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MYO1C,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MYO1C,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PSMB10,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PSMB10,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PSMB10,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MFAP2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MFAP2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MFAP2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CDCA4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CDCA4,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CDCA4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TRIM33,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TRIM33,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TRIM33,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TUSC3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TUSC3,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TUSC3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RNA,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RNA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MEF2D,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MEF2D,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MEF2D,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SERPINH1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SERPINH1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SERPINH1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FADS1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FADS1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FADS1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MADS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MADS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MADS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAA2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAA2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAA2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",COL6A3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",COL6A3,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",COL6A3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EXOSC7,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EXOSC7,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EXOSC7,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CYB5A,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CYB5A,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CYB5A,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ZNF516,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ZNF516,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ZNF516,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFV,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFV,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFV,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SFTPB,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SFTPB,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SFTPB,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IRF4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IRF4,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IRF4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRG2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRG2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRG2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",b-5,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",b-5,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",b-5,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TM9SF2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TM9SF2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TM9SF2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CLIP4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CLIP4,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CLIP4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FDPS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FDPS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FDPS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CAP,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CAP,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CAP,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GLY,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GLY,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GLY,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EIF4G1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EIF4G1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EIF4G1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BMI1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BMI1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BMI1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MMP11,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MMP11,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MMP11,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FABP3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FABP3,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FABP3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",T,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",T,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",T,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FGFR4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FGFR4,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FGFR4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFX,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFX,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFX,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PLA2R1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PLA2R1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PLA2R1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",NUTF2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",NUTF2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",NUTF2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KDELR3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KDELR3,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KDELR3,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA4,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA4,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A2,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A2,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAD11,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAD11,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAD11,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",X,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",X,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",X,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",gamma,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",gamma,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",gamma,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ATP,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ATP,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ATP,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",UBE1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",UBE1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",UBE1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",WSB1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",WSB1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",WSB1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",AYTL1,Selenium,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",AYTL1,Zinc,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",AYTL1,Selenium,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In the analysis of factors predicting for OS, development of brain metastases as well as early development of brain metastases (&#60; 12 months after initiation of trastuzumab) were also included.

",OS,trastuzumab,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Briefly, cells were exposed to DMSO or differing doses of MP470, Erlotinib, or IM (1 to 10 mM) for 24 h and were harvested by trypsinization.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Briefly, cells were exposed to DMSO or differing doses of MP470, Erlotinib, or IM (1 to 10 mM) for 24 h and were harvested by trypsinization.",DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","When marrow is invaded by BC cells, osteoclasts are recruited and differentiated at an increased rate by the production of high amounts of tumor-derived cytokines such as transforming growth factor b (TGF-b), interleukin-6 (IL-6), parathyroid hormone-related protein (PTHrP) [19].",IL-6,parathyroid hormone,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","A LNCaP mouse xenograft model was also used to determine the tumor growth inhibition by MP470, Erlotinib or the combination treatments.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","On the other hand, positive Topo I expression seems to have a prophylactic effect in terms of OS in irinotecan treated patients by reducing the hazard for death by 53% (HR = 0.47, 95% CI 0.23-0.94, wald p = 0.033).",CI,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","On the other hand, positive Topo I expression seems to have a prophylactic effect in terms of OS in irinotecan treated patients by reducing the hazard for death by 53% (HR = 0.47, 95% CI 0.23-0.94, wald p = 0.033).",HR,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","On the other hand, positive Topo I expression seems to have a prophylactic effect in terms of OS in irinotecan treated patients by reducing the hazard for death by 53% (HR = 0.47, 95% CI 0.23-0.94, wald p = 0.033).",OS,irinotecan,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech, Norcross, GA) was employed to assay the relative levels of phosphorylation of 71 different human RTKs after MP470 or Erlotinib or MP470 plus Erlotinib treatment.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech, Norcross, GA) was employed to assay the relative levels of phosphorylation of 71 different human RTKs after MP470 or Erlotinib or MP470 plus Erlotinib treatment.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech, Norcross, GA) was employed to assay the relative levels of phosphorylation of 71 different human RTKs after MP470 or Erlotinib or MP470 plus Erlotinib treatment.",GA,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech, Norcross, GA) was employed to assay the relative levels of phosphorylation of 71 different human RTKs after MP470 or Erlotinib or MP470 plus Erlotinib treatment.",GA,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech, Norcross, GA) was employed to assay the relative levels of phosphorylation of 71 different human RTKs after MP470 or Erlotinib or MP470 plus Erlotinib treatment.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech, Norcross, GA) was employed to assay the relative levels of phosphorylation of 71 different human RTKs after MP470 or Erlotinib or MP470 plus Erlotinib treatment.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Methods
Cell culture and processing
MCF-7 cells were cultured in EMEM with 10 mg/mL bovine insulin and 10% FBS, in an incubator maintained at 37degC with 5% CO2 [35].",FBS,insulin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Methods
Cell culture and processing
MCF-7 cells were cultured in EMEM with 10 mg/mL bovine insulin and 10% FBS, in an incubator maintained at 37degC with 5% CO2 [35].",MCF-7,insulin,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Methods
Cell culture and processing
MCF-7 cells were cultured in EMEM with 10 mg/mL bovine insulin and 10% FBS, in an incubator maintained at 37degC with 5% CO2 [35].",EMEM,insulin,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Methods
Cell culture and processing
MCF-7 cells were cultured in EMEM with 10 mg/mL bovine insulin and 10% FBS, in an incubator maintained at 37degC with 5% CO2 [35].",CO2,insulin,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","5-fluorouracil (5-FU) inhibits TS by forming a stable ternary complex among 5,10-methylenetetrahydrofolate, TS, and fluoro-dUMP, the metabolite of 5-FU.",FU,fluorouracil,-1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","5-fluorouracil (5-FU) inhibits TS by forming a stable ternary complex among 5,10-methylenetetrahydrofolate, TS, and fluoro-dUMP, the metabolite of 5-FU.",FU,fluorouracil,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","5-fluorouracil (5-FU) inhibits TS by forming a stable ternary complex among 5,10-methylenetetrahydrofolate, TS, and fluoro-dUMP, the metabolite of 5-FU.",TS,fluorouracil,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","5-fluorouracil (5-FU) inhibits TS by forming a stable ternary complex among 5,10-methylenetetrahydrofolate, TS, and fluoro-dUMP, the metabolite of 5-FU.",dUMP,fluorouracil,-1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","5-fluorouracil (5-FU) inhibits TS by forming a stable ternary complex among 5,10-methylenetetrahydrofolate, TS, and fluoro-dUMP, the metabolite of 5-FU.",TS,fluorouracil,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Figure 1 Effects of MP470 or the MP470-Erlotinib combination on prostate cancer cell proliferation and apoptosis.,MP470,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",F12,insulin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",F12,hydrocortisone,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",EGF,insulin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",EGF,hydrocortisone,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",HCSMC,insulin,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",HCSMC,hydrocortisone,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",FBS,insulin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The MCF-10A cells were maintained in Ham's F12 media (Mediatech) supplemented with 5% FBS, 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml epidermal growth factor (EGF), 100 mg/ml cholera toxin, and 1% P/S. Normal human bladder smooth muscle cells (HdSMC) were purchased from Lonza (Walkersville, MD) and Normal human colonic smooth muscle cells (HCSMC) were purchased from ScienCell (Carlsbad, CA).

",FBS,hydrocortisone,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",FBS,Penicillin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",FBS,Streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",FBS,glutamine,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",DMEM,Penicillin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",DMEM,Streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",DMEM,glutamine,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,Etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,Etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",SD,Etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",SD,Etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,Etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,Etoposide,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",RTK,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",RTK,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",HER1,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",HER1,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",PI3K,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",PI3K,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",HER2,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Therefore, inhibition of HER1 and HER2 by Erlotinib and multi-targeted RTK inhibition by MP470 may explain the complete inhibition of the HER3/PI3K/Akt pathway by Erlotinib-MP470 combination in LNCaP cells.",HER2,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Treatment of the resistant cells with a TKI specific for c-Met or gefitinib alone did not inhibit cell viability or affect HER3 and Akt phosphorylation.,Met,gefitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Treatment of the resistant cells with a TKI specific for c-Met or gefitinib alone did not inhibit cell viability or affect HER3 and Akt phosphorylation.,HER3,gefitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Treatment of the resistant cells with a TKI specific for c-Met or gefitinib alone did not inhibit cell viability or affect HER3 and Akt phosphorylation.,TKI,gefitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Erlotinib or MP470 alone did not totally inhibit phosphorylation of the HER family.,HER,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",Erlotinib or MP470 alone did not totally inhibit phosphorylation of the HER family.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In gefitinib-resistant NSCLC cell lines, c-Met, an oncogenic RTK phosphorylates HER3 and leads to activation of the PI3K/Akt pathway.",Met,gefitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In gefitinib-resistant NSCLC cell lines, c-Met, an oncogenic RTK phosphorylates HER3 and leads to activation of the PI3K/Akt pathway.",NSCLC,gefitinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In gefitinib-resistant NSCLC cell lines, c-Met, an oncogenic RTK phosphorylates HER3 and leads to activation of the PI3K/Akt pathway.",HER3,gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In gefitinib-resistant NSCLC cell lines, c-Met, an oncogenic RTK phosphorylates HER3 and leads to activation of the PI3K/Akt pathway.",RTK,gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In gefitinib-resistant NSCLC cell lines, c-Met, an oncogenic RTK phosphorylates HER3 and leads to activation of the PI3K/Akt pathway.",PI3K,gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","When combined with Erlotinib, MP470 induced apoptosis and cell growth arrest with abolition of tumor growth in a dose-dependent manner in an LNCaP xenograft mouse model.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, MP470-Erlotinib combination completely inhibited the phosphorylation of HER1, HER2 and HER3, the binding of PI3K regulatory subunit p85 to HER3 and downstream Akt activity (Fig.",p85,MP470-Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, MP470-Erlotinib combination completely inhibited the phosphorylation of HER1, HER2 and HER3, the binding of PI3K regulatory subunit p85 to HER3 and downstream Akt activity (Fig.",HER3,MP470-Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, MP470-Erlotinib combination completely inhibited the phosphorylation of HER1, HER2 and HER3, the binding of PI3K regulatory subunit p85 to HER3 and downstream Akt activity (Fig.",HER1,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, MP470-Erlotinib combination completely inhibited the phosphorylation of HER1, HER2 and HER3, the binding of PI3K regulatory subunit p85 to HER3 and downstream Akt activity (Fig.",HER3,MP470-Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, MP470-Erlotinib combination completely inhibited the phosphorylation of HER1, HER2 and HER3, the binding of PI3K regulatory subunit p85 to HER3 and downstream Akt activity (Fig.",PI3,MP470-Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","However, MP470-Erlotinib combination completely inhibited the phosphorylation of HER1, HER2 and HER3, the binding of PI3K regulatory subunit p85 to HER3 and downstream Akt activity (Fig.",HER2,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",HMG,Maternity,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",HMG,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Ireland2,Maternity,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Ireland2,Maternity,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden2010,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden2010,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",BMC,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",BMC,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Ireland3,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Ireland3,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Cancer1471,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Cancer1471,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",CREATE,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",CREATE,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",UCD,Maternity,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",UCD,Maternity,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden7,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden7,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",UCD,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",UCD,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden4,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden4,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden6,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Sweden6,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Ireland5,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",Ireland5,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",UCD,Maternity,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1252035935810.1186/1471-2407-10-125Research ArticleTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer Brennan Donal J 12donal.brennan@ucd.ieBrandstedt Jenny 3jenny.brandstedt@spray.seRexhepaj Elton 2elton.rexhepaj@ucd.ieFoley Michael 4mfoley@nmh.iePonten Fredrik 5fredrik.ponten@genpat.uu.seUhlen Mathias 6mathias@biotech.kth.seGallagher William M 2william.gallagher@ucd.ieO'Connor Darran P 2darran.oconnor@ucd.ieO'Herlihy Colm 4colm.oherlihy@ucd.ieJirstrom Karin 37karin.jirstrom@med.lu.se1 Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland2 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland3 Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden4 UCD School of Medicine and Medical Science, National Maternity Hospital, Holles Street, Dublin 2, Ireland5 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden6 Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden7 CREATE Health Center for Translational Cancer Research, Lund University, Lund, Sweden2010 1 4 2010 10 125 125 7 9 2009 1 4 2010 Copyright (c)2010 Brennan et al; licensee BioMed Central Ltd.2010Brennan et al; licensee BioMed Central Ltd.",UCD,Maternity,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Based on this finding, we hypothesize that selenium treatment and survivin knockdown would complement the action of each other, leading to a greater anticancer effect.",survivin,selenium,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",Two patients (P3 and P8) were treated with anthracycline ex vivo and protein expression analyzed using Western blots (C).,P8,anthracycline,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",Two patients (P3 and P8) were treated with anthracycline ex vivo and protein expression analyzed using Western blots (C).,P3,anthracycline,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","FBS = fetal bovine serum, SF = serum-free.

",FBS,SF,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",QPRT is a potential useful marker for immunohistochemical screening analysis of solitary thyroid nodules.,QPRT,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","In contrast, the cells collected after approximately 24 h of chemotherapy demonstrated an increasing number of genes related to cell-cell contact (Figure 3); this included subunits of the T cell receptor complex and chondroitin sulphate-containing proteins involved in cell recognition.",T,chondroitin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","After removal of the supernatant, 200 ml of dimethyl sulfoxide (DMSO; Sigma) was added to dissolve the crystals.",DMSO,dimethyl sulfoxide,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum-starved for 24 hr, pretreated with DMSO, 10 mM of MP470 or MP470-Erlotinib, and then stimulated by pervanadate for 10 min.",DMSO,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum-starved for 24 hr, pretreated with DMSO, 10 mM of MP470 or MP470-Erlotinib, and then stimulated by pervanadate for 10 min.",MP470,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","For example, AMPK activation causes a G1-S phase cell cycle arrest [30,31], while it also inhibits cell growth by switching off the target-of-rapamycin (TOR) pathway [32,33].",G1-S,rapamycin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","For example, AMPK activation causes a G1-S phase cell cycle arrest [30,31], while it also inhibits cell growth by switching off the target-of-rapamycin (TOR) pathway [32,33].",TOR,rapamycin,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","For example, AMPK activation causes a G1-S phase cell cycle arrest [30,31], while it also inhibits cell growth by switching off the target-of-rapamycin (TOR) pathway [32,33].",AMPK,rapamycin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Concomitantly, Akt and Erk phosphorylation were also reduced by MP470 or MP470 plus Erlotinib (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Concomitantly, Akt and Erk phosphorylation were also reduced by MP470 or MP470 plus Erlotinib (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In addition, consistent with the above apoptosis data, we also observed a sub-G1 population in cells treated with Erlotinib plus MP470 (Fig. 2).",G1,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In addition, consistent with the above apoptosis data, we also observed a sub-G1 population in cells treated with Erlotinib plus MP470 (Fig. 2).",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, patients who received CMF more often had only 1-3 involved lymph nodes and also had smaller tumors (pT1) when compared with untreated patients and with patients who received anthracycline-based chemotherapy.",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, patients who received CMF more often had only 1-3 involved lymph nodes and also had smaller tumors (pT1) when compared with untreated patients and with patients who received anthracycline-based chemotherapy.",pT1,anthracycline,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Immune complexes were enriched by Protein G-Agarose beads and probed by Western blotting for the p85 subunit of PI3K.

Since RTKs bind and activate PI3K and then Akt, we further attempted to identify the RTKs which were targeted by MP470 or MP470 plus Erlotinib.",PI3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Immune complexes were enriched by Protein G-Agarose beads and probed by Western blotting for the p85 subunit of PI3K.

Since RTKs bind and activate PI3K and then Akt, we further attempted to identify the RTKs which were targeted by MP470 or MP470 plus Erlotinib.",p85,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Immune complexes were enriched by Protein G-Agarose beads and probed by Western blotting for the p85 subunit of PI3K.

Since RTKs bind and activate PI3K and then Akt, we further attempted to identify the RTKs which were targeted by MP470 or MP470 plus Erlotinib.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Immune complexes were enriched by Protein G-Agarose beads and probed by Western blotting for the p85 subunit of PI3K.

Since RTKs bind and activate PI3K and then Akt, we further attempted to identify the RTKs which were targeted by MP470 or MP470 plus Erlotinib.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",A second study was also conducted with MP470 at 10 mg/kg and 20 mg/kg with 80 mg/kg Erlotinib to assess for biological efficacy (pharmacodynamics) and efficacy with 12 mice per group with the control arm of 5% DMSO.,DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",A second study was also conducted with MP470 at 10 mg/kg and 20 mg/kg with 80 mg/kg Erlotinib to assess for biological efficacy (pharmacodynamics) and efficacy with 12 mice per group with the control arm of 5% DMSO.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","For the androgen-depletion experiments, LNCaP cells were grown in androgen-depleted medium, phenol red-free RPMI 1640 supplemented with 10% charcoal/",RPMI,charcoal,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In contrast to Erlotinib or Imatinib, MP470 inhibits cell proliferation, induces cell growth arrest and promotes apoptosis in prostate LNCaP cancer cells.",MP470,Imatinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In contrast to Erlotinib or Imatinib, MP470 inhibits cell proliferation, induces cell growth arrest and promotes apoptosis in prostate LNCaP cancer cells.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 was kindly provided by SuperGen (Dublin, CA) and Erlotinib [4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazolium hydrochloride] was isolated from clinical Tarceva tablets.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 was kindly provided by SuperGen (Dublin, CA) and Erlotinib [4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazolium hydrochloride] was isolated from clinical Tarceva tablets.",MP470,Tarceva,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Anti-Phosphotyrosine (PY20) was from BD Biosciences (San Jose, CA).",PY20,BD,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Anti-Phosphotyrosine (PY20) was from BD Biosciences (San Jose, CA).",San,BD,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, it appears that TIMP-1 may be combined with TOP2A for prediction of response to anthracycline-based chemotherapy [8].",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, it appears that TIMP-1 may be combined with TOP2A for prediction of response to anthracycline-based chemotherapy [8].",TOP2A,anthracycline,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Discussion
A role for Egr-1 in human bladder cancer progression would be expected from the fact that Egr-1 regulates heparanase and HYAL-1 hyaluronidase expression in human bladder cancer cells [8,9].",Egr-1,hyaluronidase,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Discussion
A role for Egr-1 in human bladder cancer progression would be expected from the fact that Egr-1 regulates heparanase and HYAL-1 hyaluronidase expression in human bladder cancer cells [8,9].",HYAL-1,hyaluronidase,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Discussion
A role for Egr-1 in human bladder cancer progression would be expected from the fact that Egr-1 regulates heparanase and HYAL-1 hyaluronidase expression in human bladder cancer cells [8,9].",Egr-1,hyaluronidase,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Especially when combined with Erlotinib MP470 abolished HER family/PI3K/Akt pathway with associated tumor growth inhibition in a LNCaP mouse xenograft model.

",PI3K,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Especially when combined with Erlotinib MP470 abolished HER family/PI3K/Akt pathway with associated tumor growth inhibition in a LNCaP mouse xenograft model.

",HER,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Especially when combined with Erlotinib MP470 abolished HER family/PI3K/Akt pathway with associated tumor growth inhibition in a LNCaP mouse xenograft model.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Nocodazole was purchased from Calbiochem (La Jolla, CA).",La,Nocodazole,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Cell Culture and Chemical Compounds
Human cell lines from ATCC, were maintained in Dulbecco's minimal essential medium(Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 mg/mL streptomycin at 37degC in a 5% CO2-humidified atmosphere.",ATCC,streptomycin,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Cell Culture and Chemical Compounds
Human cell lines from ATCC, were maintained in Dulbecco's minimal essential medium(Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 mg/mL streptomycin at 37degC in a 5% CO2-humidified atmosphere.",ATCC,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","ODN 2006 (10 uM), ODN 2006 control (10 uM), same volume of the control medium, or TLR signaling inhibitor chloroquine (10 uM) were added and incubated for 24 hours, the number of invaded cells was stained and counted, all analysis were performed in triplicate.",TLR,chloroquine,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","ODN 2006 (10 uM), ODN 2006 control (10 uM), same volume of the control medium, or TLR signaling inhibitor chloroquine (10 uM) were added and incubated for 24 hours, the number of invaded cells was stained and counted, all analysis were performed in triplicate.",ODN,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","ODN 2006 (10 uM), ODN 2006 control (10 uM), same volume of the control medium, or TLR signaling inhibitor chloroquine (10 uM) were added and incubated for 24 hours, the number of invaded cells was stained and counted, all analysis were performed in triplicate.",ODN,chloroquine,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","The proteins on acrylamide gel were transferred to a nylon membrane, which was blocked overnight (4degC in PBS with 0.1% Tween and 10% milk powder).",PBS,acrylamide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",CO2,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",RPMI-1640,etoposide,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","The thyroid and skin tissue cores served as negative IHC controls for the TS and Topo I, while the tonsil tissue as a positive control for Topo I. A known positive colorectal carcinoma case and an ovarian carcinoma case were used as external positive IHC controls for TS and Topo I, respectively.

",IHC,thyroid,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","The thyroid and skin tissue cores served as negative IHC controls for the TS and Topo I, while the tonsil tissue as a positive control for Topo I. A known positive colorectal carcinoma case and an ovarian carcinoma case were used as external positive IHC controls for TS and Topo I, respectively.

",TS,thyroid,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","The thyroid and skin tissue cores served as negative IHC controls for the TS and Topo I, while the tonsil tissue as a positive control for Topo I. A known positive colorectal carcinoma case and an ovarian carcinoma case were used as external positive IHC controls for TS and Topo I, respectively.

",IHC,thyroid,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","The thyroid and skin tissue cores served as negative IHC controls for the TS and Topo I, while the tonsil tissue as a positive control for Topo I. A known positive colorectal carcinoma case and an ovarian carcinoma case were used as external positive IHC controls for TS and Topo I, respectively.

",TS,thyroid,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Effect of Infliximab, a neutralizing antibody to TNF-a, on the induction of CXCR4 expression by H. Pylori
The finding of upregulation of TNF-a expression in this case brought us to further research on its involvement in the induction of CXCR4 expression by H. pylori.",CXCR4,Infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Effect of Infliximab, a neutralizing antibody to TNF-a, on the induction of CXCR4 expression by H. Pylori
The finding of upregulation of TNF-a expression in this case brought us to further research on its involvement in the induction of CXCR4 expression by H. pylori.",CXCR4,Infliximab,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were grown in androgen-depleted medium, phenol red-free RPMI 1640 supplemented with 10% charcoal/dextran-treated FBS for 10 days.",RPMI,charcoal,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were grown in androgen-depleted medium, phenol red-free RPMI 1640 supplemented with 10% charcoal/dextran-treated FBS for 10 days.",FBS,charcoal,1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Although association between rs12255372 and risk of Type 2 diabetes is thought to be due to impairment of insulin secretion [14], TCF7L2 has also long been known to have a role in Wnt/b-catenin signaling.",TCF7L2,insulin,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Table 2 Univariate and multivariate COX regression analysis

	Univariate analysis	Multivariate analysisa	
		
Factor	Hazard ratiob	P	Hazard ratiob	P	
Egr-1					
	
Low expression (score 1) versus Egr-1 negative (score 0)	1.59 (1.01-2.50)	0.044	1.41 (0.89-2.24)	0.143	
	
Moderate-high expression (score 2-3) versus Egr-1 negative (score 0)	1.95 (1.11-3.44)	0.021	1.38 (0.76-2.49)	0.285	
	
Age (5 year intervals)	1.19 (1.08-1.31)	0.001	1.11 (0.99-1.25)	0.078	
	
Tumor type (Papillary versus solid/mixed)	2.33 (1.43-3.80)	0.001	1.78 (1.03-3.08)	0.038	
	
Tumor stage (T1 versus Ta)	3.01 (2.07-4.38)	&#60;0.001	0.42 (0.16-1.10)	0.078	
	
Tumor grade (High grade versus PUNLMP+low grade)	3.42 (2.34-4.98)	&#60;0.001	6.12 (2.27-16.55)	0.000	
	
Sex	0.99 (0.63-1.56)	0.981			
	
Size (&#62; 3 cm versus &#60; 3 cm)	1.02 (0.65-1.60)	0.941			
	
Bacillus Calmette-Guerin (BCG) treatment	0.55 (0.32-0.93)	0.026			
	
Concomitant CIS	1.02 (0.65-1.60)	0.941			
aOnly risk factors that were significant (P &#60; 0.01) in the univariate analysis was included in the multivariate analysis.

",T1,BCG,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Table 2 Univariate and multivariate COX regression analysis

	Univariate analysis	Multivariate analysisa	
		
Factor	Hazard ratiob	P	Hazard ratiob	P	
Egr-1					
	
Low expression (score 1) versus Egr-1 negative (score 0)	1.59 (1.01-2.50)	0.044	1.41 (0.89-2.24)	0.143	
	
Moderate-high expression (score 2-3) versus Egr-1 negative (score 0)	1.95 (1.11-3.44)	0.021	1.38 (0.76-2.49)	0.285	
	
Age (5 year intervals)	1.19 (1.08-1.31)	0.001	1.11 (0.99-1.25)	0.078	
	
Tumor type (Papillary versus solid/mixed)	2.33 (1.43-3.80)	0.001	1.78 (1.03-3.08)	0.038	
	
Tumor stage (T1 versus Ta)	3.01 (2.07-4.38)	&#60;0.001	0.42 (0.16-1.10)	0.078	
	
Tumor grade (High grade versus PUNLMP+low grade)	3.42 (2.34-4.98)	&#60;0.001	6.12 (2.27-16.55)	0.000	
	
Sex	0.99 (0.63-1.56)	0.981			
	
Size (&#62; 3 cm versus &#60; 3 cm)	1.02 (0.65-1.60)	0.941			
	
Bacillus Calmette-Guerin (BCG) treatment	0.55 (0.32-0.93)	0.026			
	
Concomitant CIS	1.02 (0.65-1.60)	0.941			
aOnly risk factors that were significant (P &#60; 0.01) in the univariate analysis was included in the multivariate analysis.

",Egr-1,BCG,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Table 2 Univariate and multivariate COX regression analysis

	Univariate analysis	Multivariate analysisa	
		
Factor	Hazard ratiob	P	Hazard ratiob	P	
Egr-1					
	
Low expression (score 1) versus Egr-1 negative (score 0)	1.59 (1.01-2.50)	0.044	1.41 (0.89-2.24)	0.143	
	
Moderate-high expression (score 2-3) versus Egr-1 negative (score 0)	1.95 (1.11-3.44)	0.021	1.38 (0.76-2.49)	0.285	
	
Age (5 year intervals)	1.19 (1.08-1.31)	0.001	1.11 (0.99-1.25)	0.078	
	
Tumor type (Papillary versus solid/mixed)	2.33 (1.43-3.80)	0.001	1.78 (1.03-3.08)	0.038	
	
Tumor stage (T1 versus Ta)	3.01 (2.07-4.38)	&#60;0.001	0.42 (0.16-1.10)	0.078	
	
Tumor grade (High grade versus PUNLMP+low grade)	3.42 (2.34-4.98)	&#60;0.001	6.12 (2.27-16.55)	0.000	
	
Sex	0.99 (0.63-1.56)	0.981			
	
Size (&#62; 3 cm versus &#60; 3 cm)	1.02 (0.65-1.60)	0.941			
	
Bacillus Calmette-Guerin (BCG) treatment	0.55 (0.32-0.93)	0.026			
	
Concomitant CIS	1.02 (0.65-1.60)	0.941			
aOnly risk factors that were significant (P &#60; 0.01) in the univariate analysis was included in the multivariate analysis.

",COX,BCG,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Table 2 Univariate and multivariate COX regression analysis

	Univariate analysis	Multivariate analysisa	
		
Factor	Hazard ratiob	P	Hazard ratiob	P	
Egr-1					
	
Low expression (score 1) versus Egr-1 negative (score 0)	1.59 (1.01-2.50)	0.044	1.41 (0.89-2.24)	0.143	
	
Moderate-high expression (score 2-3) versus Egr-1 negative (score 0)	1.95 (1.11-3.44)	0.021	1.38 (0.76-2.49)	0.285	
	
Age (5 year intervals)	1.19 (1.08-1.31)	0.001	1.11 (0.99-1.25)	0.078	
	
Tumor type (Papillary versus solid/mixed)	2.33 (1.43-3.80)	0.001	1.78 (1.03-3.08)	0.038	
	
Tumor stage (T1 versus Ta)	3.01 (2.07-4.38)	&#60;0.001	0.42 (0.16-1.10)	0.078	
	
Tumor grade (High grade versus PUNLMP+low grade)	3.42 (2.34-4.98)	&#60;0.001	6.12 (2.27-16.55)	0.000	
	
Sex	0.99 (0.63-1.56)	0.981			
	
Size (&#62; 3 cm versus &#60; 3 cm)	1.02 (0.65-1.60)	0.941			
	
Bacillus Calmette-Guerin (BCG) treatment	0.55 (0.32-0.93)	0.026			
	
Concomitant CIS	1.02 (0.65-1.60)	0.941			
aOnly risk factors that were significant (P &#60; 0.01) in the univariate analysis was included in the multivariate analysis.

",Egr-1,BCG,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Table 2 Univariate and multivariate COX regression analysis

	Univariate analysis	Multivariate analysisa	
		
Factor	Hazard ratiob	P	Hazard ratiob	P	
Egr-1					
	
Low expression (score 1) versus Egr-1 negative (score 0)	1.59 (1.01-2.50)	0.044	1.41 (0.89-2.24)	0.143	
	
Moderate-high expression (score 2-3) versus Egr-1 negative (score 0)	1.95 (1.11-3.44)	0.021	1.38 (0.76-2.49)	0.285	
	
Age (5 year intervals)	1.19 (1.08-1.31)	0.001	1.11 (0.99-1.25)	0.078	
	
Tumor type (Papillary versus solid/mixed)	2.33 (1.43-3.80)	0.001	1.78 (1.03-3.08)	0.038	
	
Tumor stage (T1 versus Ta)	3.01 (2.07-4.38)	&#60;0.001	0.42 (0.16-1.10)	0.078	
	
Tumor grade (High grade versus PUNLMP+low grade)	3.42 (2.34-4.98)	&#60;0.001	6.12 (2.27-16.55)	0.000	
	
Sex	0.99 (0.63-1.56)	0.981			
	
Size (&#62; 3 cm versus &#60; 3 cm)	1.02 (0.65-1.60)	0.941			
	
Bacillus Calmette-Guerin (BCG) treatment	0.55 (0.32-0.93)	0.026			
	
Concomitant CIS	1.02 (0.65-1.60)	0.941			
aOnly risk factors that were significant (P &#60; 0.01) in the univariate analysis was included in the multivariate analysis.

",Egr-1,BCG,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","Table 2 Univariate and multivariate COX regression analysis

	Univariate analysis	Multivariate analysisa	
		
Factor	Hazard ratiob	P	Hazard ratiob	P	
Egr-1					
	
Low expression (score 1) versus Egr-1 negative (score 0)	1.59 (1.01-2.50)	0.044	1.41 (0.89-2.24)	0.143	
	
Moderate-high expression (score 2-3) versus Egr-1 negative (score 0)	1.95 (1.11-3.44)	0.021	1.38 (0.76-2.49)	0.285	
	
Age (5 year intervals)	1.19 (1.08-1.31)	0.001	1.11 (0.99-1.25)	0.078	
	
Tumor type (Papillary versus solid/mixed)	2.33 (1.43-3.80)	0.001	1.78 (1.03-3.08)	0.038	
	
Tumor stage (T1 versus Ta)	3.01 (2.07-4.38)	&#60;0.001	0.42 (0.16-1.10)	0.078	
	
Tumor grade (High grade versus PUNLMP+low grade)	3.42 (2.34-4.98)	&#60;0.001	6.12 (2.27-16.55)	0.000	
	
Sex	0.99 (0.63-1.56)	0.981			
	
Size (&#62; 3 cm versus &#60; 3 cm)	1.02 (0.65-1.60)	0.941			
	
Bacillus Calmette-Guerin (BCG) treatment	0.55 (0.32-0.93)	0.026			
	
Concomitant CIS	1.02 (0.65-1.60)	0.941			
aOnly risk factors that were significant (P &#60; 0.01) in the univariate analysis was included in the multivariate analysis.

",CIS,BCG,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,epirubicin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,cyclophosphamide,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CAF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,fluorouracil,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,epirubicin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,adriamycin,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CEF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,epirubicin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,epirubicin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,adriamycin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","To further study the possible use of TIMP-1 as a biomarker in breast cancer patients, the present study investigates the association between levels of TIMP-1 in cytosolic tumor tissue extracts and outcome following adjuvant chemotherapy with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or an anthracycline-containing regimen (cyclophosphamide and 5-fluorouracil with adriamycin/epirubicin (CAF/CEF); or single-agent adriamycin (A)), or following no adjuvant treatment.",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Figure 3 Effects of MP470, Erlotinib, and MP470-Erlotinib treatment on Akt activity.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Figure 3 Effects of MP470, Erlotinib, and MP470-Erlotinib treatment on Akt activity.",MP470,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","For growth factor deprivation, the medium was made without serum, EGF, and insulin.",EGF,insulin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","The next day, the slides were washed with PBS and incubated with a horseradish peroxidase (HRP)-conjugated affinity purified goat anti-mouse IgG (H+L) secondary antibody for one hour at room temperature and with a biotin-avidin peroxidase conjugate (ABC kit, Vector Laboratories) for 15 minutes at room temperature.",ABC,biotin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","The next day, the slides were washed with PBS and incubated with a horseradish peroxidase (HRP)-conjugated affinity purified goat anti-mouse IgG (H+L) secondary antibody for one hour at room temperature and with a biotin-avidin peroxidase conjugate (ABC kit, Vector Laboratories) for 15 minutes at room temperature.",PBS,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",X-100,dimethyl sulfoxide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",X-100,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",LMPA,dimethyl sulfoxide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",LMPA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",RPMI-1640,dimethyl sulfoxide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",RPMI-1640,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",DMSO,dimethyl sulfoxide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",DMSO,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",PHA,dimethyl sulfoxide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Methods
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively.",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Together, our data indicate that MP470 has inhibitory effects on cell growth and cell cycle progression, promotes apoptosis and that these effects are enhanced by Erlotinib.

",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
","Table 1 Characteristics of patients and tumors

	Median (range)	n (%)	
Age in years	51.8 (30-74)		
Histological type			
 Invasive ductal		43 (76.80)	
 Invasive lobular		4 (7.15)	
 DCIS		5 (8.90)	
 Mucinous Adenocarcinoma		4 (7.15)	
Nodal status			
 Negative		32	
 Positive		24	
Histological grade			
 Grade 1		7	
 Grade 2		19	
 Grade 3		17	
Estrogen receptors			
 Negative		27 (48.2)	
 Positive		29 (51.8)	
Progesterone receptors			
 Negative		37 (66.1)	
 Positive		19 (33.9)	
ErbB2			
 Negative		30 (53.5)	
 ",DCIS,Progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
","Table 1 Characteristics of patients and tumors

	Median (range)	n (%)	
Age in years	51.8 (30-74)		
Histological type			
 Invasive ductal		43 (76.80)	
 Invasive lobular		4 (7.15)	
 DCIS		5 (8.90)	
 Mucinous Adenocarcinoma		4 (7.15)	
Nodal status			
 Negative		32	
 Positive		24	
Histological grade			
 Grade 1		7	
 Grade 2		19	
 Grade 3		17	
Estrogen receptors			
 Negative		27 (48.2)	
 Positive		29 (51.8)	
Progesterone receptors			
 Negative		37 (66.1)	
 Positive		19 (33.9)	
ErbB2			
 Negative		30 (53.5)	
 ",ErbB2,Progesterone,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470, especially in combination with Erlotinib continues to inhibit these activating phosphorylation events following androgen deprivation.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",2) showed that MP470 induced G1 arrest in A549 and LNCaP cells as they cannot be synchronized in G2/M by nocodazole compared to DMSO control.,A549,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",2) showed that MP470 induced G1 arrest in A549 and LNCaP cells as they cannot be synchronized in G2/M by nocodazole compared to DMSO control.,DMSO,nocodazole,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",2) showed that MP470 induced G1 arrest in A549 and LNCaP cells as they cannot be synchronized in G2/M by nocodazole compared to DMSO control.,MP470,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",2) showed that MP470 induced G1 arrest in A549 and LNCaP cells as they cannot be synchronized in G2/M by nocodazole compared to DMSO control.,G1,nocodazole,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",NIH3T3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",NIH3T3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",NIH3T3,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The cells were treated with 10 mM of Erlotinib, MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus IM for 24 hr, and Akt phosphorylation was analyzed by Western blotting.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The cells were treated with 10 mM of Erlotinib, MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus IM for 24 hr, and Akt phosphorylation was analyzed by Western blotting.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The cells were treated with 10 mM of Erlotinib, MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus IM for 24 hr, and Akt phosphorylation was analyzed by Western blotting.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The cells were treated with 10 mM of Erlotinib, MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus IM for 24 hr, and Akt phosphorylation was analyzed by Western blotting.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The cells were treated with 10 mM of Erlotinib, MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus IM for 24 hr, and Akt phosphorylation was analyzed by Western blotting.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The cells were treated with 10 mM of Erlotinib, MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus IM for 24 hr, and Akt phosphorylation was analyzed by Western blotting.

",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Further, MP470 plus Erlotinib blocked the interaction between the PI3K p85 subunit and phosphorylated tyrosine kinases, an essential process for PI3K activation (Fig.",p85,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Further, MP470 plus Erlotinib blocked the interaction between the PI3K p85 subunit and phosphorylated tyrosine kinases, an essential process for PI3K activation (Fig.",PI3,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Further, MP470 plus Erlotinib blocked the interaction between the PI3K p85 subunit and phosphorylated tyrosine kinases, an essential process for PI3K activation (Fig.",PI3,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Further, MP470 plus Erlotinib blocked the interaction between the PI3K p85 subunit and phosphorylated tyrosine kinases, an essential process for PI3K activation (Fig.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","As shown in figure 3A, Akt activity (as measured by phosphorylation on Ser473) was significantly reduced by 10 mM MP470 alone but was not reduced by Erlotinib or IM.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","As shown in figure 3A, Akt activity (as measured by phosphorylation on Ser473) was significantly reduced by 10 mM MP470 alone but was not reduced by Erlotinib or IM.",Ser473,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Histone H3 modifications contribute to leptin gene regulation in HCC cells
In order to investigate whether the amount of acetylated H3 interacting with leptin's proximal promoter was correlated with the regulation of leptin gene transcription, we used trichostatin A (TSA), an inhibitor of histone deacetylation.",HCC,trichostatin,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Histone H3 modifications contribute to leptin gene regulation in HCC cells
In order to investigate whether the amount of acetylated H3 interacting with leptin's proximal promoter was correlated with the regulation of leptin gene transcription, we used trichostatin A (TSA), an inhibitor of histone deacetylation.",H3,trichostatin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Histone H3 modifications contribute to leptin gene regulation in HCC cells
In order to investigate whether the amount of acetylated H3 interacting with leptin's proximal promoter was correlated with the regulation of leptin gene transcription, we used trichostatin A (TSA), an inhibitor of histone deacetylation.",H3,trichostatin,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Histone H3 modifications contribute to leptin gene regulation in HCC cells
In order to investigate whether the amount of acetylated H3 interacting with leptin's proximal promoter was correlated with the regulation of leptin gene transcription, we used trichostatin A (TSA), an inhibitor of histone deacetylation.",TSA,trichostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative sections showing immunohistochemical staining of MMP-9 (A, B, and C), TIMP-1 (D, E, and F), TIMP-2 (G, H, and I), endostatin (J, K, and L), COX-2 (M, N, and O), and NOS-2 (P, Q, and R) in healthy controls (A, D, G, J, M, and P), adjacent non-tumor tissues (B, E, H, K, N, and Q) and tumor tissues (C, F, I, L, O, and R).",TIMP-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative sections showing immunohistochemical staining of MMP-9 (A, B, and C), TIMP-1 (D, E, and F), TIMP-2 (G, H, and I), endostatin (J, K, and L), COX-2 (M, N, and O), and NOS-2 (P, Q, and R) in healthy controls (A, D, G, J, M, and P), adjacent non-tumor tissues (B, E, H, K, N, and Q) and tumor tissues (C, F, I, L, O, and R).",MMP-9,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative sections showing immunohistochemical staining of MMP-9 (A, B, and C), TIMP-1 (D, E, and F), TIMP-2 (G, H, and I), endostatin (J, K, and L), COX-2 (M, N, and O), and NOS-2 (P, Q, and R) in healthy controls (A, D, G, J, M, and P), adjacent non-tumor tissues (B, E, H, K, N, and Q) and tumor tissues (C, F, I, L, O, and R).",NOS-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative sections showing immunohistochemical staining of MMP-9 (A, B, and C), TIMP-1 (D, E, and F), TIMP-2 (G, H, and I), endostatin (J, K, and L), COX-2 (M, N, and O), and NOS-2 (P, Q, and R) in healthy controls (A, D, G, J, M, and P), adjacent non-tumor tissues (B, E, H, K, N, and Q) and tumor tissues (C, F, I, L, O, and R).",TIMP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Representative sections showing immunohistochemical staining of MMP-9 (A, B, and C), TIMP-1 (D, E, and F), TIMP-2 (G, H, and I), endostatin (J, K, and L), COX-2 (M, N, and O), and NOS-2 (P, Q, and R) in healthy controls (A, D, G, J, M, and P), adjacent non-tumor tissues (B, E, H, K, N, and Q) and tumor tissues (C, F, I, L, O, and R).",COX-2,endostatin,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",MP470 alone or MP470 plus Erlotinib decreased total tyrosine phosphorylation (Fig.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",MP470 alone or MP470 plus Erlotinib decreased total tyrosine phosphorylation (Fig.,MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",CO2,glutamine,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",WM266,glutamine,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",A375,glutamine,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",RPMI,glutamine,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 mM), in the presence of RPMI-1640 culture medium and maintained at 37degC under 5% CO2 conditions.

",CO2,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 mM), in the presence of RPMI-1640 culture medium and maintained at 37degC under 5% CO2 conditions.

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 mM), in the presence of RPMI-1640 culture medium and maintained at 37degC under 5% CO2 conditions.

",RPMI-1640,etoposide,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
",Figure 3 Effect of infliximab on the induction of CXCR4 expression by H. Pylori.,CXCR4,infliximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","It is of note that one patient with a KRAS-mutant tumor was reported by Khambata et al to have had a PFS of &#62; 1 year on cetuximab, although radiographic response in this patient was not recorded.",KRAS,cetuximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","It is of note that one patient with a KRAS-mutant tumor was reported by Khambata et al to have had a PFS of &#62; 1 year on cetuximab, although radiographic response in this patient was not recorded.",PFS,cetuximab,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
",CHEK-1 was established by transduction of human papillomavirus type 16 E6/E7 into primary cultures of esophageal keratinocytes [30].,CHEK-1,human papillomavirus,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","The increase in migration of MKN45 cells induced by 26695 was inhibited when AMD 3100 (**P &#60; 0.01, vs 26695 + AMD), or infliximab (***P &#60; 0.01, vs 26695 + inf) was added.",AMD,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","The increase in migration of MKN45 cells induced by 26695 was inhibited when AMD 3100 (**P &#60; 0.01, vs 26695 + AMD), or infliximab (***P &#60; 0.01, vs 26695 + inf) was added.",AMD,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","The increase in migration of MKN45 cells induced by 26695 was inhibited when AMD 3100 (**P &#60; 0.01, vs 26695 + AMD), or infliximab (***P &#60; 0.01, vs 26695 + inf) was added.",MKN45,infliximab,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","The TMA was incubated with avidin for 10 minutes and washed twice in TBST wash buffer (0.05 M Tris-HCl pH 7.6, 0.3 M NaCl and 0.1% Tween 20) followed by biotin incubation for 10 minutes.

",TBST,biotin,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","The TMA was incubated with avidin for 10 minutes and washed twice in TBST wash buffer (0.05 M Tris-HCl pH 7.6, 0.3 M NaCl and 0.1% Tween 20) followed by biotin incubation for 10 minutes.

",TMA,biotin,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","DNA samples were assayed at 50 mg/well and quantitated relative to an imidazole ring-opened AFB1-DNA standard, which has a modification level of 4 adducts/10 nucleotides.",AFB1-DNA,imidazole,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","DNA samples were assayed at 50 mg/well and quantitated relative to an imidazole ring-opened AFB1-DNA standard, which has a modification level of 4 adducts/10 nucleotides.",DNA,imidazole,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","As a 1st-line systemic treatment, IFN was administered to 15 patients (22.7%), somatostatin-analogue to 2 patients (3.0%), and chemotherapeutic agent to 49 patients (74.2%).",IFN,somatostatin,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(A) and (B) CXCR4 upregulation induced by H. pylori 26695 was inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P &#60; 0.01, respectively, vs 26695 + inf.",CXCR4,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(A) and (B) CXCR4 upregulation induced by H. pylori 26695 was inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P &#60; 0.01, respectively, vs 26695 + inf.",HGC27,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(A) and (B) CXCR4 upregulation induced by H. pylori 26695 was inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P &#60; 0.01, respectively, vs 26695 + inf.",MKN45,infliximab,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",GEPR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",GEPR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",GEPR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",NSCLC,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",NSCLC,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",NSCLC,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",mCRC,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",mCRC,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",mCRC,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",EGFR,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Results
The gene expression predictor of response to erlotinib also predicts response and disease control to cetuximab in mCRC
The 180-gene GEPR provides a model which weights genes based on the expression values determined from a panel of NSCLC cell lines stratified by their sensitivity to the EGFR inhibitor erlotinib.",EGFR,erlotinib,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
",Allegra et al. failed to demonstrate a consistent and significant association between TS and either OS or DFS in 465 patients with Dukes B and C disease[20].,TS,Allegra,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
",Allegra et al. failed to demonstrate a consistent and significant association between TS and either OS or DFS in 465 patients with Dukes B and C disease[20].,DFS,Allegra,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
",Allegra et al. failed to demonstrate a consistent and significant association between TS and either OS or DFS in 465 patients with Dukes B and C disease[20].,OS,Allegra,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","Among them FBLN2, a gene reported to be up-regulated in elderly breast cancer patients who are not responsive to pre-operative treatment with toremifene [11] and FGFR4 whose up-regulation predicts poor response to tamoxifen [27].",FGFR4,tamoxifen,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","Among them FBLN2, a gene reported to be up-regulated in elderly breast cancer patients who are not responsive to pre-operative treatment with toremifene [11] and FGFR4 whose up-regulation predicts poor response to tamoxifen [27].",FGFR4,toremifene,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","Among them FBLN2, a gene reported to be up-regulated in elderly breast cancer patients who are not responsive to pre-operative treatment with toremifene [11] and FGFR4 whose up-regulation predicts poor response to tamoxifen [27].",FBLN2,tamoxifen,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","Among them FBLN2, a gene reported to be up-regulated in elderly breast cancer patients who are not responsive to pre-operative treatment with toremifene [11] and FGFR4 whose up-regulation predicts poor response to tamoxifen [27].",FBLN2,toremifene,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Abbreviations
NHEM: normal human epidermal melanocytes; DAC: 5-aza-2'-deoxycytidine; TSA: Trichostatin",TSA,Trichostatin,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Abbreviations
NHEM: normal human epidermal melanocytes; DAC: 5-aza-2'-deoxycytidine; TSA: Trichostatin",NHEM,Trichostatin,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Abbreviations
NHEM: normal human epidermal melanocytes; DAC: 5-aza-2'-deoxycytidine; TSA: Trichostatin",DAC,Trichostatin,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH6,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH6,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",DAB,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",DAB,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",EDTA,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",EDTA,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",C20,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",C20,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH6,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH6,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",EDTA,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",EDTA,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH8,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH8,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH6,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH6,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",PR,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",PR,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",C19,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",C19,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",COX-2,Glycine,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",COX-2,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH8,Glycine,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Table 2 Details of primary antibodies

Target		Clone	Supplier	DAB concentration	Antigen retrieval	
ERa	mouse	6F-11	Novocastra	1:120	0.01 M Citrate buffer (pH6) for 5 minutes	
ERb1	mouse	PPG5/10	Serotec, [60]	1:40	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb2	mouse	57/3	Serotec, [38]	1:30	0.05 M Glycine/EDTA (pH8) for 5 minutes	
ERb5	mouse	5/25	Serotec, [61]	1:75	0.01 M Citrate buffer (pH6) for 5 minutes	
PR (A+B)	rabbit	C19	Santa Cruz	N/A	0.01 M Citrate
(pH6) 10 min	
COX-2	goat	C20	Santa Cruz	",pH8,Glycine,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-4101993068210.1186/1471-2407-9-410Research ArticleNuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer Dahl Edgar 1edahl@ukaachen.deEn-Nia Abdelaziz 2aen-nia@ukaachen.deWiesmann Frank 1fwiesmann@ukaachen.deKrings Renate 3rkrings@ukaachen.deDjudjaj",BMC,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-4101993068210.1186/1471-2407-9-410Research ArticleNuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer Dahl Edgar 1edahl@ukaachen.deEn-Nia Abdelaziz 2aen-nia@ukaachen.deWiesmann Frank 1fwiesmann@ukaachen.deKrings Renate 3rkrings@ukaachen.deDjudjaj",YB-1,progesterone,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-4101993068210.1186/1471-2407-9-410Research ArticleNuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer Dahl Edgar 1edahl@ukaachen.deEn-Nia Abdelaziz 2aen-nia@ukaachen.deWiesmann Frank 1fwiesmann@ukaachen.deKrings Renate 3rkrings@ukaachen.deDjudjaj",Cancer1471,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-4101993068210.1186/1471-2407-9-410Research ArticleNuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer Dahl Edgar 1edahl@ukaachen.deEn-Nia Abdelaziz 2aen-nia@ukaachen.deWiesmann Frank 1fwiesmann@ukaachen.deKrings Renate 3rkrings@ukaachen.deDjudjaj",Y,progesterone,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","TTP on trastuzumab-based second-line treatment was 7 months median, and therefore not significantly different from the first-line setting.",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
","In both bladder and prostate cancer Egr-1 is shown to regulate the expression of heparanase and hyaluronidase, which are implicated in the metastatic spread of cancer cells [8-10].",Egr-1,hyaluronidase,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","In those studies, a TTP of 6 - 8 months on second-line trastuzumab-based therapy was reported [13-17].

",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-931932101410.1186/1471-2407-9-93Research ArticleQPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study Hinsch Nora 1n.hinsch@em.uni-frankfurt.deFrank Matthias 1matthias.frank@em.uni-frankfurt.deDoring Claudia 12c.doering@em.uni-frankfurt.deVorlander",BMC,thyroid,-1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-931932101410.1186/1471-2407-9-93Research ArticleQPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study Hinsch Nora 1n.hinsch@em.uni-frankfurt.deFrank Matthias 1matthias.frank@em.uni-frankfurt.deDoring Claudia 12c.doering@em.uni-frankfurt.deVorlander",RNA,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-931932101410.1186/1471-2407-9-93Research ArticleQPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study Hinsch Nora 1n.hinsch@em.uni-frankfurt.deFrank Matthias 1matthias.frank@em.uni-frankfurt.deDoring Claudia 12c.doering@em.uni-frankfurt.deVorlander",Cancer1471,thyroid,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Despite the small size of the anthracycline-treated subgroup, the analysis of DFS clearly indicated an association between high levels of tumor tissue TIMP-1 and a shorter survival.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Despite the small size of the anthracycline-treated subgroup, the analysis of DFS clearly indicated an association between high levels of tumor tissue TIMP-1 and a shorter survival.",DFS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","A recent study showed a similar association between TIMP-1 and decreased benefit from anthracyclines [7], thus indicating that further validation of TIMP-1 as a predictive marker for anthracycline sensitivity is justified.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","A recent study showed a similar association between TIMP-1 and decreased benefit from anthracyclines [7], thus indicating that further validation of TIMP-1 as a predictive marker for anthracycline sensitivity is justified.

",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","BuCy120: busulphan (1 mg/kg), given 4 consecutive days four times a day, starting 8 days before the transplantation (days minus 8 to minus 5) + cyclophosphamide (60 mg/kg), given 2 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 3) for acute and chronic myeloid leukemia and syndrome mielodysplastic in autologous PBSCT or allogeneic BMT.",BuCy120,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","BuCy120: busulphan (1 mg/kg), given 4 consecutive days four times a day, starting 8 days before the transplantation (days minus 8 to minus 5) + cyclophosphamide (60 mg/kg), given 2 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 3) for acute and chronic myeloid leukemia and syndrome mielodysplastic in autologous PBSCT or allogeneic BMT.",PBSCT,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","BuCy120: busulphan (1 mg/kg), given 4 consecutive days four times a day, starting 8 days before the transplantation (days minus 8 to minus 5) + cyclophosphamide (60 mg/kg), given 2 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 3) for acute and chronic myeloid leukemia and syndrome mielodysplastic in autologous PBSCT or allogeneic BMT.",BMT,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at primary treatments, more patients had a lumpectomy among CMF-treated and patients receiving no adjuvant chemotherapy than among anthracycline-treated patients.",CMF,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at OS, high levels of TIMP-1 were associated with a significantly shorter survival and we found a statistically significant interaction between TIMP-1 and anthracycline therapy.",OS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at OS, high levels of TIMP-1 were associated with a significantly shorter survival and we found a statistically significant interaction between TIMP-1 and anthracycline therapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at OS, high levels of TIMP-1 were associated with a significantly shorter survival and we found a statistically significant interaction between TIMP-1 and anthracycline therapy.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","*	MST (95% CI, month)	Crude HR (95% CI)	P+	",CI,MST,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","*	MST (95% CI, month)	Crude HR (95% CI)	P+	",CI,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","*	MST (95% CI, month)	Crude HR (95% CI)	P+	",HR,MST,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","For selenium treatment, MSC was given by daily intragastric administration starting at day 15.",MSC,selenium,1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Statistical significance was retained in both median PFS and the log-rank analyses when patients were not stratified based on KRAS status, suggesting that the signature is an independent predictor of benefit to cetuximab therapy in mCRC.",KRAS,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Statistical significance was retained in both median PFS and the log-rank analyses when patients were not stratified based on KRAS status, suggesting that the signature is an independent predictor of benefit to cetuximab therapy in mCRC.",mCRC,cetuximab,-1
"PMC 
BMC_Cancer_2009_May_13_9_145.txt
","Statistical significance was retained in both median PFS and the log-rank analyses when patients were not stratified based on KRAS status, suggesting that the signature is an independent predictor of benefit to cetuximab therapy in mCRC.",PFS,cetuximab,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Median tumor tissue TIMP-1 levels in subgroups according to adjuvant treatment were as follows: In CMF-treated patients 12.0 ng/mg of total protein (range, 0-106 ng/mg); in patients who received an anthracycline-containing regimen 13.5 ng/mg protein (range, 0-51.2 ng/mg); and in patients who received no adjuvant chemotherapy 13.8 ng/mg protein (range, 0-113 ng/mg).",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Median tumor tissue TIMP-1 levels in subgroups according to adjuvant treatment were as follows: In CMF-treated patients 12.0 ng/mg of total protein (range, 0-106 ng/mg); in patients who received an anthracycline-containing regimen 13.5 ng/mg protein (range, 0-51.2 ng/mg); and in patients who received no adjuvant chemotherapy 13.8 ng/mg protein (range, 0-113 ng/mg).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
",It seems counterintuitive that statins cause an increase in tumour-specifc HMG-CoAR expression however this is felt to be secondary to a loss of sterol mediated inhibition of HMG-CoAR transcription in tumour cells [2].,HMG,sterol,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
",It seems counterintuitive that statins cause an increase in tumour-specifc HMG-CoAR expression however this is felt to be secondary to a loss of sterol mediated inhibition of HMG-CoAR transcription in tumour cells [2].,HMG,sterol,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In the cohort studied here we were not able to find any, or only a very limited, prognostic impact of TIMP-1 and still, we observed a difference in outcome of TIMP-1 high and low patients after adjuvant anthracycline-based chemotherapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In the cohort studied here we were not able to find any, or only a very limited, prognostic impact of TIMP-1 and still, we observed a difference in outcome of TIMP-1 high and low patients after adjuvant anthracycline-based chemotherapy.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The results, though, show an association between TIMP-1 and lack of benefit from anthracycline-based therapy, which is widely used in the adjuvant setting.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","The TMA, used in this study was constructed from a consecutive cohort of 76 patients diagnosed with primary invasive epithelial ovarian cancer at the National Maternity Hospital, Dublin, with a median follow-up of 4.3 years.",TMA,Maternity,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Melanoma cells were also treated by 5-aza-2'-deoxycytidine (DAC), a demethylating agent, and/or histone deacetylase inhibitor, Trichostatin A (TSA), to evaluate their effects on 14-3-3s gene expression.

",TSA,Trichostatin,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Melanoma cells were also treated by 5-aza-2'-deoxycytidine (DAC), a demethylating agent, and/or histone deacetylase inhibitor, Trichostatin A (TSA), to evaluate their effects on 14-3-3s gene expression.

",DAC,Trichostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",MCP-1,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",bFGF,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",COX-2,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",HCC,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",TIMP-1,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",TSP-1,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",TIMP-2,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",HCC,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",VEGF,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",MMP-9,Endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays

	HC	AT	HCC	
				
	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	(-)	(+)	(++)	Positive Percent	
VEGF-A	35	3	6	20.5%	43	9	46	56.1%**	41	29	27	57.7%^^##	
bFGF	27	4	13	38.6%	29	13	55	70.1%**	32	41	23	66.7%^^##	
TGF-b	20	8	16	54.5%	11	4	83	88.8%**	14	15	68	85.6%^^#	
MCP-1	20	8	8	44.4%	32	21	44	67.0%*	59	21	17	39.2%##	
TSP-1	38	4	1	11.6%	43	14	41	56.1%**	37	33	27	61.9%^^##	
MMP-9	28	7	9	36.4%	25	13	59	74.2%**	40	23	35	59.2%^##	
TIMP-1	24	2	13	38.5%	63	14	17	33.0%	69	10	17	28.1%	
TIMP-2	21	6	17	52.3%	19	13	66	80.6%**	26	37	35	73.5%^^##	
Endostatin	23	9	10	45.2%	14	9	75	85.7%**	37	21	40	62.2%##	
COX-2	25	9	10	43.2%	7	39	51	92.8%**	9	46	43	90.8%^^	
NOS-2	32	9	3	27.3%	37	21	40	62.2%**	43	30	",NOS-2,Endostatin,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Methods
From our original retrospectively collected tumor samples we selected a group of 525 pre-menopausal lymph node-positive patients (adjuvant treatment: CMF, 324 patients; anthracycline-based, 99 patients; no adjuvant chemotherapy, 102 patients).",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Moreover, MP470 plus Erlotinib completely abolished Akt phosphorylation in LNCaP cells with an unchanged total protein level of Akt.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","There was a significant increase in the migration of MKN45 cells treated with H. pylori 26695, and a strong inhibition when AMD 3100, a CXCR4 antagonist, or infliximab, was added.

",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","There was a significant increase in the migration of MKN45 cells treated with H. pylori 26695, and a strong inhibition when AMD 3100, a CXCR4 antagonist, or infliximab, was added.

",MKN45,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","There was a significant increase in the migration of MKN45 cells treated with H. pylori 26695, and a strong inhibition when AMD 3100, a CXCR4 antagonist, or infliximab, was added.

",AMD,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Indeed, in nude mice bearing PC-3M xenografts, survivin knockdown in combination with selenium treatment stopped tumor growth completely.",survivin,selenium,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Indeed, in nude mice bearing PC-3M xenografts, survivin knockdown in combination with selenium treatment stopped tumor growth completely.",PC-3,selenium,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Adjuvant irinotecan containing chemotherapy might confer a survival advantage in CRC patients expressing Topo I, but this is still an open issue amenable to further investigation.

",CRC,irinotecan,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",PR,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",PR,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",ER,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",ER,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",Ki-67,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",Ki-67,vinorelbine,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",HER-2,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Table 1 shows immunohistochemical protein expression levels (ER, PR, HER-2, and Ki-67) before (pre-)and after (post-)surgery.

Toxicity of the regimens
The combination of vinorelbine and epirubicin was well tolerated with no case of death due to drug-related toxicity.",HER-2,vinorelbine,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",TIMP-2,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",DAKO,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",MMP-9,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",bFGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",MCP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",TIMP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",VEGF,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",TSP-1,endostatin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",COX-2,endostatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","These included the165-amino acid isoform of vascular endothelial growth factor (VEGF-A), basic fibroblast growth factor (bFGF; Santa Cruz), matrix metalloproteinase-9 (MMP-9), endostatin, tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1, TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53, transforming growth factor-b (TGF-b), cyclooxygenase 2 (COX-2; DAKO), and monocyte chemotactic protein 1 (MCP-1; Chemicon).",p53,endostatin,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several phase III randomized trials did not show any incremental benefit from the addition of irinotecan to 5-FU/LV adjuvant chemotherapy in patients with colorectal cancer[18,31].",FU,irinotecan,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several phase III randomized trials did not show any incremental benefit from the addition of irinotecan to 5-FU/LV adjuvant chemotherapy in patients with colorectal cancer[18,31].",III,irinotecan,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",T,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",VEGF,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",CT,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",CT,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",CI,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",T,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",VEGF,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",CG,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",HR,MST,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Adjusted HR (95% CI)	P++	
VEGF -460T &#62; C (rs833061)						
 TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00		
 CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018	
 CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212	
 CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022	
VEGF -634G &#62; C (rs2010963)						
 GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00		
 CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502	
 CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399	
 CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379	
VEGF +936C &#62; T (rs3025039)						
 CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00		
 CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992	
 TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367	
 CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839	
Abbreviation: MST, median survival time.

",VEGF,MST,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Results
Median TTP on second-line trastuzumab-based therapy was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line, respectively (n.s.).",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Results
Median TTP on second-line trastuzumab-based therapy was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line, respectively (n.s.).",TTP,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Results
Median TTP on second-line trastuzumab-based therapy was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line, respectively (n.s.).",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
",The four genes were analysed with QPCR in 30 of the 98 serous adenocarcinomas from patients treated with paclitaxel and carboplatin.,QPCR,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
",The four genes were analysed with QPCR in 30 of the 98 serous adenocarcinomas from patients treated with paclitaxel and carboplatin.,QPCR,paclitaxel,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",Our result shows that both LY294002 and rapamycin inhibit the up-regulation effect of HCCR-1 by EGF (Figs.,HCCR-1,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",Our result shows that both LY294002 and rapamycin inhibit the up-regulation effect of HCCR-1 by EGF (Figs.,EGF,rapamycin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",Our result shows that both LY294002 and rapamycin inhibit the up-regulation effect of HCCR-1 by EGF (Figs.,LY294002,rapamycin,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The dual cell-stain assay described by Hartman and Speit [32] was employed to determine the viability of the PHA-stimulated and the non stimulated whole blood cells after etoposide treatments.,PHA,etoposide,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",We conducted a phase II prospective clinical trial of vinorelbine and epirubicin (VE) as a NC regimen in the treatment of Chinese LABC at the Cancer Hospital of Fudan University from September 2001 to December 2004; this study was approved by the institutional review board of my institution [13].,LABC,epirubicin,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
",We conducted a phase II prospective clinical trial of vinorelbine and epirubicin (VE) as a NC regimen in the treatment of Chinese LABC at the Cancer Hospital of Fudan University from September 2001 to December 2004; this study was approved by the institutional review board of my institution [13].,LABC,vinorelbine,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","However, before 2001, there were no published clinical trials of epirubicin-vinorelbine based combinations for neoadjuvant treatment in LABC.",LABC,epirubicin,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","However, before 2001, there were no published clinical trials of epirubicin-vinorelbine based combinations for neoadjuvant treatment in LABC.",LABC,vinorelbine,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
",OS was 43 months suggesting improved survival in patients treated with trastuzumab in multiple-lines.,OS,trastuzumab,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Between several molecules tested, they found that high levels of Topo I (assessed by similar to our study IHC methods) were associated with a major survival benefit from first line chemotherapy regimens containing either irinotecan or oxaliplatin, corresponding to a median survival advantage of 5.3 months.",IHC,irinotecan,-1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Between several molecules tested, they found that high levels of Topo I (assessed by similar to our study IHC methods) were associated with a major survival benefit from first line chemotherapy regimens containing either irinotecan or oxaliplatin, corresponding to a median survival advantage of 5.3 months.",IHC,oxaliplatin,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","List of abbreviations
MGMT: O6-methylguanine-DNA methyltransferase; MSP-PCR: Methylation-Specific PCR; HPV: human papillomavirus.

",DNA,human papillomavirus,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","List of abbreviations
MGMT: O6-methylguanine-DNA methyltransferase; MSP-PCR: Methylation-Specific PCR; HPV: human papillomavirus.

",PCR,human papillomavirus,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","List of abbreviations
MGMT: O6-methylguanine-DNA methyltransferase; MSP-PCR: Methylation-Specific PCR; HPV: human papillomavirus.

",MSP,human papillomavirus,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","List of abbreviations
MGMT: O6-methylguanine-DNA methyltransferase; MSP-PCR: Methylation-Specific PCR; HPV: human papillomavirus.

",MGMT,human papillomavirus,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","List of abbreviations
MGMT: O6-methylguanine-DNA methyltransferase; MSP-PCR: Methylation-Specific PCR; HPV: human papillomavirus.

",HPV,human papillomavirus,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","List of abbreviations
MGMT: O6-methylguanine-DNA methyltransferase; MSP-PCR: Methylation-Specific PCR; HPV: human papillomavirus.

",PCR,human papillomavirus,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
",The ERETIC signal was quantified to 3.17 x 10-7 moles using a series of creatine calibration standards as previously described [31].,ERETIC,creatine,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","For example, imatinib mesylate (IM, Gleevec; Novartis), an inhibitor of Bcr-Abl, c-Kit and platelet-derived growth factor receptor (PDGFR), has been successfully used in the treatments of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) [12].",PDGFR,imatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","For example, imatinib mesylate (IM, Gleevec; Novartis), an inhibitor of Bcr-Abl, c-Kit and platelet-derived growth factor receptor (PDGFR), has been successfully used in the treatments of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) [12].",PDGFR,Gleevec,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","For example, imatinib mesylate (IM, Gleevec; Novartis), an inhibitor of Bcr-Abl, c-Kit and platelet-derived growth factor receptor (PDGFR), has been successfully used in the treatments of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) [12].",CML,imatinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","For example, imatinib mesylate (IM, Gleevec; Novartis), an inhibitor of Bcr-Abl, c-Kit and platelet-derived growth factor receptor (PDGFR), has been successfully used in the treatments of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) [12].",CML,Gleevec,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Conclusion
We propose that MP470-Erlotinib targets the HER family/PI3K/Akt pathway and may represent a novel therapeutic strategy for prostate cancer.
",PI3K,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Conclusion
We propose that MP470-Erlotinib targets the HER family/PI3K/Akt pathway and may represent a novel therapeutic strategy for prostate cancer.
",HER,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Erlotinib (Tarceva; OSI Pharmaceuticals), an inhibitor of the epidermal growth factor receptor (EGFR), is also approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer and pancreatic carcinoma in combination with gemcitabine [13].",OSI,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Erlotinib (Tarceva; OSI Pharmaceuticals), an inhibitor of the epidermal growth factor receptor (EGFR), is also approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer and pancreatic carcinoma in combination with gemcitabine [13].",OSI,Tarceva,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Erlotinib (Tarceva; OSI Pharmaceuticals), an inhibitor of the epidermal growth factor receptor (EGFR), is also approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer and pancreatic carcinoma in combination with gemcitabine [13].",OSI,gemcitabine,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Erlotinib (Tarceva; OSI Pharmaceuticals), an inhibitor of the epidermal growth factor receptor (EGFR), is also approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer and pancreatic carcinoma in combination with gemcitabine [13].",EGFR,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Erlotinib (Tarceva; OSI Pharmaceuticals), an inhibitor of the epidermal growth factor receptor (EGFR), is also approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer and pancreatic carcinoma in combination with gemcitabine [13].",EGFR,Tarceva,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Erlotinib (Tarceva; OSI Pharmaceuticals), an inhibitor of the epidermal growth factor receptor (EGFR), is also approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer and pancreatic carcinoma in combination with gemcitabine [13].",EGFR,gemcitabine,-1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",Both the in vitro and in vivo efficacies of selenium were greatly enhanced when survivin expression was silenced.,survivin,selenium,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Furthermore, in a LNCaP mouse xenograft model, the MP470-Erlotinib combination produced 30-65% dose-dependent tumor growth inhibition (TGI).

",TGI,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",C666,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",NPC,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",RPMI-1640,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",HNE-1,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",CNE-1,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",HONE-1,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",SUNE-1,glutamine,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",CNE-2,glutamine,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(C) and (D) The coculture system of MKN45 and RAW264.7 cells expressed more CXCR4, *P &#60; 0.001, vs M; **P &#60; 0.001, vs R. The upregulation of CXCR4 expression was inhibited after treatment with infliximab, ***P &#60; 0.001, vs M + R + inf.",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(C) and (D) The coculture system of MKN45 and RAW264.7 cells expressed more CXCR4, *P &#60; 0.001, vs M; **P &#60; 0.001, vs R. The upregulation of CXCR4 expression was inhibited after treatment with infliximab, ***P &#60; 0.001, vs M + R + inf.",MKN45,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(C) and (D) The coculture system of MKN45 and RAW264.7 cells expressed more CXCR4, *P &#60; 0.001, vs M; **P &#60; 0.001, vs R. The upregulation of CXCR4 expression was inhibited after treatment with infliximab, ***P &#60; 0.001, vs M + R + inf.",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","The statin induced increase in HMG-CoAR results in an increase non-sterol isoprenoid side products, with their associated tumour-suppressive properties, which may explain the efficacy of statin in treating tumour cells in vitro [2]

Kato et al recently demonstrated that lypophillic statins induce apoptosis in ovarian cancer cells, and also postulated that HMG-CoAR expression predicted response to statin treatment [29].",HMG,sterol,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_125.txt
","The statin induced increase in HMG-CoAR results in an increase non-sterol isoprenoid side products, with their associated tumour-suppressive properties, which may explain the efficacy of statin in treating tumour cells in vitro [2]

Kato et al recently demonstrated that lypophillic statins induce apoptosis in ovarian cancer cells, and also postulated that HMG-CoAR expression predicted response to statin treatment [29].",HMG,sterol,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
",We have previously reported that automated quantitation of ER immunostaining on the same TMA series can produce results that do not differ from pathologist scoring and dextran-coated charcoal biochemical assay [28].,TMA,charcoal,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
",We have previously reported that automated quantitation of ER immunostaining on the same TMA series can produce results that do not differ from pathologist scoring and dextran-coated charcoal biochemical assay [28].,ER,charcoal,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",HER2,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",IHC,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",ISH,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",ISH,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",HER2,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",HER2,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","The effectiveness of Herceptin therapy depends on accurately evaluating HER2 status, which can be done either by immunohistochemical (IHC) assessment of HER2 protein expression or by evaluating HER2 gene amplification using in situ hybridization (ISH), most commonly, fluorescent ISH (FISH).",FISH,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In addition to its prognostic role, HER2 has now become more important as a predictive marker of treatment response to Trastuzumab, a humanized murine monoclonal antibody to the HER2 protein.",HER2,Trastuzumab,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In addition to its prognostic role, HER2 has now become more important as a predictive marker of treatment response to Trastuzumab, a humanized murine monoclonal antibody to the HER2 protein.",HER2,Trastuzumab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
",M: MKN45; R: RAW264.7; inf: infliximab.,MKN45,infliximab,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",FDA,Trastuzumab,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",FDA,Herceptin,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",USA,Trastuzumab,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",USA,Herceptin,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",USA,Trastuzumab,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",USA,Herceptin,1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",San,Trastuzumab,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","In 1998, Trastuzumab (marketed as Herceptin, Genentech, San Francisco, California, USA) was approved for the targeted therapy of HER2-overexpressing metastatic breast cancer patients by the Food and Drug Administration (FDA) of the USA, and it has also recently been shown to be very effective in the adjuvant setting [2].

",San,Herceptin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",cSD,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",cSD,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",cSD,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",FEC,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",FEC,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",FEC,epirubicin,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",cPD,fluorouracil,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",cPD,cyclophosphamide,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The FEC regimen, consisting of 500 mg/m2 of intravenous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide given on day1 and then every 3 weeks for 3 cycles was administered in patients with clinically stable disease (cSD) and clinically progressive disease (cPD).",cPD,epirubicin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",HER1,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",HER1,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","MP470 plus Erlotinib Inhibits HER1, 2 and 3 phosphorylation
Because MP470 or the combination of MP470 and Erlotinib inhibits Akt phosphorylation, we next addressed whether they affect the upstream components of the Akt pathway",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In order to glean whether MP470 inhibits cell cycle progression, we treated the lung cancer cell line A549 and two prostate cell lines, LNCaP and PC-3 with DMSO, 10 mM of Erlotinib, MP470, IM or combinations for 32 hr.",DMSO,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In order to glean whether MP470 inhibits cell cycle progression, we treated the lung cancer cell line A549 and two prostate cell lines, LNCaP and PC-3 with DMSO, 10 mM of Erlotinib, MP470, IM or combinations for 32 hr.",PC-3,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In order to glean whether MP470 inhibits cell cycle progression, we treated the lung cancer cell line A549 and two prostate cell lines, LNCaP and PC-3 with DMSO, 10 mM of Erlotinib, MP470, IM or combinations for 32 hr.",A549,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In order to glean whether MP470 inhibits cell cycle progression, we treated the lung cancer cell line A549 and two prostate cell lines, LNCaP and PC-3 with DMSO, 10 mM of Erlotinib, MP470, IM or combinations for 32 hr.",MP470,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In order to glean whether MP470 inhibits cell cycle progression, we treated the lung cancer cell line A549 and two prostate cell lines, LNCaP and PC-3 with DMSO, 10 mM of Erlotinib, MP470, IM or combinations for 32 hr.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,Sodium Bicarbonate,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,glutamine,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,Penicillin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,penicillin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,Streptomycin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,Sodium Bicarbonate,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,glutamine,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,Penicillin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,streptomycin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,penicillin,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,Streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",MCF-7,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",MCF-7,penicillin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",FBS,streptomycin,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",FBS,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","A co-culture of MKN45 cells with RAW264.7 cells for 24 hours indicated it expressed significantly more CXCR4 mRNA and protein (P &#60; 0.001, Figure 4C, D); this increase, however, was significantly inhibited by infliximab (P &#60; 0.001, Figure 4C, D).

",MKN45,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","A co-culture of MKN45 cells with RAW264.7 cells for 24 hours indicated it expressed significantly more CXCR4 mRNA and protein (P &#60; 0.001, Figure 4C, D); this increase, however, was significantly inhibited by infliximab (P &#60; 0.001, Figure 4C, D).

",mRNA,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","A co-culture of MKN45 cells with RAW264.7 cells for 24 hours indicated it expressed significantly more CXCR4 mRNA and protein (P &#60; 0.001, Figure 4C, D); this increase, however, was significantly inhibited by infliximab (P &#60; 0.001, Figure 4C, D).

",CXCR4,infliximab,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Regarding breast cancer, Stoesz and coworkers originally reported heterogeneous expression of NGAL mRNA and protein levels in breast cancer tissue that significantly correlated with other markers of poor prognosis including estrogen and progesterone receptor-negative status and high proliferation [10].",NGAL,progesterone,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Regarding breast cancer, Stoesz and coworkers originally reported heterogeneous expression of NGAL mRNA and protein levels in breast cancer tissue that significantly correlated with other markers of poor prognosis including estrogen and progesterone receptor-negative status and high proliferation [10].",mRNA,progesterone,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Secondly, a variety of growth factors and their receptors are expressed at increased levels, such as transforming growth factor-b (TGF-b), epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin growth factor (IGF), and their receptors.",IGF,insulin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Secondly, a variety of growth factors and their receptors are expressed at increased levels, such as transforming growth factor-b (TGF-b), epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin growth factor (IGF), and their receptors.",FGF,insulin,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Secondly, a variety of growth factors and their receptors are expressed at increased levels, such as transforming growth factor-b (TGF-b), epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin growth factor (IGF), and their receptors.",EGF,insulin,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",SKOV3,penicillin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",SKOV3,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",RPMI1640,penicillin,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",RPMI1640,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",FBS,penicillin,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",FBS,streptomycin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",CO2,penicillin,-1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","SKOV3 cells were maintained in RPMI1640 (Gibco) containing 10% FBS, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humid atmosphere with 5% CO2 at 37degC.

",CO2,streptomycin,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","The gene expressions of p53-associated genes implicated in the response to oxidative stress, cell cycle arrest, DNA repair, autophagy and apoptosis using standard anthracycline and cytarabine-based chemotherapy are shown.",DNA,cytarabine,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","The gene expressions of p53-associated genes implicated in the response to oxidative stress, cell cycle arrest, DNA repair, autophagy and apoptosis using standard anthracycline and cytarabine-based chemotherapy are shown.",DNA,anthracycline,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Moreover, the reduced DNA damage in the presence of the antioxidant AA suggests that etoposide-hydroquinone phenoxyl radical is the responsible mediator of these effects [27,49].

",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses the molecular processes involved in the etoposide treatment-induced breaks, we compared the non-stimulated whole blood cells genotoxicity data generated by the SCGE assay under both highly basic (= 12.3) and extremely basic (&#62; 13) pH conditions and thus generated the ALS index values (see results section).",ALS,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses the molecular processes involved in the etoposide treatment-induced breaks, we compared the non-stimulated whole blood cells genotoxicity data generated by the SCGE assay under both highly basic (= 12.3) and extremely basic (&#62; 13) pH conditions and thus generated the ALS index values (see results section).",SCGE,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The present findings of etoposide-induced DNA damage in non-stimulated cells differ from the findings of Olive and Banath [40] which indicated an absence of DNA damage induction by etoposide in non-cycling cells.,DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The present findings of etoposide-induced DNA damage in non-stimulated cells differ from the findings of Olive and Banath [40] which indicated an absence of DNA damage induction by etoposide in non-cycling cells.,DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The present findings of etoposide-induced DNA damage in non-stimulated cells differ from the findings of Olive and Banath [40] which indicated an absence of DNA damage induction by etoposide in non-cycling cells.,DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The present findings of etoposide-induced DNA damage in non-stimulated cells differ from the findings of Olive and Banath [40] which indicated an absence of DNA damage induction by etoposide in non-cycling cells.,DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Table displaying clinical and biological characteristics of acute myeloid leukemia patients

Click here for file

 Additional file 2
p53-interacting genes expressed in AML blasts following treatment in vivo with anthracycline and cytarabine and ex vivo with anthracycline.",AML,anthracycline,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Table displaying clinical and biological characteristics of acute myeloid leukemia patients

Click here for file

 Additional file 2
p53-interacting genes expressed in AML blasts following treatment in vivo with anthracycline and cytarabine and ex vivo with anthracycline.",AML,anthracycline,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Table displaying clinical and biological characteristics of acute myeloid leukemia patients

Click here for file

 Additional file 2
p53-interacting genes expressed in AML blasts following treatment in vivo with anthracycline and cytarabine and ex vivo with anthracycline.",AML,cytarabine,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Thus the ability of the antioxidant to protect the DNA suggests that phenoxyl radicals are the major radicals involved in the oxidative DNA-damage induced by etoposide, especially in non-stimulated cells [[27,43], and [44]].

",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Thus the ability of the antioxidant to protect the DNA suggests that phenoxyl radicals are the major radicals involved in the oxidative DNA-damage induced by etoposide, especially in non-stimulated cells [[27,43], and [44]].

",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment induces ROS, principally phenoxyl radicals in non-stimulated whole blood cells, then an antioxidant exposure should reduce the DNA damage induced by etoposide.",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment induces ROS, principally phenoxyl radicals in non-stimulated whole blood cells, then an antioxidant exposure should reduce the DNA damage induced by etoposide.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment induces ROS, principally phenoxyl radicals in non-stimulated whole blood cells, then an antioxidant exposure should reduce the DNA damage induced by etoposide.",ROS,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment induces ROS, principally phenoxyl radicals in non-stimulated whole blood cells, then an antioxidant exposure should reduce the DNA damage induced by etoposide.",ROS,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Tornov and colleagues [46] observed DNA damage in leukocytes evidenced by SCGE assay at pH 13, suggesting that etoposide might cause oxidative damage in leukocytes by a mechanism involving inhibition of the enzyme topoisomerase IIb. Although the exact function of this enzyme has not been resolved, it is known that its concentration is generally independent of cell cycle and cell growth [[12,37,39], and [46]].",SCGE,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Tornov and colleagues [46] observed DNA damage in leukocytes evidenced by SCGE assay at pH 13, suggesting that etoposide might cause oxidative damage in leukocytes by a mechanism involving inhibition of the enzyme topoisomerase IIb. Although the exact function of this enzyme has not been resolved, it is known that its concentration is generally independent of cell cycle and cell growth [[12,37,39], and [46]].",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Because non-stimulated cells are not cycling, they have relatively low Topoisomerase II activity compared to PHA-stimulated whole blood cells, and thus would be expected to be relatively insensitive to DNA-damaging effects of etoposide.

",PHA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Because non-stimulated cells are not cycling, they have relatively low Topoisomerase II activity compared to PHA-stimulated whole blood cells, and thus would be expected to be relatively insensitive to DNA-damaging effects of etoposide.

",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Our search also identified a fourth small feasibility study conducted prior to the last one, with irinotecan and 5-FU/LV adjuvant chemotherapy given to patients with rectal cancer.",FU,irinotecan,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","These have two principal components: DNA strand breaks due to the inhibition of topoisomerase II by etoposide and etoposide-quinone free radical effects [25,45].",DNA,etoposide,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","These have two principal components: DNA strand breaks due to the inhibition of topoisomerase II by etoposide and etoposide-quinone free radical effects [25,45].",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","The ALS index data indicated that ALSs, which can be generated by an oxidative stress [6,33], constituted the primary form of DNA damage induced by etoposide in whole blood cells.

",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","The ALS index data indicated that ALSs, which can be generated by an oxidative stress [6,33], constituted the primary form of DNA damage induced by etoposide in whole blood cells.

",ALS,etoposide,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","4.65-7.35	0.69		
	
Response to first-line trastuzumab-based therapy	7 vs. 6	5.25-8.75	0.89	n.s.	
		3.77-8.23	1.14		
	
New metastatic sites at progression upon first-line trastuzumab-based therapy	7 vs. 6	4.81-9.19	1.12	n.s.	
		5.12-6.88	0.45		
* SE: Standard error

Table 4 Cox proportional hazard model: Prediction of TTP (second-line)

Factor	p =	OR*	95% CI	
Age &#60; 35 years	",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","4.65-7.35	0.69		
	
Response to first-line trastuzumab-based therapy	7 vs. 6	5.25-8.75	0.89	n.s.	
		3.77-8.23	1.14		
	
New metastatic sites at progression upon first-line trastuzumab-based therapy	7 vs. 6	4.81-9.19	1.12	n.s.	
		5.12-6.88	0.45		
* SE: Standard error

Table 4 Cox proportional hazard model: Prediction of TTP (second-line)

Factor	p =	OR*	95% CI	
Age &#60; 35 years	",TTP,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","4.65-7.35	0.69		
	
Response to first-line trastuzumab-based therapy	7 vs. 6	5.25-8.75	0.89	n.s.	
		3.77-8.23	1.14		
	
New metastatic sites at progression upon first-line trastuzumab-based therapy	7 vs. 6	4.81-9.19	1.12	n.s.	
		5.12-6.88	0.45		
* SE: Standard error

Table 4 Cox proportional hazard model: Prediction of TTP (second-line)

Factor	p =	OR*	95% CI	
Age &#60; 35 years	",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","4.65-7.35	0.69		
	
Response to first-line trastuzumab-based therapy	7 vs. 6	5.25-8.75	0.89	n.s.	
		3.77-8.23	1.14		
	
New metastatic sites at progression upon first-line trastuzumab-based therapy	7 vs. 6	4.81-9.19	1.12	n.s.	
		5.12-6.88	0.45		
* SE: Standard error

Table 4 Cox proportional hazard model: Prediction of TTP (second-line)

Factor	p =	OR*	95% CI	
Age &#60; 35 years	",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Moreover, when non-stimulated cells were exposed to etoposide in the presence of the antioxidant AA, less DNA damage was observed.",DNA,etoposide,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER1,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER1,Canertinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER1,Gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Canertinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER,Canertinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER,Gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Canertinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Gefitinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Canertinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Clinical efficacy studies reported that the HER1 selective Erlotinib and Gefitinib, the HER1/HER2 selective Lapatanib and the pan-HER selective Canertinib have shown limited activity in the treatment of HER2 over-expressing breast cancer, despite evidence suggesting these cancers are highly dependent on HER2 function [37].",HER2,Gefitinib,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Table 2 Efficacy endpoints

Endpoint	Results	
Median time to progression second-line trastuzumab-based therapy (months)	7 (95% CI 5.74-8.26)	
	
",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Since allergic-like reactions appeared with the lower dose levels, prophylactic antihistaminic medication (50 mg intramuscular diphenhydramine) was given 20 minutes before CIGB 300 injections to groups III and IV.

",CIGB,diphenhydramine,1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Since allergic-like reactions appeared with the lower dose levels, prophylactic antihistaminic medication (50 mg intramuscular diphenhydramine) was given 20 minutes before CIGB 300 injections to groups III and IV.

",III,diphenhydramine,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","the hypothesis that subgroups (CMF- or anthracycline treated and untreated) are similar

2Pearson X2 test

3Events when censored at 60 months

4Kruskal-Wallis equality-of-populations rank test

Follow-up consisted of routine examinations every 3-6 months during the first 5 years and once a year thereafter.",CMF-,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","the hypothesis that subgroups (CMF- or anthracycline treated and untreated) are similar

2Pearson X2 test

3Events when censored at 60 months

4Kruskal-Wallis equality-of-populations rank test

Follow-up consisted of routine examinations every 3-6 months during the first 5 years and once a year thereafter.",X2,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Discussion
We recently reported that metastatic breast cancer patients with high tumor tissue levels of TIMP-1 had no benefit from chemotherapy with CMF and anthracycline-containing regimens suggesting that tissue TIMP-1 may be a predictive marker for response to chemotherapy [6], and data from studies of adjuvant treatment are now emerging [7,8].",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Discussion
We recently reported that metastatic breast cancer patients with high tumor tissue levels of TIMP-1 had no benefit from chemotherapy with CMF and anthracycline-containing regimens suggesting that tissue TIMP-1 may be a predictive marker for response to chemotherapy [6], and data from studies of adjuvant treatment are now emerging [7,8].",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Discussion
We recently reported that metastatic breast cancer patients with high tumor tissue levels of TIMP-1 had no benefit from chemotherapy with CMF and anthracycline-containing regimens suggesting that tissue TIMP-1 may be a predictive marker for response to chemotherapy [6], and data from studies of adjuvant treatment are now emerging [7,8].",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(C) and (D) CXCR4 upregulation induced by H. pylori Tx30a was also inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P &#60; 0.01, respectively, vs Tx30a + inf.",HGC27,infliximab,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(C) and (D) CXCR4 upregulation induced by H. pylori Tx30a was also inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P &#60; 0.01, respectively, vs Tx30a + inf.",CXCR4,infliximab,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(C) and (D) CXCR4 upregulation induced by H. pylori Tx30a was also inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P &#60; 0.01, respectively, vs Tx30a + inf.",MKN45,infliximab,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Moreover, looking closely at the HRs and CIs of the anthracycline-treated TIMP-1 low and high groups, TIMP-1 high patients appear to benefit even less than TIMP-1 low patients from the chemotherapy, compared with patients who received no adjuvant chemotherapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Moreover, looking closely at the HRs and CIs of the anthracycline-treated TIMP-1 low and high groups, TIMP-1 high patients appear to benefit even less than TIMP-1 low patients from the chemotherapy, compared with patients who received no adjuvant chemotherapy.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Moreover, looking closely at the HRs and CIs of the anthracycline-treated TIMP-1 low and high groups, TIMP-1 high patients appear to benefit even less than TIMP-1 low patients from the chemotherapy, compared with patients who received no adjuvant chemotherapy.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, treatment with anthracycline-based chemotherapy appears to be associated with a very small benefit in both TIMP-1 high and low patients but it should be kept in mind that the anthracycline-treated subgroup is characterized by very poor prognostic features (larger tumors, many tumor-involved lymph nodes, Table 1).",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, treatment with anthracycline-based chemotherapy appears to be associated with a very small benefit in both TIMP-1 high and low patients but it should be kept in mind that the anthracycline-treated subgroup is characterized by very poor prognostic features (larger tumors, many tumor-involved lymph nodes, Table 1).",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Results
Characterization and comparison of patient subgroups
Patients were subdivided according to adjuvant chemotherapy regimen received (CMF, 324 patients; anthracycline-containing, 99 patients; no adjuvant chemotherapy, 102 patients).",CMF,anthracycline,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",FCS,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",FCS,penicillin,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",CO2,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",CO2,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",DMEM,streptomycin,-1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",DMEM,penicillin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Eleven patients received biotherapy such as IFN and somatostatin analogues as the 1st-line.,IFN,somatostatin,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median TTP (second-line trastuzumab-based therapy) was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line trastuzumab-based therapy respectively",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median TTP (second-line trastuzumab-based therapy) was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line trastuzumab-based therapy respectively",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median TTP (second-line trastuzumab-based therapy) was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line trastuzumab-based therapy respectively",CI,trastuzumab,1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median TTP (second-line trastuzumab-based therapy) was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line trastuzumab-based therapy respectively",CI,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median TTP (second-line trastuzumab-based therapy) was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line trastuzumab-based therapy respectively",TTP,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Oct_17_9_367.txt
","Median TTP (second-line trastuzumab-based therapy) was 7 months (95% CI 5.74-8.26), and 8 months (95% CI 6.25-9.74) on first-line trastuzumab-based therapy respectively",TTP,trastuzumab,-1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","The potential that ERb-dependent gene activation can occur in the endometrial cancers is supported by the results of studies using tamoxifen, a SERM that acts as a potent transcriptional activator of ERb at AP-1 response elements [55].",SERM,tamoxifen,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","The potential that ERb-dependent gene activation can occur in the endometrial cancers is supported by the results of studies using tamoxifen, a SERM that acts as a potent transcriptional activator of ERb at AP-1 response elements [55].",AP-1,tamoxifen,-1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Briefly, reactions were performed in 50 ml reaction volumes in 96-well polystyrene plates with final conditions as follows: 25 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 5 mM b-glycerophosphate, 0.1 mM NaVO3, 2 mM DTT, 200 mM ATP, 1.5 mM biotin-IkBa peptide, and the IKK complex which was immunoprecipitated with anti- IKKa antibody(1:100).",IKK,biotin,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Briefly, reactions were performed in 50 ml reaction volumes in 96-well polystyrene plates with final conditions as follows: 25 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 5 mM b-glycerophosphate, 0.1 mM NaVO3, 2 mM DTT, 200 mM ATP, 1.5 mM biotin-IkBa peptide, and the IKK complex which was immunoprecipitated with anti- IKKa antibody(1:100).",HCL,biotin,-1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Briefly, reactions were performed in 50 ml reaction volumes in 96-well polystyrene plates with final conditions as follows: 25 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 5 mM b-glycerophosphate, 0.1 mM NaVO3, 2 mM DTT, 200 mM ATP, 1.5 mM biotin-IkBa peptide, and the IKK complex which was immunoprecipitated with anti- IKKa antibody(1:100).",ATP,biotin,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Briefly, reactions were performed in 50 ml reaction volumes in 96-well polystyrene plates with final conditions as follows: 25 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 5 mM b-glycerophosphate, 0.1 mM NaVO3, 2 mM DTT, 200 mM ATP, 1.5 mM biotin-IkBa peptide, and the IKK complex which was immunoprecipitated with anti- IKKa antibody(1:100).",MgCL2,biotin,-1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Briefly, reactions were performed in 50 ml reaction volumes in 96-well polystyrene plates with final conditions as follows: 25 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 5 mM b-glycerophosphate, 0.1 mM NaVO3, 2 mM DTT, 200 mM ATP, 1.5 mM biotin-IkBa peptide, and the IKK complex which was immunoprecipitated with anti- IKKa antibody(1:100).",DTT,biotin,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Briefly, reactions were performed in 50 ml reaction volumes in 96-well polystyrene plates with final conditions as follows: 25 mM Tris-HCL (pH 7.5), 10 mM MgCL2, 5 mM b-glycerophosphate, 0.1 mM NaVO3, 2 mM DTT, 200 mM ATP, 1.5 mM biotin-IkBa peptide, and the IKK complex which was immunoprecipitated with anti- IKKa antibody(1:100).",NaVO3,biotin,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Further, the MP470-Erlotinib combination completely inhibited tyrosine phosphorylation and p85 binding (Fig.",p85,MP470-Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",During the secretory phase when circulating concentrations of progesterone are maximal activation of PR results in reduced proliferation and increased cellular differentiation.,PR,progesterone,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",SDAd/SDCa_FC is the fold change of the gene expression in follicular thyroid adenoma (FTA) in relation to follicular thyroid carcinoma (FTC).,FTA,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",SDAd/SDCa_FC is the fold change of the gene expression in follicular thyroid adenoma (FTA) in relation to follicular thyroid carcinoma (FTC).,FTA,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",SDAd/SDCa_FC is the fold change of the gene expression in follicular thyroid adenoma (FTA) in relation to follicular thyroid carcinoma (FTC).,FTC,thyroid,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",SDAd/SDCa_FC is the fold change of the gene expression in follicular thyroid adenoma (FTA) in relation to follicular thyroid carcinoma (FTC).,FTC,thyroid,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In addition, the combination treatment of MP470 and Erlotinib completely inhibited HER family activation, and the downstream signaling pathway PI3K/Akt in LNCaP and T47D cells.",MP470,Erlotinib,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In addition, the combination treatment of MP470 and Erlotinib completely inhibited HER family activation, and the downstream signaling pathway PI3K/Akt in LNCaP and T47D cells.",PI3K,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In addition, the combination treatment of MP470 and Erlotinib completely inhibited HER family activation, and the downstream signaling pathway PI3K/Akt in LNCaP and T47D cells.",T47D,Erlotinib,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In addition, the combination treatment of MP470 and Erlotinib completely inhibited HER family activation, and the downstream signaling pathway PI3K/Akt in LNCaP and T47D cells.",HER,Erlotinib,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",In normal endometrium expression of progesterone receptor (PR) is induced during the oestrogen-dominated proliferative phase and a number of response elements capable of activation by ERs have been described within the regulatory region of the PR gene [13].,PR,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",In normal endometrium expression of progesterone receptor (PR) is induced during the oestrogen-dominated proliferative phase and a number of response elements capable of activation by ERs have been described within the regulatory region of the PR gene [13].,PR,progesterone,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at anthracycline-treated patients, a comparison with patients who did not receive adjuvant chemotherapy (Table 3) showed that neither TIMP-1 low nor TIMP-1 high patients treated with anthracycline-based adjuvant therapy had a significantly better DFS than untreated patients.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at anthracycline-treated patients, a comparison with patients who did not receive adjuvant chemotherapy (Table 3) showed that neither TIMP-1 low nor TIMP-1 high patients treated with anthracycline-based adjuvant therapy had a significantly better DFS than untreated patients.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at anthracycline-treated patients, a comparison with patients who did not receive adjuvant chemotherapy (Table 3) showed that neither TIMP-1 low nor TIMP-1 high patients treated with anthracycline-based adjuvant therapy had a significantly better DFS than untreated patients.",DFS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at anthracycline-treated patients, a comparison with patients who did not receive adjuvant chemotherapy (Table 3) showed that neither TIMP-1 low nor TIMP-1 high patients treated with anthracycline-based adjuvant therapy had a significantly better DFS than untreated patients.",DFS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at anthracycline-treated patients, a comparison with patients who did not receive adjuvant chemotherapy (Table 3) showed that neither TIMP-1 low nor TIMP-1 high patients treated with anthracycline-based adjuvant therapy had a significantly better DFS than untreated patients.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Looking at anthracycline-treated patients, a comparison with patients who did not receive adjuvant chemotherapy (Table 3) showed that neither TIMP-1 low nor TIMP-1 high patients treated with anthracycline-based adjuvant therapy had a significantly better DFS than untreated patients.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-3,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C3,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TRAP,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",HGF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TSH,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-13,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",AFP,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sIL-6R,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2R,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-2,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PAI,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PROLACTIN,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIG,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CSF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sICAM-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-2,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",tPAI-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RANTES,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-3,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MICA,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ELISA,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SCC,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IGFBP-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IP-10,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TTR,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FSH,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MPO,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",DR5,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-10,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-8,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGF,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",S-100,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-3,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-7,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GH,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGFR,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-9,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SAA,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C2,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CD40L,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GM,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-5,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA-125,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CSF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-4,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EOTAXIN,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-6,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-13,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CEA,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GROa,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",VEGF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA72,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",NGF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ErbB2,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ACTH,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-15,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-7,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-12,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-2,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FGF,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sVCAM-1,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RII,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A2,Angiostatin,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-17,Angiostatin,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-8,Angiostatin,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Sunitinib showed 16.7% of ORR and 68% of DCR in pancreatic NETs in a nonrandomized study [27].,DCR,Sunitinib,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Sunitinib showed 16.7% of ORR and 68% of DCR in pancreatic NETs in a nonrandomized study [27].,ORR,Sunitinib,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","T1N0	
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without known disease was extracted in PAXgene Blood RNA tubes (BD, Franklin Lakes, New Jersey USA).",RNA,BD,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","T1N0	
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without known disease was extracted in PAXgene Blood RNA tubes (BD, Franklin Lakes, New Jersey USA).",USA,BD,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",Upregulation of cytidine deaminases (cyclic amidines) represents a significant mechanism for inactivation of cytarabine and thereby confers therapy resistance in AML (Figure 3 and Additional File 3) [36].,AML,cytarabine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",DCR,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",DCR,octreotide,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",RAD001,everolimus,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",RAD001,octreotide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",ORR,everolimus,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",ORR,octreotide,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",LAR,everolimus,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","In a phase II trial, everolimus (RAD001) and octreotide long-acting repeatable (LAR) showed 22% of ORR and 70% of DCR in advanced low to intermediate-grade NETs [7].",LAR,octreotide,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Later the treatment in older children (over three years of age) started with radiation therapy with weekly vincristin doses (craniospinal dose 36 Gy and total tumor dose 54-55 Gy), and after irradiation a chemotherapy protocol using cisplatin, CCNU and vincristine was applied [36].",CCNU,vincristine,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Later the treatment in older children (over three years of age) started with radiation therapy with weekly vincristin doses (craniospinal dose 36 Gy and total tumor dose 54-55 Gy), and after irradiation a chemotherapy protocol using cisplatin, CCNU and vincristine was applied [36].",CCNU,cisplatin,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",D2,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",D1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",X,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",CTL1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PLA2G3,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",B1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PLA2G12A,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",CHPT1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",A2,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",SLC44A1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PCYT1A,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",LYPLA2,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",A2,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PLA2G10,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",CHKB,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",III,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PLD2,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",LCAT,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",XII,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PLD1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",LYPLA1,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",A2,cholesterol,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Phosphatidylserine synthase I	0.9	9.6E-7	
	
10434	A_23_P19192	LYPLA1	Lysophospholipase 1	0.9	0.001	
	
3931	A_23_P218237	LCAT	Lecithin-cholesterol acyltransferase	0.8	0.0002	
	
151056	A_23_P56356	PLB1	Phospholipase B1	0.7	0.0001	
	
5337	A_23_P155335	PLD1	Phospholipase D1	0.7	0.0005	
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors

Table 5 Differentially expressed genes

Entrez ID	Probe name	Gene name	Encoded protein	Log2-fold difference	Adjusted p-value (false discovery rate)	
50487	A_23_P17814	PLA2G3	Phospholipase A2, group III	-3.1	1.1E-12	
	
81579	A_23_P30020	PLA2G12A	Phospholipase A2, group XII A	-1.6	2.5E-9	
	
56994	A_23_P105571	CHPT1	Choline phosphotransferase 1	-1.4	1.6E-7	
	
23446	A_23_P216630	SLC44A1	Solute carrier family 44, member 1 (CTL1)	-1.1	7.9E-7	
	
5338	A_23_P4308	PLD2	Phospholipase D2	-1.1	1.2E-6	
	
8399	A_23_P88767	PLA2G10	Phospholipase A2, group X	-1.1	3.1E-6	
	
1119	A_23_P314120	CHKB	Choline kinase beta	-0.8	2.0E-6	
	
11313	A_24_P276490	LYPLA2	Lysophospholipase II	-0.4	0.005	
	
5130	A_23_P252681	PCYT1A	",PLB1,cholesterol,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",CMF,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","All patients N = 525: anthracycline-treated low TIMP-1, 46 patients; anthracycline-treated high TIMP-1, 53 patients; CMF-treated low TIMP-1, 172 patients; CMF-treated high TIMP-1, 152 patients; untreated (high and low TIMP-1, combined), 102 patients.

",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, in the subgroup analyses of anthracycline-treated patients (Tables 4 and 5) we observed a strong tendency for increasing TIMP-1 levels (continuous variable) to be associated with shorter DFS, and in the analyses of OS increasing TIMP-1 was strongly correlated with shorter survival in both univariate and multivariable analyses.",TIMP-1,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, in the subgroup analyses of anthracycline-treated patients (Tables 4 and 5) we observed a strong tendency for increasing TIMP-1 levels (continuous variable) to be associated with shorter DFS, and in the analyses of OS increasing TIMP-1 was strongly correlated with shorter survival in both univariate and multivariable analyses.",TIMP-1,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, in the subgroup analyses of anthracycline-treated patients (Tables 4 and 5) we observed a strong tendency for increasing TIMP-1 levels (continuous variable) to be associated with shorter DFS, and in the analyses of OS increasing TIMP-1 was strongly correlated with shorter survival in both univariate and multivariable analyses.",DFS,anthracycline,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","In addition, in the subgroup analyses of anthracycline-treated patients (Tables 4 and 5) we observed a strong tendency for increasing TIMP-1 levels (continuous variable) to be associated with shorter DFS, and in the analyses of OS increasing TIMP-1 was strongly correlated with shorter survival in both univariate and multivariable analyses.",OS,anthracycline,1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","the role of AMPK in the mechanism of action of metformin [47-49], evidence in support of a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer [50], and the reduced risk of cancer in patients with type 2 diabetes taking metformin compared with those on other medications such as sulphonylureas [35,51], are all indicative of the need to explore this relationship and its potential to discover a novel targeted therapy in breast cancer.",AMPK,metformin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","the role of AMPK in the mechanism of action of metformin [47-49], evidence in support of a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer [50], and the reduced risk of cancer in patients with type 2 diabetes taking metformin compared with those on other medications such as sulphonylureas [35,51], are all indicative of the need to explore this relationship and its potential to discover a novel targeted therapy in breast cancer.",AMPK,metformin,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","On the other hand, expression of estrogen and/or progesterone receptors is a typical feature of luminal A and B subtypes, whereas the ERBB2 and basal-like subtypes of breast cancer rarely express hormone receptors [38,39].",ERBB2,progesterone,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
",The TMA were washed 3 times in TBST and underwent 5 sequential incubations with 3x washes in TBST between each step: 15 minutes with biotinylated goat anti-rabbit IgG (diluted in TBST); 15 minutes with streptavidin-biotin complex; 15 minutes with amplification reagent; 15 minutes with streptavidin-peroxidase; and 5 minutes with substrate chromagen solution.,TBST,biotin,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
",The TMA were washed 3 times in TBST and underwent 5 sequential incubations with 3x washes in TBST between each step: 15 minutes with biotinylated goat anti-rabbit IgG (diluted in TBST); 15 minutes with streptavidin-biotin complex; 15 minutes with amplification reagent; 15 minutes with streptavidin-peroxidase; and 5 minutes with substrate chromagen solution.,TBST,biotin,1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
",The TMA were washed 3 times in TBST and underwent 5 sequential incubations with 3x washes in TBST between each step: 15 minutes with biotinylated goat anti-rabbit IgG (diluted in TBST); 15 minutes with streptavidin-biotin complex; 15 minutes with amplification reagent; 15 minutes with streptavidin-peroxidase; and 5 minutes with substrate chromagen solution.,TBST,biotin,-1
"PMC 
BMC_Cancer_2009_Oct_30_9_385.txt
",The TMA were washed 3 times in TBST and underwent 5 sequential incubations with 3x washes in TBST between each step: 15 minutes with biotinylated goat anti-rabbit IgG (diluted in TBST); 15 minutes with streptavidin-biotin complex; 15 minutes with amplification reagent; 15 minutes with streptavidin-peroxidase; and 5 minutes with substrate chromagen solution.,TMA,biotin,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","The drug Orlistat (Xenical(tm)), which was developed as an inhibitor of gastric and pancreatic lipases and has been approved for weight loss by the FDA, blocks breast cancer cell cycle progression, promotes apoptotic cell death, and transcriptional repression of the HER2 oncogene [25].",HER2,Orlistat,-1
"PMC 
BMC_Cancer_2009_Sep_1_9_307.txt
","The drug Orlistat (Xenical(tm)), which was developed as an inhibitor of gastric and pancreatic lipases and has been approved for weight loss by the FDA, blocks breast cancer cell cycle progression, promotes apoptotic cell death, and transcriptional repression of the HER2 oncogene [25].",FDA,Orlistat,1
"PMC 
BMC_Cancer_2009_Nov_21_9_407.txt
","In accordance with our result, [45,61] aspirin has been shown to induce COX-2 transcription in some tissues, among others intestinal myofibroblasts, especially in the presence of IL-1b [71].",COX-2,aspirin,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Interestingly, STAMP does not interact with ER or members of the nuclear receptor sub-family such as thyroid receptor, PPAR, RAR, or RXR [15].

",RAR,thyroid,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Interestingly, STAMP does not interact with ER or members of the nuclear receptor sub-family such as thyroid receptor, PPAR, RAR, or RXR [15].

",RXR,thyroid,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Interestingly, STAMP does not interact with ER or members of the nuclear receptor sub-family such as thyroid receptor, PPAR, RAR, or RXR [15].

",PPAR,thyroid,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Interestingly, STAMP does not interact with ER or members of the nuclear receptor sub-family such as thyroid receptor, PPAR, RAR, or RXR [15].

",ER,thyroid,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Interestingly, STAMP does not interact with ER or members of the nuclear receptor sub-family such as thyroid receptor, PPAR, RAR, or RXR [15].

",STAMP,thyroid,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","In addition, significant differences of ITGB3 expression were also detected when tumours were divided according to treatment, with p = 0.05 for paclitaxel and carboplatin treated patients and p = 0.04 for farmorubicine-, carboplatin-, and cyclophosphamide-treated patients.

",ITGB3,carboplatin,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","In addition, significant differences of ITGB3 expression were also detected when tumours were divided according to treatment, with p = 0.05 for paclitaxel and carboplatin treated patients and p = 0.04 for farmorubicine-, carboplatin-, and cyclophosphamide-treated patients.

",ITGB3,paclitaxel,-1
"PMC 
BMC_Cancer_2009_Sep_23_9_336.txt
","In addition, significant differences of ITGB3 expression were also detected when tumours were divided according to treatment, with p = 0.05 for paclitaxel and carboplatin treated patients and p = 0.04 for farmorubicine-, carboplatin-, and cyclophosphamide-treated patients.

",ITGB3,cyclophosphamide,-1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Tissues were incubated overnight at 4degC in the following antisera: ER-a monoclonal mouse anti-human antibody clone NCL-ER-6F11 at 1:40 dilution (Novocastra Ltd.), progesterone receptor monoclonal antibody PR 10A9 at 1: 50 dilution (Immunotech, Marselle, France), Ki67 monoclonal mouse anti-human antibody clone MIB-1 at 1:50 dilution (DakoCytomation), and HER-2/neu polyclonal rabbit anti-human antibody at 1:100 dilution (DakoCytomation), followed by biotinylated goat anti-mouse or goat anti-rabbit secondary antibodies (DakoCytomation).",PR,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Tissues were incubated overnight at 4degC in the following antisera: ER-a monoclonal mouse anti-human antibody clone NCL-ER-6F11 at 1:40 dilution (Novocastra Ltd.), progesterone receptor monoclonal antibody PR 10A9 at 1: 50 dilution (Immunotech, Marselle, France), Ki67 monoclonal mouse anti-human antibody clone MIB-1 at 1:50 dilution (DakoCytomation), and HER-2/neu polyclonal rabbit anti-human antibody at 1:100 dilution (DakoCytomation), followed by biotinylated goat anti-mouse or goat anti-rabbit secondary antibodies (DakoCytomation).",ER-6F11,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Tissues were incubated overnight at 4degC in the following antisera: ER-a monoclonal mouse anti-human antibody clone NCL-ER-6F11 at 1:40 dilution (Novocastra Ltd.), progesterone receptor monoclonal antibody PR 10A9 at 1: 50 dilution (Immunotech, Marselle, France), Ki67 monoclonal mouse anti-human antibody clone MIB-1 at 1:50 dilution (DakoCytomation), and HER-2/neu polyclonal rabbit anti-human antibody at 1:100 dilution (DakoCytomation), followed by biotinylated goat anti-mouse or goat anti-rabbit secondary antibodies (DakoCytomation).",NCL,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Tissues were incubated overnight at 4degC in the following antisera: ER-a monoclonal mouse anti-human antibody clone NCL-ER-6F11 at 1:40 dilution (Novocastra Ltd.), progesterone receptor monoclonal antibody PR 10A9 at 1: 50 dilution (Immunotech, Marselle, France), Ki67 monoclonal mouse anti-human antibody clone MIB-1 at 1:50 dilution (DakoCytomation), and HER-2/neu polyclonal rabbit anti-human antibody at 1:100 dilution (DakoCytomation), followed by biotinylated goat anti-mouse or goat anti-rabbit secondary antibodies (DakoCytomation).",Ki67,progesterone,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Tissues were incubated overnight at 4degC in the following antisera: ER-a monoclonal mouse anti-human antibody clone NCL-ER-6F11 at 1:40 dilution (Novocastra Ltd.), progesterone receptor monoclonal antibody PR 10A9 at 1: 50 dilution (Immunotech, Marselle, France), Ki67 monoclonal mouse anti-human antibody clone MIB-1 at 1:50 dilution (DakoCytomation), and HER-2/neu polyclonal rabbit anti-human antibody at 1:100 dilution (DakoCytomation), followed by biotinylated goat anti-mouse or goat anti-rabbit secondary antibodies (DakoCytomation).",MIB-1,progesterone,-1
